

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

06 April 2023 (06.04.2023)



(10) International Publication Number

WO 2023/056446 A1

(51) International Patent Classification:

A61P 9/12 (2006.01) A61K 31/712 (2006.01)

C07H 21/02 (2006.01) A61K 31/713 (2006.01)

C12N 15/113 (2010.01) A61K 31/7125 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/077389

(22) International Filing Date:

30 September 2022 (30.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/251,562 01 October 2021 (01.10.2021) US

63/287,960 09 December 2021 (09.12.2021) US

(71) Applicant: ADARX PHARMACEUTICALS, INC.

[US/US]; 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).

(72) Inventors: LI, Zhen; c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).

ZHU, Rui; c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).

ZHOU, Zhiqing (Joel); c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).

FULTZ, Kimberly; c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).

(74) Agent: BOWLER, Joseph, M. et al.; Wolf, Greenfield &

Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANGIOTENSINOGEN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: Aspects of the disclosure provide compounds, compositions, and methods for modulating the expression or activity of angiotensinogen (AGT). In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT mRNA in a cell or animal. In some aspects, the compounds, compositions, and methods of the disclosure can be used to reduce the expression of AGT protein in a cell or animal.

WO 2023/056446 A1

ANGIOTENSINOGEN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of U.S. Provisional Application No. 63/251,562, filed October 1, 2021; and U.S. Provisional Application No. 63/287,960, filed December 9, 2021. The disclosure of each of the prior applications is considered part of and is incorporated by reference in its entirety in the disclosure of this application.

BACKGROUND

[0002] Angiotensinogen (AGT), also known as SERPINA8, is a member of the serpin family. The encoded protein is angiotensinogen precursor which is largely expressed in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. The product, angiotensin I, is subsequently cleaved by angiotensin converting enzyme (ACE) to generate the physiologically active angiotensin II. Angiotensin II is the active peptide of the renin-angiotensin-aldosterone system (RAAS). Angiotensin II interacts with receptors to mediate vasoconstriction, thirst, release of vasopressin and aldosterone, renal sodium reabsorption, fibrosis, inflammation, angiogenesis, vascular aging, and atherosclerosis. Release of aldosterone causes the kidneys to increase reabsorption of sodium and water, leading to an increase of the fluid volume in a body which, in turn, can increase blood pressure. Therefore, overstimulation or activity of the RAAS pathway can lead to high blood pressure. High levels of angiotensin II are associated with chronic high blood pressure (systemic arterial hypertension, essential hypertension or hypertension), renal failure and cardiac fibrosis.

[0003] Hypertension is the most common risk factor for cardiovascular disease (CVD; including coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation and peripheral artery disease), chronic kidney disease (CKD) and cognitive impairment, and is the leading single contributor to all-cause death and disability worldwide (Forouzanfar et al., Lancet, 2016, 388:1659-1724). The World Health Organization estimates that 1.28 billion adults aged 30-79 years worldwide have hypertension. Less than half that population is diagnosed and treated and of those only about 20% are able to control their hypertension through pharmacological treatment, diet and lifestyle changes.

[0004] The American Heart Association has defined resistant hypertension as uncontrolled blood pressure (BP) $\geq 130/80$ mmHg, despite concurrent use of 3 anti-hypertension drug classes comprising a calcium channel blocker, a blocker of renin-angiotensin system, and a thiazide diuretic, preferably chlorthalidone. Resistant hypertension may also be defined as

treatment with ≥ 4 classes of anti-hypertension medication regardless of BP. The global prevalence of resistant hypertension is estimated to be approximately 14.7% among the treated population. Therapies currently approved for treating hypertension have significant limitations. Drugs such as ACE inhibitors and angiotensin receptor blockers are the primary treatments for hypertension. Such drugs are limited in their ability to inhibit the RAAS pathway and have considerable adverse effects and contraindications in certain patient populations (Momoniati et al., Cleveland Clinic Journal of Medicine, 2019, 86:601-607).

[0005] Factors such as increased age and obesity predispose individuals to risk of resistant hypertension. With an aging and increasingly overweight population and lack of effective treatments, the prevalence of hypertension, resistant hypertension and related disease is expected to continue to rise. Accordingly, there is a need to find effective treatments for RAAS related diseases.

SUMMARY

[0006] The present disclosure provides compounds, compositions, and methods for modulating the expression or activity of AGT. In certain embodiments, the compounds, compositions, and methods can be used to reduce the expression of AGT mRNA in a cell or animal. In certain embodiments, the compounds, compositions, and methods can be used to reduce the amount of AGT protein in a cell or animal.

[0007] In certain embodiments, the animal has a RAAS related disease, disorder or condition. In certain embodiments, the disease, disorder, or condition is hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment. Certain compounds, compositions and methods provided herein are directed to reducing a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment in an animal. In certain embodiments, the compounds and compositions provided herein are potent and tolerable and inhibit AGT expression, which can be used to treat, prevent, ameliorate, or slow progression of a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic

kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment.

[0008] In certain embodiments, the compounds and compositions comprise one or more features that are effective for increasing potency. In certain embodiments, the compounds and compositions comprise one or more features that are effective for increasing tolerability. In certain embodiments, compounds and compositions comprise one or more features that are effective for targeting the compound or composition to a cell or tissue. In certain embodiments, the compounds and compositions are more potent, have greater duration of action or have greater therapeutic value than compounds publicly disclosed.

DETAILED DESCRIPTION

[0009] It is to be understood that both the foregoing summary and the following detailed description are exemplary and explanatory only and are not restrictive of the embodiments, as claimed. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.

[0010] All documents, or portions of documents, cited in this application, including, but not limited to, patents, patent applications, articles, books, treatises, and GenBank, NCBI and other sequence reference records are hereby expressly incorporated by reference for the portions of the document discussed herein, as well as in their entirety as of the date of filing this application.

[0011] It is understood that the sequence set forth in each SEQ ID NO contained herein is independent of any modification to a sugar moiety, an internucleoside linkage, or a nucleobase even if shown in context with a modified compound. As such, compounds defined by a SEQ ID NO may comprise, independently, one or more modifications to a sugar moiety, an internucleoside linkage, or a nucleobase. Oligomeric compounds referenced by Compound Number or Ref ID NO indicate a combination of nucleobase sequence, chemical modification, and motif.

[0012] Herein, the use of the singular includes the plural unless specifically stated otherwise. For example, the articles “a” and “an” are used herein to refer to one or to more than one (i.e., to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element, e.g., a plurality of elements. As used herein, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term

“including” as well as other forms, such as “includes” and “included” is not limiting and is used interchangeably with the phrase “including but not limited to”.

Definitions

[0013] Unless otherwise indicated, the following terms have the following meanings:

[0014] “Angiotensinogen,” used interchangeably with the term “AGT,” refers to any nucleic acid or protein of AGT. Exemplary nucleotide and amino acid sequences of AGT can be found, for example, at GenBank Accession No. NM_000029.4 (incorporated herein as SEQ ID NO: 1), the complement of nucleotides 230702523 to 230745583 of NC_000001.11 (incorporated herein as SEQ ID NO: 2), NM_001382817.3 (incorporated herein as SEQ ID NO: 3) and nucleotides 5469 to 17068 of NG_008836.2 (incorporated herein as SEQ ID NO: 4). Additional examples of AGT sequences are readily available through publicly available databases, e.g., GenBank, UniProt, and OMIM. Further information on AGT can be found, for example, at ncbi.nlm.nih.gov/gene/?term=AGT. AGT, as used herein, also refers to variations of the AGT gene including variants provided in the SNP database. Numerous sequence variations within the AGT gene have been identified and may be found at, for example, NCBI dbSNP and UniProt (see, e.g., ncbi.nlm.nih.gov/snp/?term=AGT). “AGT mRNA” means an mRNA encoding a AGT protein. AGT may be referred to in either upper or lower case.

[0015] “AGT specific inhibitor” refers to any agent capable of specifically inhibiting AGT RNA and/or AGT protein expression or activity at the molecular level. For example, AGT specific inhibitors include nucleic acids (including oligonucleotide compounds), peptides, antibodies, small molecules, and other agents capable of inhibiting the expression of AGT RNA and/or AGT protein.

[0016] “2’-O-methoxyethyl” or “2’-MOE” means a 2’-O(CH₂)₂-OCH₃ modification. A 2’-O-methoxyethyl modified sugar is a modified sugar with 2’-O(CH₂)₂-OCH₃ in the place of the 2’-OH group of a ribosyl ring.

[0017] “5’ start site” means the nucleotide of the target nucleic acid or region which is aligned to the 3’-most nucleoside of an antisense oligonucleotide.

[0018] “3’ stop site” means the nucleotide of the target nucleic acid or region which is aligned to the 5’-most nucleoside of an antisense oligonucleotide.

[0019] “About” means within $\pm 10\%$ of a value. For example, if it is stated, “a compound achieved about 70% inhibition of AGT”, it is implied that AGT levels are inhibited within a

range of 60% and 80%. When about is present before a series of numbers or a range, it is understood that “about” can modify each of the numbers in the series or range.

[0020] “Administer” or “administering” refers to routes of introducing a compound or composition provided herein to an individual to perform its intended function. An example, routes of administration that can be used include, but are not limited to, parenteral administration, such as subcutaneous, intravenous, or intramuscular injection or infusion.

[0021] “Ameliorate” refers to an improvement or lessening of at least one indicator, sign, or symptom of an associated disease, disorder, or condition. In certain embodiments, amelioration includes a delay or slowing in the progression or severity of one or more indicators of a condition or disease. The progression or severity of indicators may be determined by subjective or objective measures, which are known to those skilled in the art.

[0022] “Animal” refers to a human or non-human animal, including, but not limited to, mice, rats, rabbits, dogs, cats, pigs, and non-human primates, including, but not limited to, monkeys and chimpanzees.

[0023] “Antisense oligonucleotide” or “antisense strand” means an oligonucleotide which includes a region that is complementary to a target nucleic acid, e.g., a AGT RNA or a region thereof.

[0024] “Complementarity” in reference to an oligonucleotide means the nucleobase sequence of such oligonucleotide or one or more regions thereof that is complementary to the nucleobase sequence of another oligonucleotide or nucleic acid or one or more regions thereof when the two nucleobase sequences are aligned in opposing directions.

Complementary nucleobases, as described herein, are limited to the following pairs: adenine (A) and thymine (T), adenine (A) and uracil (U), and cytosine (C) and guanine (G) unless otherwise specified. Complementary oligonucleotides and/or nucleic acids need not have nucleobase complementarity at each nucleoside and may include one or more nucleobase mismatches. By contrast, “fully complementary” or “100% complementary” in reference to oligonucleotides means that such oligonucleotides have nucleobase matches at each nucleoside without any nucleobase mismatches.

[0025] “Composition” or “pharmaceutical composition” means a mixture of substances suitable for administering to an individual. For example, a composition may comprise one or more compounds or salt thereof and a sterile aqueous solution.

[0026] “Co-administration” means administration of two or more compounds in any manner in which the pharmacological effects of both are manifest in the patient. Co-administration does not require both compounds to be administered in a single pharmaceutical composition,

in the same dosage form, by the same route of administration, or at the same time. The effects of both compounds need not manifest themselves at the same time. The effects need only be overlapping for a period of time and need not be coextensive. Co-administration includes parallel or sequential administration of the one or more compounds.

[0027] “Conjugate group” means a group of atoms that is attached to an oligonucleotide. A conjugate group is optionally attached to an oligonucleotide through a conjugate linker. A conjugate group may, for example, alter the distribution, targeting, or half-life of a compound into which it is incorporated. Conjugate groups include targeting moieties.

[0028] “Conjugate linker” means a group of atoms comprising at least one bond that connects a linked moiety to an oligonucleotide.

[0029] “Identity” in reference to an oligonucleotide means the nucleobase sequence of such oligonucleotide or one or more regions thereof that matches the nucleobase sequence of another oligonucleotide or nucleic acid or one or more regions thereof. Identity of an oligonucleotide to another oligonucleotide or nucleic acid need not require each nucleobase to match and may include one or more different nucleobases. By contrast, “fully identical” or “100% identity” in reference to oligonucleotides means that such oligonucleotides have the same nucleobase at each relative position over its length as the other oligonucleotide or nucleic acid.

[0030] “Individual” means a human or non-human animal selected for treatment or therapy.

[0031] “Inhibiting the expression or activity” with reference to a target nucleic acid or protein means to reduce or block the expression or activity of such target relative to the expression or activity in an untreated or control sample and does not necessarily indicate a total elimination of expression or activity.

[0032] As used herein, the term “internucleoside linkage” is the covalent linkage between adjacent nucleosides in an oligonucleotide. As used herein, “modified internucleoside linkage” means any internucleoside linkage other than a phosphodiester internucleoside linkage. “Phosphorothioate internucleoside linkage” is a modified internucleoside linkage in which one of the non-bridging oxygen atoms of a phosphodiester internucleoside linkage is replaced with a sulfur atom.

[0033] Representative internucleoside linkages having a chiral center include but are not limited to alkylphosphonates and phosphorothioates. Modified oligonucleotides comprising internucleoside linkages having a chiral center can be prepared as populations of modified oligonucleotides comprising stereorandom internucleoside linkages, or as populations of modified oligonucleotides comprising phosphorothioate linkages in particular stereochemical

configurations as further described below. Unless otherwise indicated, chiral internucleoside linkages of modified oligonucleotides described herein can be stereorandom or in a particular stereochemical configuration.

[0034] The compounds of the present disclosure may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (^3H), iodine-125 (^{125}I), or carbon-14 (^{14}C). All isotopic variations of the compounds of the present disclosure, whether radioactive or not, are encompassed within the scope of the present disclosure.

[0035] The term “isotopic variant” refers to a therapeutic agent (e.g., a compound and/or modified oligonucleotide disclosed herein) that contains an unnatural proportion of an isotope at one or more of the atoms that constitute such a therapeutic agent. In certain embodiments, an “isotopic variant” of a therapeutic agent contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen (H), deuterium (^2H), tritium (^3H), carbon-11 (^{11}C), carbon-12 (^{12}C), carbon-13 (^{13}C), carbon-14 (^{14}C), nitrogen-13 (^{13}N), nitrogen-14 (^{14}N), nitrogen-15 (^{15}N), oxygen-14 (^{14}O), oxygen-15 (^{15}O), oxygen-16 (^{16}O), oxygen-17 (^{17}O), oxygen-18 (^{18}O), fluorine-17 (^{17}F), fluorine-18 (^{18}F), phosphorus-31 (^{31}P), phosphorus-32 (^{32}P), phosphorus-33 (^{33}P), sulfur-32 (^{32}S), sulfur-33 (^{33}S), sulfur-34 (^{34}S), sulfur-35 (^{35}S), sulfur-36 (^{36}S), chlorine-35 (^{35}Cl), chlorine-36 (^{36}Cl), chlorine-37 (^{37}Cl), bromine-79 (^{79}Br), bromine-81 (^{81}Br), iodine 123 (^{123}I), iodine-125 (^{125}I), iodine-127 (^{127}I), iodine-129 (^{129}I), and iodine-131 (^{131}I). In certain embodiments, an “isotopic variant” of a therapeutic agent contains unnatural proportions of one or more isotopes, including, but not limited to, hydrogen (H), deuterium (^2H), tritium (^3H), carbon-11 (^{11}C), carbon-12 (^{12}C), carbon-13 (^{13}C), carbon-14 (^{14}C), nitrogen-13 (^{13}N), nitrogen-14 (^{14}N), nitrogen-15 (^{15}N), oxygen-14 (^{14}O), oxygen-15 (^{15}O), oxygen-16 (^{16}O), oxygen-17 (^{17}O), oxygen-18 (^{18}O), fluorine-17 (^{17}F), fluorine-18 (^{18}F), phosphorus-31 (^{31}P), phosphorus-32 (^{32}P), phosphorus-33 (^{33}P), sulfur-32 (^{32}S), sulfur-33 (^{33}S), sulfur-34 (^{34}S), sulfur-35 (^{35}S), sulfur-36 (^{36}S), chlorine-35 (^{35}Cl), chlorine-36 (^{36}Cl), chlorine-37 (^{37}Cl), bromine-79 (^{79}Br), bromine-81 (^{81}Br), iodine 123 (^{123}I), iodine-125 (^{125}I), iodine-127 (^{127}I), iodine-129 (^{129}I), and iodine-131 (^{131}I).

[0036] It will be understood that, in a therapeutic agent (e.g., a compound and/or modified oligonucleotide disclosed herein), any hydrogen can be ^2H , for example, or any carbon can be ^{13}C , for example, or any nitrogen can be ^{15}N , for example, or any oxygen can be ^{18}O , for example, where feasible according to the judgment of one of skill. In certain embodiments, an “isotopic variant” of a therapeutic agent contains unnatural proportions of deuterium (D).

[0037] “Mismatch” or “non-complementary” means a nucleobase of a first oligonucleotide or nucleic acid that is not complementary to the corresponding nucleobase of a second oligonucleotide or nucleic acid when the first oligonucleotide/nucleic acid and second oligonucleotide/nucleic acid are aligned in an antiparallel orientation. For example, nucleobases including, but not limited to, a universal nucleobase, inosine, and hypoxanthine, are capable of hybridizing with at least one nucleobase but are still mismatched or non-complementary with respect to the nucleobase to which they are hybridized. As another example, a nucleobase of a first oligonucleotide/nucleic acid that is not capable of hybridizing to the corresponding nucleobase of a second oligonucleotide/nucleic acid when the first and second oligonucleotides are aligned in an antiparallel orientation is a mismatch or non-complementary nucleobase.

[0038] “Modified oligonucleotide” means an oligonucleotide, wherein at least one sugar, nucleobase, or internucleoside linkage is modified.

[0039] “Modulating” refers to changing or adjusting a feature in a cell, tissue, organ or organism. For example, modulating AGT RNA can mean to increase or decrease the level of AGT RNA and/or AGT protein in a cell, tissue, organ, or organism. A “modulator” effects the change in the cell, tissue, organ or organism. For example, a AGT compound can be a modulator that decreases the amount of AGT RNA and/or AGT protein in a cell, tissue, organ or organism.

[0040] “Motif” means the pattern of unmodified and modified sugar moieties, nucleobases, and/or internucleoside linkages, in an oligonucleotide.

[0041] “Nucleic acid” refers to molecules composed of monomeric nucleotides. A nucleic acid includes, but is not limited to, ribonucleic acids (RNA), deoxyribonucleic acids (DNA), single-stranded nucleic acids, and double-stranded nucleic acids.

[0042] “Nucleobase” means a heterocyclic moiety capable of pairing with a base of another nucleic acid. As used herein a “naturally occurring nucleobase” is adenine (A), thymine (T), cytosine (C), uracil (U), and guanine (G). A “modified nucleobase” is a naturally occurring nucleobase that is chemically modified. A “universal base” or “universal nucleobase” is a nucleobase other than a naturally occurring nucleobase and modified nucleobase and is capable of pairing with any nucleobase.

[0043] “Nucleobase sequence” means the order of contiguous nucleobases in a nucleic acid or oligonucleotide independent of any sugar or internucleoside linkage.

[0044] “Nucleoside” means a compound comprising a nucleobase and a sugar moiety. The nucleobase and sugar moiety are each, independently, unmodified or modified. “Modified

nucleoside” means a nucleoside comprising a modified nucleobase and/or a modified sugar moiety. Modified nucleosides include abasic nucleosides, which lack a nucleobase.

[0045] “Oligomeric Compound” means a compound comprising one or more oligonucleotides and optionally one or more additional features, such as a conjugate group or terminal group. Examples of oligomeric compounds include single-stranded and double-stranded compounds, such as, oligonucleotides, antisense oligonucleotides, interfering RNA compounds (RNAi compounds), microRNA targeting oligonucleotides, occupancy-based compounds (e.g., mRNA processing or translation blocking compounds and splicing compounds). RNAi compounds include double-stranded compounds (e.g., short-interfering RNA (siRNA) and double-stranded RNA (dsRNA)) and single-stranded compounds (e.g., single-stranded siRNA (ssRNA), single-stranded RNAi (ssRNAi), short hairpin RNA (shRNA) and microRNA mimics) which work at least in part through the RNA-induced silencing complex (RISC) pathway resulting in sequence specific degradation and/or sequestration of a target nucleic acid through a process known as RNA interference (RNAi). The term “RNAi compound” is meant to be equivalent to other terms used to describe nucleic acid compounds that are capable of mediating sequence-specific RNA interference, for example, interfering RNA (iRNA), iRNA agent, RNAi agent, short interfering oligonucleotide, short interfering nucleic acid, short interfering modified oligonucleotide, chemically modified siRNA, and others. Additionally, the term “RNAi” is meant to be equivalent to other terms used to describe sequence-specific RNA interference.

[0046] “Oligonucleotide” means a polymer of linked nucleosides, each of which can be modified or unmodified, independent from one another.

[0047] The term “oligomeric duplex” means a duplex formed by two oligomeric compounds having complementary nucleobase sequences. Each oligomeric compound of an oligomeric duplex may be referred to as a “duplexed oligomeric compound.” The oligonucleotides of each oligomeric compound of an oligomeric duplex may include non-complementary overhanging nucleosides. In some embodiments, the terms “duplexed oligomeric compound” and “modified oligonucleotide” are used interchangeably. In other embodiments, the terms “oligomeric duplex” and “compound” are used interchangeably.

[0048] “Parenteral administration” means administration through injection or infusion. Parenteral administration includes subcutaneous administration, intravenous administration, intramuscular administration, intraarterial administration, intraperitoneal administration, or intracranial administration, e.g., intrathecal or intracerebroventricular administration.

[0049] “Pharmaceutically acceptable carrier or diluent” means any substance suitable for use in administering to an individual. In certain embodiments, a pharmaceutically acceptable carrier or diluent aids the administration of a compound to and absorption by an individual and can be included in the compositions of the present disclosure without causing a significant adverse toxicological effect on the patient. Non-limiting examples of pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, and the like. For example, a pharmaceutically acceptable carrier can be a sterile aqueous solution, such as PBS or water-for-injection. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present disclosure.

[0050] “Pharmaceutically acceptable salts” means or refers to physiologically and pharmaceutically acceptable salts of compounds, such as oligomeric compounds or oligonucleotides, i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto. As used herein, a pharmaceutically acceptable salt is any salt of a compound provided herein which retains its biological properties and which is not toxic or otherwise undesirable for pharmaceutical use. The pharmaceutically acceptable salts of the therapeutic agents disclosed herein include salts that are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds or modified oligonucleotides described herein.

[0051] When compounds of the present disclosure contain relatively acidic functionalities, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired base, either neat or in a suitable inert solvent.

[0052] When compounds of the present disclosure contain relatively basic functionalities, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, either neat or in a suitable inert solvent.

[0053] Thus, the compounds of the present disclosure may exist as salts, such as with pharmaceutically acceptable acids. Such salts may be derived from a variety of organic and inorganic counter-ions well known in the art. Such salts include, but are not limited to: (1) acid addition salts formed with organic or inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric, sulfamic, acetic, trifluoroacetic, trichloroacetic, propionic, hexanoic, cyclopentylpropionic, glycolic, glutaric, pyruvic, lactic, malonic, succinic, sorbic, ascorbic, malic, maleic, fumaric, tartaric, citric, benzoic, 3-(4-hydroxybenzoyl)benzoic, picric, cinnamic, mandelic, phthalic, lauric, methanesulfonic, ethanesulfonic, 1,2-ethane-disulfonic, 2-hydroxyethanesulfonic, benzenesulfonic, 4-chlorobenzenesulfonic, 2-naphthalenesulfonic, 4-toluenesulfonic, camphoric, camphorsulfonic, 4-methylbicyclo[2.2.2]-

oct-2-ene-1-carboxylic, glucoheptonic, 3-phenylpropionic, trimethylacetic, *tert*-butylacetic, lauryl sulfuric, gluconic, benzoic, glutamic, hydroxynaphthoic, salicylic, stearic, cyclohexylsulfamic, quinic, muconic acid and the like acids; or (2) salts formed when an acidic proton present in the parent compound either (a) is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion or an aluminum ion, or alkali metal or alkaline earth metal hydroxides, such as sodium, potassium, calcium, magnesium, aluminum, lithium, zinc, and barium hydroxide, ammonia, or (b) coordinates with an organic base, such as aliphatic, alicyclic, or aromatic organic amines, such as ammonia, methylamine, dimethylamine, diethylamine, picoline, ethanolamine, diethanolamine, triethanolamine, ethylenediamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylene-diamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, N-methylglucamine piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, and the like (see, for example, Berge et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977, 66, 1-19).

[0054] Pharmaceutically acceptable salts further include, by way of example only and without limitation, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like, and when the compound contains a basic functionality, salts of non-toxic organic or inorganic acids, such as hydrohalides, e.g. hydrochloride and hydrobromide, sulfate, phosphate, sulfamate, nitrate, acetate, trifluoroacetate, trichloroacetate, propionate, hexanoate, cyclopentylpropionate, glycolate, glutarate, pyruvate, lactate, malonate, succinate, sorbate, ascorbate, malate, maleate, fumarate, tartarate, citrate, benzoate, 3-(4-hydroxybenzoyl)benzoate, picrate, cinnamate, mandelate, phthalate, laurate, methanesulfonate (mesylate), ethanesulfonate, 1,2-ethane-disulfonate, 2-hydroxyethanesulfonate, benzenesulfonate (besylate), 4-chlorobenzenesulfonate, 2-naphthalenesulfonate, 4-toluenesulfonate, camphorate, camphorsulfonate, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylate, glucoheptonate, 3-phenylpropionate, trimethylacetate, *tert*-butylacetate, lauryl sulfate, gluconate, benzoate, glutamate, hydroxynaphthoate, salicylate, stearate, cyclohexylsulfamate, quinate, muconate, and the like. In some embodiments, the pharmaceutically acceptable salt of the compounds and modified oligonucleotides disclosed herein is a sodium or a potassium salt. In some embodiments, the pharmaceutically acceptable salt of the compounds and modified oligonucleotides disclosed herein is a sodium salt.

[0055] The neutral forms of the compounds are preferably regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent

form of the compound may differ from the various salt forms in certain physical properties, such as solubility in polar solvents. In embodiments, compounds of the present disclosure contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts. The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in a conventional manner. The parent form of the compounds differs from the various salt forms in certain physical properties, such as solubility in polar solvents, but, unless specifically indicated, the salts disclosed herein are equivalent to the parent form of the compound for the purposes of the present disclosure.

[0056] “Pharmaceutical agent” means a compound that provides a therapeutic benefit when administered to an individual.

[0057] “Phosphorothioate linkage” means a modified phosphate linkage in which one of the non-bridging oxygen atoms is replaced with a sulfur atom.

[0058] “Portion” means a defined number of contiguous (i.e., linked) nucleobases of a nucleic acid. In certain embodiments, a portion is a defined number of contiguous nucleobases of a target nucleic acid. In certain embodiments, a portion is a defined number of contiguous nucleobases of an oligonucleotide.

[0059] “Prevent” refers to delaying or forestalling the onset, development or progression of a disease, disorder, or condition for a period of time.

[0060] “RNA interference compound” or “RNAi compound” means a compound that acts, at least in part, through an RNA-induced silencing complex (RISC) pathway or Ago2, but not through RNase H, to modulate a target nucleic acid and/or protein encoded by a target nucleic acid. RNAi compounds include, but are not limited to double-stranded siRNA, single-stranded siRNA, and microRNA, including microRNA mimics.

[0061] “Sense oligonucleotide” or “sense strand” means the strand of a double-stranded compound that includes a region that is substantially complementary to a region of the antisense strand of the compound.

[0062] “Specifically inhibit” with reference to a target nucleic acid or protein means to reduce or block expression or activity of the target nucleic acid or protein while minimizing or eliminating effects on non-target nucleic acids or proteins.

[0063] “Subunit” with reference to an oligonucleotide means a nucleotide, nucleoside, nucleobase or sugar or a modified nucleotide, nucleoside, nucleobase or sugar as provided herein.

[0064] “Target nucleic acid,” “target RNA,” and “nucleic acid target” all mean a nucleic acid capable of being targeted by compounds described herein.

[0065] “Target region” means a portion of a target nucleic acid to which one or more compounds is targeted.

[0066] “Targeting moiety” means a conjugate group that provides an enhanced affinity for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a compound absent such a moiety.

[0067] “Terminal group” means a chemical group or group of atoms that is covalently linked to a terminus of an oligonucleotide.

[0068] “Therapeutically effective amount” or “effective amount” means an amount of a compound, pharmaceutical agent, or composition that provides a therapeutic benefit to an individual. A “therapeutically effective amount” or “effective amount” is an amount sufficient for a compound to accomplish a stated purpose relative to the absence of the compound (e.g., achieve the effect for which it is administered, treat, prevent or ameliorate a disease or reduce one or more symptoms of a disease or condition). An example of a “therapeutically effective amount” or “effective amount” is an amount sufficient to contribute to the treatment, prevention, amelioration, or reduction of a symptom or symptoms of a disease. A “reduction” of a symptom or symptoms (and grammatical equivalents of this phrase) means decreasing of the severity or frequency of the symptom(s), or elimination of the symptom(s). A “prophylactically effective amount” of a drug is an amount of a drug that, when administered to a subject, will have the intended prophylactic effect, e.g., preventing or delaying the onset (or reoccurrence) of an injury, disease, pathology or condition, or reducing the likelihood of the onset (or reoccurrence) of an injury, disease, pathology, or condition, or their symptoms. The term “therapeutically effective amount,” as used herein, refers to that amount of the therapeutic agent sufficient to provide a therapeutic benefit to an individual, such as treating, preventing or ameliorating the disease or disorder or symptom thereof, as described above. For example, for the given parameter, a therapeutically effective amount will show an increase or decrease of at least 5%, 10%, 15%, 20%, 25%, 40%, 50%, 60%, 75%, 80%, 90%, or at least 100%. Therapeutic efficacy can also be expressed as “-fold” increase or decrease. For example, a therapeutically effective amount can have at least a 1.2-fold, 1.5-fold, 2-fold, 5-fold, or more effect over a control.

[0069] The terms “treating” or “treatment” refer to any indicia of success in the therapy or amelioration of an injury, disease, pathology or condition, including any objective or

subjective parameter such as abatement; remission; diminishing of symptoms or making the injury, pathology or condition more tolerable to the patient; slowing in the rate of degeneration or decline; making the final point of degeneration less debilitating; improving a patient's physical or mental well-being. The treatment or amelioration of symptoms can be based on objective or subjective parameters, including the results of a physical examination. The term “treating” and conjugations thereof, may include prevention of an injury, pathology, condition, or disease. In embodiments, treating is preventing. In embodiments, treating does not include preventing.

[0070] “Treating” or “treatment” as used herein (and as well-understood in the art) also broadly includes any approach for obtaining beneficial or desired results in a subject's condition, including clinical results. Beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (i.e., not worsening) the state of disease, prevention of a disease's transmission or spread, delay or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable. In other words, “treatment” as used herein includes any cure, amelioration, or prevention of a disease. Treatment may prevent the disease from occurring; inhibit the disease's spread; relieve the disease's symptoms, fully or partially remove the disease's underlying cause, shorten a disease's duration, or do a combination of these things.

[0071] “Treating” and “treatment” as used herein include prophylactic treatment. Treatment methods include administering to a subject a therapeutically effective amount of a compound described herein. The administering step may consist of a single administration or may include a series of administrations. The length of the treatment period depends on a variety of factors, such as the severity of the condition, the age of the patient, the concentration of the compound, the activity of the compositions used in the treatment, or a combination thereof. It will also be appreciated that the effective dosage of an agent used for the treatment or prophylaxis may increase or decrease over the course of a particular treatment or prophylaxis regime. In some instances, chronic administration may be required. For example, the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient.

[0072] “Treat” refers to administering a compound or pharmaceutical composition to an animal in order to effect an alteration or improvement of a disease, disorder, or condition in the animal.

[0073] Certain compounds of the present disclosure possess asymmetric carbon atoms (optical or chiral centers) or double bonds; the enantiomers, racemates, diastereomers, tautomers, geometric isomers, stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids, and individual isomers are encompassed within the scope of the present disclosure. The compounds of the present disclosure do not include those that are known in art to be too unstable to synthesize and/or isolate. The present disclosure is meant to include compounds in racemic and optically pure forms. Optically active (R)- and (S)-, or (D)- and (L)-isomers may be prepared using chiral synthons or chiral reagents or resolved using conventional techniques. When the compounds described herein contain olefinic bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers.

[0074] As used herein, the term “isomers” refers to compounds having the same number and kind of atoms, and hence the same molecular weight, but differing in respect to the structural arrangement or configuration of the atoms.

[0075] The term “tautomer,” as used herein, refers to one of two or more structural isomers which exist in equilibrium, and which are readily converted from one isomeric form to another.

[0076] It will be apparent to one skilled in the art that certain compounds of this disclosure may exist in tautomeric forms, all such tautomeric forms of the compounds being within the scope of the disclosure.

[0077] Unless otherwise stated, structures depicted herein are also meant to include all stereochemical forms of the structure (i.e., the R and S configurations for each asymmetric center). Therefore, single stereochemical isomers as well as enantiomeric and diastereomeric mixtures of the present compounds are within the scope of the disclosure.

[0078] As used herein, “chirally enriched population” means a plurality of molecules of identical molecular formula, wherein the number or percentage of molecules within the population that contain a particular stereochemical configuration at a particular chiral center is greater than the number or percentage of molecules expected to contain the same particular stereochemical configuration at the same particular chiral center within the population if the particular chiral center were stereorandom. Chirally enriched populations of molecules having multiple chiral centers within each molecule may contain one or more stereorandom chiral centers. In certain embodiments, the molecules are modified oligonucleotides. In certain embodiments, the molecules are compounds comprising modified oligonucleotides.

[0079] Unless otherwise stated, structures depicted herein are also meant to include compounds which differ only in the presence of one or more isotopically enriched atoms. For example, compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by ^{13}C - or ^{14}C -enriched carbon are within the scope of this disclosure.

[0080] As used herein, “stereorandom chiral center” in the context of a population of molecules of identical molecular formula means a chiral center having a random stereochemical configuration. For example, in a population of molecules comprising a stereorandom chiral center, the number of molecules having the (S) configuration of the stereorandom chiral center may be but is not necessarily the same as the number of molecules having the (R) configuration of the stereorandom chiral center. The stereochemical configuration of a chiral center is considered random when it is the results of a synthetic method that is not designed to control the stereochemical configuration. In certain embodiments, a stereorandom chiral center is a stereorandom phosphorothioate internucleoside linkage.

Certain Embodiments

[0081] In certain aspects, the disclosure relates to methods, compounds, and compositions for inhibiting AGT. In certain embodiments, AGT is specifically inhibited. In certain embodiments, AGT is specifically degraded. In certain embodiments, AGT expression is inhibited. In certain embodiments, AGT translation is inhibited. In certain embodiments, AGT activity is inhibited. In certain embodiments, AGT expression, translation, or activity is reduced by at least 10% relative to the expression, translation, or activity in an untreated or control sample. For example, in certain embodiments, AGT expression, translation, or activity is reduced by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, 10-50%, 25-50%, 25-75%, 50-75%, 50-99%, or 75-99% relative to the expression, translation, or activity in an untreated or control sample. In certain embodiments, AGT expression, translation, or activity is reduced as measured by any suitable assay, including but not limited to, an immunoassay, a hybridization-based assay, or a sequencing-based assay (e.g., RNA-Seq).

[0082] In certain aspects, the disclosure relates to compounds targeted to a AGT nucleic acid. In certain embodiments, the AGT nucleic acid has the sequence set forth in GENBANK Accession No. NM_000029.4 (incorporated herein as SEQ ID NO: 1), the complement of nucleotides 230702523 to 230745583 of NC_000001.11 (incorporated herein as SEQ ID NO:

2), NM_001382817.3 (incorporated herein as SEQ ID NO: 3) and nucleotides 5469 to 17068 of NG_008836.2 (incorporated herein as SEQ ID NO: 4).

[0083] In certain embodiments, the compound is an oligomeric compound. In certain embodiments, the compound is single-stranded. In certain embodiments, the compound is double-stranded.

[0084] Certain embodiments provide a compound comprising a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166.

[0085] Certain embodiments provide a compound comprising a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166.

[0086] Certain embodiments provide a compound comprising a modified oligonucleotide having a nucleobase sequence selected from any one of the nucleobase sequences of SEQ ID NOs: 10-166.

[0087] In certain embodiments, the modified oligonucleotide has a nucleobase sequence that is at least 80%, at least 85%, at least 90%, or at least 95% complementary to the nucleobase sequence of SEQ ID NO: 1 or 3. In certain embodiments, the modified oligonucleotide comprises at least one modification selected from a modified internucleoside linkage, a modified sugar, and a modified nucleobase. In certain embodiments, the compound is double-stranded.

[0088] Certain embodiments provide a compound comprising a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide.

[0089] In certain embodiments, the compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences provided in Tables 2-25, 42, 45, 50, and 51, and a second modified oligonucleotide

(e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide.

[0090] Certain embodiments provide a compound comprising a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequences of any one of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide.




[0091] Certain embodiments provide a compound comprising a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166 and 167-327 and a second modified oligonucleotide 19 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide.

[0092] In certain embodiments, the first modified oligonucleotide has a nucleobase sequence that has at least 80%, at least 85%, at least 90%, or at least 95% complementarity or identity to the nucleobase sequence of SEQ ID NO: 1 or 3 over its length. In certain embodiments, the first modified oligonucleotide having a nucleobase sequence has at least 1, at least 2, at least 3 mismatches to a region of the nucleobase sequence of SEQ ID NO: 1 or 3. In certain embodiments, the region of complementarity between the first strand and the second strand is 14 to 30 linked nucleosides in length. In certain embodiments, the region of complementarity between the first strand and the second strand is 14 to 23 linked nucleosides in length. In certain embodiments, the region of complementarity between the first strand and the second strand is 19 to 23 linked nucleosides in length. In certain embodiments, the region of complementarity between the first strand and the second strand is 21 to 23 linked nucleosides in length. In certain embodiments, the first modified oligonucleotide is fully complementary to the second modified oligonucleotide.



[0093] In certain embodiments, the first modified oligonucleotide of any preceding compound comprises at least one modification selected from a modified internucleoside linkage, a modified sugar, and a modified nucleobase. In certain embodiments, the second modified oligonucleotide of any preceding compound comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar, and a modified nucleobase. In certain embodiments, the modified internucleoside linkage is a phosphorothioate internucleoside linkage or a methylphosphonate internucleoside linkage. In certain embodiments, the phosphorothioate internucleoside linkage or methylphosphonate

internucleoside linkage is at the 3' terminus of the first or second modified oligonucleotide or at the 5' terminus of the first modified oligonucleotide. In certain embodiments, the modified sugar comprises a modification selected from the group consisting of a halogen, an alkoxy group and a bicyclic sugar. In certain embodiments, the modified sugar comprises a 2'-F modification. In certain embodiments, the modified sugar comprises a 2'-OMe modification. In certain embodiments, each nucleoside of the first modified oligonucleotide comprises a modified sugar. In certain embodiments, each nucleoside of the second modified oligonucleotide comprises a modified sugar. In certain embodiments, the modified sugar comprises a modification selected from the group consisting of a halogen, an alkoxy group and a bicyclic sugar or a combination thereof. In certain embodiments, the modified sugar comprises a modification selected from the group consisting of 2'-MOE, 2'-F, and 2'-OMe or a combination thereof. In certain embodiments, the first modified oligonucleotide comprises no more than ten 2'-F sugar modifications. In certain embodiments, the second modified oligonucleotide comprises no more than five 2'-F sugar modifications.

[0094] In certain embodiments, the compound of any preceding embodiment comprises a conjugate group. In certain embodiments, the conjugate group is attached to the 5' end of the modified oligonucleotide. In certain embodiments, the conjugate group is a targeting moiety. In certain embodiments, the targeting moiety comprises one or more GalNAc. In certain embodiments, the modified oligonucleotide is the second modified oligonucleotide or sense oligonucleotide. In certain embodiments, the one or more GalNAc is attached to the 2' or 3' position of the ribosyl ring. In certain embodiments, the one or more GalNAc is attached to the 5' nucleoside of the modified oligonucleotide. In certain embodiments, the 5' nucleoside of a modified oligonucleotide is selected from the following Formulae or a salt, solvate, or hydrate thereof, wherein R is the portion of the modified oligonucleotide other than the 5' nucleoside:

**Formula I****Formula II****Formula III**



Formula VI**Formula VII****Formula VIII**

[0095] In certain embodiments, R' is O. In certain embodiments, R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula I and R' is O. In

certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula I and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula II and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula II and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula III and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula III and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula IV and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula IV and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula V and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula V and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VI and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VI and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VII and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VII and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VIII and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VIII and R' is S.

[0096] Certain embodiments provide a compound comprising a first modified oligonucleotide selected from any one of Ref ID NOs: IA0297, IA0300, IA0301, IA0304, IA0305, IA0335-338, IA0343-359, IA0431-432, IA0435, IA440-446, IA0727-728, IA0500-501, and IA0868, and a second modified oligonucleotide 14 to 21 linked nucleosides in length fully complementary to the first modified oligonucleotide.

[0097] Certain embodiments provide a compound comprising a first modified oligonucleotide consisting of IA0443 and a second modified oligonucleotide consisting of IS0505. In certain embodiments, the compound comprises a first modified oligonucleotide consisting of IA0445 and a second modified oligonucleotide consisting of IS0509.

[0098] In certain embodiments, the compound of any foregoing embodiment is in a pharmaceutically acceptable salt form. In certain embodiments, the pharmaceutically acceptable salt is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt is a potassium salt.

[0099] Certain embodiments provide a composition comprising the compound of any one of the foregoing embodiments and a pharmaceutically acceptable carrier.

[0100] Certain embodiments provide a composition comprising a compound of any preceding embodiment, for use in therapy.

[0101] Certain embodiments provide a method of treating, preventing, or ameliorating a disease, disorder or condition associated with AGT in an individual comprising administering to the individual a compound targeted to AGT, thereby treating, preventing, or ameliorating the disease.

[0102] In certain embodiments, the compound or composition of any foregoing embodiment is administered to an individual. In certain embodiments, the disease, disorder, or condition is a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment.

[0103] In certain embodiments, administering the compound inhibits or reduces or improves a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment.

[0104] In certain embodiments, a compound or composition comprising a compound of any preceding embodiment is administered to an individual in a therapeutically effective amount. In certain embodiments, a compound or composition comprising a compound of any preceding embodiment is administered to an individual at a dosage level sufficient to deliver about 1 to 100 mg/kg of body weight of the individual. In certain embodiments, a compound or composition comprising a compound of any preceding embodiment is administered to an individual at a fixed dose of about 25 mg to about 1,000 mg. In certain embodiments, the compound or composition is administered to the individual one or more times in a day up to the dosage level or fixed dose.

[0105] In certain embodiments, a compound or composition comprising a compound of any preceding embodiment is administered to an individual daily, weekly, monthly, quarterly or yearly. In certain embodiments, a compound or composition comprising a compound of any preceding embodiment is administered to an individual about once per quarter (i.e., once every three months) to about once per year. In certain embodiments, a compound or

composition comprising a compound of any preceding embodiment is administered to an individual about once per quarter, about once every six months or about once per year.

[0106] Certain embodiments provide a method of inhibiting expression of AGT in a cell comprising contacting the cell with a compound targeted to AGT, thereby inhibiting expression of AGT in the cell. In certain embodiments, the cell is in the liver of an individual. In certain embodiments, the individual has, or is at risk of having, a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm, and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment.

[0107] Certain embodiments provide a method of reducing or inhibiting a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment in an individual, comprising administering a compound targeted to AGT to the individual, thereby reducing or inhibiting a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment in the individual. In certain embodiments, the individual has, or is at risk of having, a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm, and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment. In certain embodiments, the compound is a compound targeted to AGT. In certain embodiments, the compound is any of the foregoing compounds. In certain embodiments, the compound or composition is administered parenterally.

[0108] Certain embodiments provide use of a compound targeted to AGT for treating, preventing, or ameliorating a disease, disorder or condition associated with AGT. In certain embodiments, the disease, disorder, or condition is a RAAS related disease, disorder or

condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment. In certain embodiments, the compound is a compound targeted to AGT. In certain embodiments, the compound is any of the foregoing compounds.

[0109] Certain embodiments provide use of a compound targeted to AGT in the manufacture of a medicament for treating, preventing, or ameliorating a disease, disorder or condition associated with AGT. In certain embodiments, the disease, disorder, or condition is a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment. In certain embodiments, the compound is a compound targeted to AGT. In certain embodiments, the compound is any of the foregoing compounds.

Certain Indications

[0110] In certain aspects, the disclosure relates to methods of inhibiting AGT expression, which can be useful for treating, preventing, or ameliorating a disease associated with AGT in an individual, by administration of a compound that targets AGT. In certain embodiments, the compound can be a AGT specific inhibitor. In certain embodiments, the compound can be an antisense oligonucleotide, an oligomeric compound, or an oligonucleotide targeted to AGT.

[0111] In certain aspects, the disclosure relates to treating, preventing, or ameliorating a disease, disorder or condition associated with AGT. In certain embodiments, diseases, disorders or conditions associated with AGT treatable, preventable, and/or ameliorable with the methods provided herein include a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment. Certain compounds provided herein are directed to compounds and compositions that reduce a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g.,

coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment in an animal.

[0112] In certain embodiments, a method of treating, preventing, or ameliorating a disease associated with AGT in an individual comprises administering to the individual a compound comprising a AGT specific inhibitor, thereby treating, preventing, or ameliorating the disease. In certain embodiments, the individual is identified as having, or at risk of having, a disease associated with AGT. In certain embodiments, the disease is a RAAS related disease. In certain embodiments, the compound comprises an antisense oligonucleotide targeted to AGT. In certain embodiments, the compound comprises an oligonucleotide targeted to AGT. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides) in length having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 85 and 134. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In certain embodiments, a single-stranded compound can be 14 to 30, 14 to 23, 14 to 20, 16 to 20, or 14 to 16, linked nucleosides in length. In certain embodiments, a single-stranded compound can be 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30, linked nucleosides in length. In certain embodiments, a double-stranded compound can comprise two oligonucleotides of the same or different lengths, as described elsewhere herein. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or oligomeric compound. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at

least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166 and 167-327 and a second modified oligonucleotide 19 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134 and a second modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 244 and 294. In certain embodiments, the compound is administered to the individual parenterally. In certain embodiments, administering the compound improves, preserves, or prevents a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment in an animal.

[0113] In certain embodiments, a method of treating, preventing, or ameliorating a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment in an animal comprises administering to the individual a compound comprising a AGT specific inhibitor, thereby treating, preventing, or ameliorating a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g.,

heart, liver or kidney), inflammatory bowel disease or cognitive impairment. In certain embodiments, the compound comprises an antisense oligonucleotide targeted to AGT. In certain embodiments, the compound comprises an oligonucleotide targeted to AGT. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 85 and 134. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or oligomeric compound. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166 and 167-327 and a second modified oligonucleotide 19 to 23 linked nucleosides in length having a region of

complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134 and a second modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 244 and 294. In certain embodiments, administering the compound improves, preserves, or prevents a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment in an animal. In certain embodiments, the individual is identified as having, or at risk of having, a disease associated with AGT.

[0114] In certain embodiments, a method of inhibiting expression of AGT in an individual having, or at risk of having, a disease associated with AGT comprises administering to the individual a compound comprising a AGT specific inhibitor, thereby inhibiting expression of AGT in the individual. In certain embodiments, administering the compound inhibits expression of AGT in the liver. In certain embodiments, the disease is a RAAS related disease. In certain embodiments, the individual has, or is at risk of having, a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm, and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment. In certain embodiments, the compound comprises an antisense oligonucleotide targeted to AGT. In certain embodiments, the compound comprises an oligonucleotide targeted to AGT. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166. In

certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising any one of the nucleobase sequences of SEQ ID NOs: 85 and 134. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from any one of the nucleobase sequences of SEQ ID NOs: 85 and 134. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or oligomeric compound. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166 and 167-327 and a second modified oligonucleotide 19 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134 and a second modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 244 and 294. In certain embodiments, the compound is administered to the individual parenterally. In certain embodiments, administering the compound improves, preserves, or prevents a RAAS related disease, disorder or condition or a symptom thereof, hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment.

[0115] In certain embodiments, a method of inhibiting expression of AGT in a cell comprises contacting the cell with a compound comprising a AGT specific inhibitor, thereby inhibiting expression of AGT in the cell. In certain embodiments, the cell is a hepatocyte. In certain embodiments, the cell is in the liver. In certain embodiments, the cell is in the liver of an individual who has, or is at risk of having, a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment. In certain embodiments, the compound comprises an antisense oligonucleotide targeted to AGT. In certain embodiments, the compound comprises an oligonucleotide targeted to AGT. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 85 and 134. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from any one of the nucleobase sequences of SEQ ID NOs: 85 and 134. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or oligomeric compound. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a

compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166 and 167-327 and a second modified oligonucleotide 19 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134 and a second modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 244 and 294.

[0116] In certain embodiments, a method of reducing or inhibiting a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment in an individual having, or at risk of having, a disease associated with AGT comprises administering to the individual a compound comprising a AGT specific inhibitor, thereby reducing or inhibiting a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment in the individual. In certain embodiments, the individual has, or is at risk of having, a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm, and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment. In certain embodiments, the compound comprises an antisense oligonucleotide targeted to AGT. In certain embodiments, the compound comprises an oligonucleotide targeted to AGT. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase

sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 85 and 134. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or oligomeric compound. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166 and 167-327 and a second modified oligonucleotide 19 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134 and a second modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 244 and 294. In certain embodiments, the compound

is administered to the individual parenterally. In certain embodiments, the individual is identified as having, or at risk of having, a disease associated with AGT.

[0117] Certain embodiments are drawn to a compound comprising a AGT specific inhibitor for use in treating a disease, disorder or condition associated with AGT. In certain embodiments, the disease, disorder or condition is a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment. In certain embodiments, the compound comprises an antisense oligonucleotide targeted to AGT. In certain embodiments, the compound comprises an oligonucleotide targeted to AGT. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising any one of the nucleobase sequences of SEQ ID NOs: 85 and 134. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or oligomeric compound. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain

embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166 and 167-327 and a second modified oligonucleotide 19 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134 and a second modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 244 and 294. In certain embodiments, the compound is administered to the individual parenterally.

[0118] Certain embodiments are drawn to a compound comprising a AGT specific inhibitor for use in reducing or inhibiting a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment. In certain embodiments, the compound comprises an antisense oligonucleotide targeted to AGT. In certain embodiments, the compound comprises an oligonucleotide targeted to AGT. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising any one of the nucleobase sequences of SEQ ID NOs: 85 and 134. In

certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from any one of the nucleobase sequences of SEQ ID NOs: 85 and 134. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or oligomeric compound. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from any one of the nucleobase sequences of SEQ ID NOs: 10-166 and 167-327 and a second modified oligonucleotide 19 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134 and a second modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 244 and 294.

[0119] Certain embodiments are drawn to the use of a compound comprising a AGT specific inhibitor for the manufacture or preparation of a medicament for treating a disease associated with AGT. Certain embodiments are drawn to the use of a compound comprising a AGT specific inhibitor for the preparation of a medicament for treating a disease, disorder or condition associated with AGT. In certain embodiments, the disease, disorder or condition is a RAAS related disease, disorder or condition or a symptom thereof. In certain embodiments, the disease, disorder or condition is hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive

impairment. In certain embodiments, the compound comprises an antisense oligonucleotide targeted to AGT. In certain embodiments, the compound comprises an oligonucleotide targeted to AGT. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising any one of the nucleobase sequences of SEQ ID NOs: 85 and 134. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from any one of the nucleobase sequences of SEQ ID NOs: 85 and 134. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or oligomeric compound. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166 and 167-327 and a second modified oligonucleotide 19 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a

compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134 and a second modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 244 and 294.

[0120] Certain embodiments are drawn to the use of a compound comprising a AGT specific inhibitor for the manufacture or preparation of a medicament for reducing or inhibiting a RAAS related disease, disorder or condition or a symptom thereof in an individual having, or at risk of having, a RAAS related disease, disorder or condition or a symptom thereof associated with AGT. In certain embodiments, the RAAS related disease, disorder or condition is hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment. Certain embodiments are drawn to use of a compound comprising a AGT specific inhibitor for the preparation of a medicament for treating a disease, disorder or condition associated with AGT. In certain embodiments, the disease, disorder or condition is a RAAS related disease, disorder or condition or a symptom thereof or hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment. In certain embodiments, the compound comprises an antisense oligonucleotide targeted to AGT. In certain embodiments, the compound comprises an oligonucleotide targeted to AGT. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) and having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166. In certain embodiments, a compound comprises a modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 85

and 134. In certain embodiments, a compound comprises a modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134. In any of the foregoing embodiments, the compound can be single-stranded or double-stranded. In any of the foregoing embodiments, the compound can be an antisense oligonucleotide or oligomeric compound. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide (e.g., of 14 to 30, for example, 14 to 23, linked nucleosides in length) having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166 and 167-327 and a second modified oligonucleotide 19 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide. In certain embodiments, a compound comprises a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 85 and 134 and a second modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 244 and 294.

[0121] In any of the foregoing methods or uses, the compound can be an oligomeric compound. In any of the foregoing methods or uses, the compound can be single-stranded or double-stranded. In any of the foregoing methods or uses, the compound can be targeted to AGT. In certain embodiments, the compound comprises or consists of a modified oligonucleotide. In certain embodiments, the compound comprises one or more modified oligonucleotides. In certain embodiments, the compound comprises a first modified oligonucleotide and a second modified oligonucleotide. In certain embodiments, a modified oligonucleotide is 8 to 80 linked nucleosides in length, 10 to 30 linked nucleosides in length, 14 to 30 linked nucleosides in length, 14 to 23 linked nucleosides in length, or 19 to 23 linked nucleosides in length. In certain embodiments, a modified oligonucleotide having a

nucleobase sequence that is at least 80%, at least 85%, at least 90%, at least 95% or 100% complementary to any of the nucleobase sequences recited in SEQ ID NOs: 1 and 3 over its length. In certain embodiments, a modified oligonucleotide comprises at least one modified internucleoside linkage, at least one modified sugar and/or at least one modified nucleobase. In certain embodiments, the modified internucleoside linkage is a phosphorothioate internucleoside linkage. In certain embodiments, the modified sugar is a bicyclic sugar, 2'-MOE, 2'-F, or 2'-OMe. In certain embodiments, the modified nucleobase is a 5-methylcytosine. In any of the foregoing embodiments, each modified oligonucleotide is independently 12 to 30, 14 to 30, 14 to 25, 14 to 24, 14 to 23, 16 to 23, 17 to 23, 18 to 23, 19 to 23, 19 to 22, or 19 to 20 linked nucleosides in length. In certain embodiments, a modified oligonucleotide having a nucleobase sequence has at least 1, at least 2, at least 3 mismatches to a region of the nucleobases of SEQ ID NOs: 1 and 3.

[0122] In any of the foregoing methods or uses, the compound comprises a first and second modified oligonucleotide, wherein there is a region of complementarity between a first modified oligonucleotide and a second modified oligonucleotide. In certain embodiments, the region of complementarity between the first oligonucleotide and the second oligonucleotide is 14 to 23, 19 to 23, or 21 to 23 linked nucleosides in length. In certain embodiments, the first modified oligonucleotide is fully complementary to the second modified oligonucleotide. In certain embodiments, the first modified oligonucleotide comprises at least one modification selected from a modified internucleoside linkage, a modified sugar, and a modified nucleobase. In certain embodiments, the second modified oligonucleotide comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar, and a modified nucleobase. In certain embodiments, the modified internucleoside linkage is a phosphorothioate internucleoside linkage or a methylphosphonate internucleoside linkage. In certain embodiments, the modified internucleoside linkage is at the 3' terminus of the first or second modified oligonucleotide or at the 5' terminus of the first or second modified oligonucleotide. In certain embodiments, the first or second modified oligonucleotide comprises one or more modified sugars. In certain embodiments, each nucleoside of the first or second modified oligonucleotide comprises a modified sugar. In certain embodiments, the modified sugar comprises a modification selected from the group consisting of a halogen, an alkoxy group and a bicyclic sugar. In certain embodiments, the modified sugar comprises a modification selected from group consisting of 2'-MOE, 2'-F, and 2'-OMe or a combination thereof. In certain embodiments, the first or second modified oligonucleotide comprises no more than

ten 2'-F sugar modifications. In certain embodiments, the first or second modified oligonucleotide comprises no more than five 2'-F sugar modifications.

[0123] In any of the forgoing methods or uses, a compound comprises a conjugate group. In certain embodiments, the conjugate group is attached to the 5' end of a modified oligonucleotide. In certain embodiments, the conjugate group is a targeting moiety. In certain embodiments, the targeting moiety comprises one or more GalNAc. In certain embodiments, the one or more GalNAc is attached to the 2' or 3' position of the ribosyl ring. In certain embodiments, the one or more GalNAc is attached to the 5' nucleoside of the modified oligonucleotide. In certain embodiments, the 5' nucleoside of a modified oligonucleotide is selected from Formulae I -VIII, or a salt, solvate, or hydrate thereof, wherein R is the modified oligonucleotide other than the 5' nucleoside. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula I and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula I and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula II and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula II and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula III and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula III and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula IV and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula IV and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula V and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula V and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VI and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VI and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VII and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VII and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VIII and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VIII and R' is S.

[0124] In any of the foregoing methods or uses, the compound comprises a first modified oligonucleotide selected from any one of Ref ID NOs: IA0297, IA0300, IA0301, IA0304, IA0305, IA0335-338, IA0343-359, IA0431-432, IA0435, IA440-446, IA0727-728, IA0500-501, and IA0868, and a second modified oligonucleotide 14 to 23 linked nucleosides in

length fully complementary to the first modified oligonucleotide. In certain embodiments, the compound comprises a first modified oligonucleotide which is Ref ID NO: IA0443 and a second modified oligonucleotide which is Ref ID NO: IS0505. In certain embodiments, the compound comprises a first modified oligonucleotide which is Ref ID NO: IA0445 and a second modified oligonucleotide which is Ref ID NO: IS0509. In certain embodiments, the compound is in a pharmaceutically acceptable salt form. In certain embodiments, the pharmaceutically acceptable salt is a sodium salt. In certain embodiments, the pharmaceutically acceptable salt is a potassium salt. In certain embodiments, a composition comprises the compound of any one of the foregoing embodiments and a pharmaceutically acceptable carrier.

[0125] In any of the foregoing methods or uses, a compound or composition comprising a compound of any preceding embodiment is administered to an individual in a therapeutically effective amount. In certain embodiments, a compound or composition comprising a compound of any preceding embodiment is administered to an individual at a dosage level sufficient to deliver about 1 to 100 mg/kg of body weight of the individual. In certain embodiments, a compound or composition comprising a compound of any preceding embodiment is administered to an individual at a fixed dose of about 25 mg to about 1,000 mg. In certain embodiments, the composition is administered to the individual one or more times in a day up to the dosage level or fixed dose.

[0126] In any of the foregoing methods or uses, a compound or composition comprising a compound of any preceding embodiment is administered to an individual daily, weekly, monthly, quarterly, or yearly. In certain embodiments, a compound or composition comprising a compound of any preceding embodiment is administered to an individual about once per quarter (i.e., once every three months) to about once per year. In certain embodiments, a compound or composition comprising a compound of any preceding embodiment is administered to an individual about once per quarter, about once every six months or about once per year.

Certain Compounds

[0127] In certain aspects, the disclosure relates to a compound that comprises or consists of an oligomeric compound. In certain embodiments, the oligomeric compound comprises a nucleobase sequence complementary to that of a target nucleic acid.

[0128] In certain aspects, the disclosure relates to a compound that comprises or consists of a modified oligonucleotide. In certain embodiments, the modified oligonucleotide has a nucleobase sequence complementary to that of a target nucleic acid.

[0129] In certain aspects, the disclosure relates to a compound that comprises or consists of an antisense oligonucleotide. In certain embodiments, the antisense oligonucleotide has a nucleobase sequence complementary to that of a target nucleic acid.

[0130] In certain aspects, the disclosure relates to a compound that is a single-stranded compound. In certain embodiments, the single-stranded compound comprises or consists of an oligomeric compound. In certain embodiments, such an oligomeric compound comprises or consists of an oligonucleotide and optionally a conjugate group. In certain embodiments, the oligonucleotide is a modified oligonucleotide. In certain embodiments, the oligonucleotide is an antisense oligonucleotide. In certain embodiments, the oligonucleotide or modified oligonucleotide of a single-stranded compound comprises a self-complementary nucleobase sequence.

[0131] In certain aspects, the disclosure relates to a compound that is a double-stranded compound. In certain embodiments, the double-stranded compound comprises or consists of an oligomeric compound. In certain embodiments, the double-stranded compound comprises a first oligonucleotide and a second oligonucleotide. In certain embodiments, the first oligonucleotide has a region complementarity to a target nucleic acid and the second oligonucleotide has a region complementarity to the first modified oligonucleotide. In certain embodiments, the double-stranded compound comprises a modified oligonucleotide. In certain embodiments, the modified oligonucleotide has a region complementarity to a target nucleic acid. In certain embodiments, the double-stranded compound comprises a first modified oligonucleotide and a second modified oligonucleotide. In certain embodiments, the first modified oligonucleotide has a region complementarity to a target nucleic acid and the second modified oligonucleotide has a region complementarity to the first modified oligonucleotide. In certain embodiments, an oligonucleotide or modified oligonucleotide of a double-stranded compound is an RNA oligonucleotide. In such embodiments, the thymine nucleobase in the modified oligonucleotide is replaced by a uracil nucleobase.

[0132] In certain embodiments, a compound described herein comprises a conjugate group. In certain embodiments, the first oligonucleotide or first modified oligonucleotide of a double-stranded compound comprises a conjugate group. In certain embodiments, the second oligonucleotide or second modified oligonucleotide of a double-stranded compound comprises a conjugate group. In certain embodiments, a first oligonucleotide or first modified

oligonucleotide and a second oligonucleotide or second modified oligonucleotide of a double-stranded compound each comprises a conjugate group.

[0133] In certain embodiments, a compound is 14-30 linked nucleosides in length. In certain embodiments, the first oligonucleotide or first modified oligonucleotide of a double-stranded compound is 14-30 linked nucleosides in length. In certain embodiments, the second oligonucleotide or second modified oligonucleotide is 14-30 linked nucleosides in length. In certain embodiments, the oligonucleotides or modified oligonucleotides of a double-stranded compound are blunt ended at one or both ends of the compound. In certain embodiments, the oligonucleotides or modified oligonucleotides of a double-stranded compound include non-complementary overhanging nucleosides at one or both ends of the compound.

[0134] In certain embodiments, a compound has a nucleobase sequence comprising at least 14 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166. In certain embodiments, one of the oligonucleotides or modified oligonucleotides of a double-stranded compound has a nucleobase sequence comprising at least 14 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166.

[0135] Examples of single-stranded and double-stranded compounds include, but are not limited to, oligonucleotides, antisense oligonucleotides, siRNAs, microRNA targeting oligonucleotides, occupancy-based compounds (e.g., mRNA processing or translation blocking compounds and splicing compounds), and single-stranded RNAi compounds (e.g., small hairpin RNAs (shRNAs), single stranded siRNAs (ssRNAs) and microRNA mimics).

[0136] In certain embodiments, a compound described herein has a nucleobase sequence that, when written in the 5' to 3' direction, comprises the reverse complement of the target region of a target nucleic acid to which it is targeted.

[0137] In certain embodiments, a compound described herein comprises an oligonucleotide 12 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 12 to 23 linked subunits in length. In certain embodiments, compound described herein comprises an oligonucleotide 14 to 30 linked subunits in length. In certain embodiments, compound described herein comprises an oligonucleotide 14 to 23 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 15 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 15 to 23 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 16 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 16 to 23 linked subunits in length. In certain embodiments, a compound

described herein comprises an oligonucleotide 17 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 17 to 23 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 18 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 18 to 23 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 19 to 30 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 19 to 23 linked subunits in length. In other words, such oligonucleotides are 12 to 30 linked subunits, 12 to 23 linked subunits, 14 to 30 linked subunits, 14 to 23 linked subunits, 15 to 30 linked subunits, 15 to 23 linked subunits, 16 to 30 linked subunits, 16 to 23 linked subunits, 17 to 30 linked subunits, 17 to 23 linked subunits, 18 to 30 linked subunits, 18 to 23 linked subunits, 19 to 30 linked subunits or 19 to 23 linked subunits, respectively. In certain embodiments, a compound described herein comprises an oligonucleotide 14 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 16 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 17 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 18 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 19 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 20 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 21 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 22 linked subunits in length. In certain embodiments, a compound described herein comprises an oligonucleotide 23 linked subunits in length. In other embodiments, a compound described herein comprises an oligonucleotide 8 to 80, 12 to 50, 13 to 30, 13 to 50, 14 to 30, 14 to 50, 15 to 30, 15 to 50, 16 to 30, 16 to 50, 17 to 30, 17 to 50, 18 to 23, 18 to 24, 18 to 25, 18 to 50, 19 to 23, 19 to 30, 19 to 50, 20 to 23 or 20 to 30 linked subunits. In certain such embodiments, the compound described herein comprises an oligonucleotide 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 linked subunits in length, or a range defined by any two of the above values.

[0138] In certain embodiments, the compound may further comprise an additional moiety, such as a conjugate group or delivery moiety. In certain embodiments, such compounds are oligomeric compounds, and the additional moiety is attached to an oligonucleotide. In certain embodiments, a conjugate group is attached to a nucleoside of an oligonucleotide.

[0139] In certain embodiments, compounds may be shortened or truncated. For example, one or more subunits may be deleted from the 5' end (5' truncation), or alternatively from the 3' end (3' truncation) of an oligonucleotide.

[0140] In certain embodiments, compounds may be lengthened. For example, one or more subunits may be attached to the 3' end or 5' end of an oligonucleotide. In certain embodiments, at least one subunit (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more subunits) is attached to the 5' end of an oligonucleotide. In certain embodiments, at least one subunit (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more subunits) is attached to the 3' end of an oligonucleotide. In certain embodiments, at least one or more subunits may be attached to the 3' end or 5' end of an oligonucleotide of a double-stranded compound creating a 3' and/or 5' end overhang. In certain embodiments, at least one subunit (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more subunits) is attached to the 5' end of both oligonucleotides of a double-stranded compound. In certain embodiments, at least one subunit (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more subunit) is attached to the 3' end of both oligonucleotides of a double-stranded compound. In certain embodiments, subunits are attached to both oligonucleotides of a double-stranded compound at the same end (e.g., that subunits are attached to the 3' end of one of the oligonucleotides and subunits are attached to the 5' end of the other oligonucleotide). In certain embodiments, when subunits are attached to both oligonucleotides of a double-stranded compound at the same end, the number of subunits attached to each oligonucleotide may be the same or may be different. In certain embodiments, when subunits are attached to both oligonucleotides of a double-stranded compound at the same end, the number of subunits attached to each oligonucleotide is the same. In certain embodiments, when subunits are attached to both oligonucleotides of a double-stranded compound at the same end, the number of subunits attached to each oligonucleotide is different. This scenario, where subunits are attached to both oligonucleotides of a double-stranded compound at the same end, may occur at one or both ends of a double-stranded compound. In certain embodiments, the subunits attached to the 3' and/or 5' end are modified.

[0141] In certain embodiments, compounds described herein are oligonucleotides. In certain embodiments, compounds described herein are modified oligonucleotides. In certain embodiments, compounds described herein are antisense oligonucleotides. In certain embodiments, compounds described herein are oligomeric compounds. In certain embodiments, compounds described herein are RNAi compounds. In certain embodiments, compounds described herein are siRNA compounds.

[0142] In certain embodiments, a compound described herein can comprise any of the oligonucleotide sequences targeted to AGT described herein. In certain embodiments, the compound can be double-stranded.

[0143] In certain embodiments, the compound comprises an oligonucleotide having a nucleobase sequence comprising at least an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or 23 contiguous nucleobase portion of any one of the nucleobase sequences of SEQ ID NOs: 10-166. In certain embodiments, the compound comprises a second oligonucleotide.

[0144] In certain embodiments, the compound comprises ribonucleotides in which the oligonucleotide has uracil (U) in place of thymine (T) for any of the sequences provided here. In certain embodiments, the compound comprises deoxyribonucleotides in which the oligonucleotide has thymine (T) in place of uracil (U) for any of the sequences provided here.

Certain Mechanisms

[0145] In certain embodiments, compounds described herein comprise or consist of modified oligonucleotides. In certain embodiments, compounds described herein comprise or consist of antisense oligonucleotides. In certain embodiments, compounds comprise or consist of oligomeric compounds. In certain embodiments, compounds described herein are capable of hybridizing to a target nucleic acid. In certain embodiments, compounds described herein selectively affect one or more target nucleic acid. Such compounds comprise a nucleobase sequence that hybridizes to one or more target nucleic acid, resulting in one or more desired activity and does not hybridize to one or more non-target nucleic acid or does not hybridize to one or more non-target nucleic acid in such a way that results in a significant undesired activity.

[0146] In certain embodiments, hybridization of a compound described herein to a target nucleic acid results in recruitment of one or more proteins that cause the cleavage of the target nucleic acid. For example, certain compounds described herein or a portion of the compound is loaded into an RNA-induced silencing complex (RISC), ultimately resulting in cleavage of the target nucleic acid. For example, certain compounds described herein result in cleavage of the target nucleic acid by Argonaute. Compounds that are loaded into RISC are

RNAi compounds. RNAi compounds may be double-stranded (siRNA) or single-stranded (ssRNA).

[0147] In certain embodiments, hybridization of compounds described herein to a target nucleic acid does not result in recruitment of a protein that cleaves that target nucleic acid. In certain such embodiments, hybridization of the compound to the target nucleic acid results in the alteration of splicing of the target nucleic acid. In certain embodiments, hybridization of the compound to a target nucleic acid results in inhibition of a binding interaction between the target nucleic acid and a protein or other nucleic acid. In certain such embodiments, hybridization of the compound to the target nucleic acid results in the alteration of RNA processing. In certain such embodiments, hybridization of the compound to a target nucleic acid results in alteration of translation of the target nucleic acid.

[0148] Activities resulting from the hybridization of a compound to a target nucleic acid may be observed directly or indirectly. In certain embodiments, observation or detection of an activity involves observation or detection of a change in an amount of a target nucleic acid or protein encoded by such target nucleic acid, a change in the ratio of splice variants of a nucleic acid or protein, and/or a phenotypic change in a cell or animal.

Certain Modifications

[0149] In certain aspects, the disclosure relates to compounds that comprise or consist of oligonucleotides. Oligonucleotides consist of linked nucleosides. In certain embodiments, oligonucleotides may be unmodified RNA or DNA or may be modified. In certain embodiments, the oligonucleotides are modified oligonucleotides. In certain embodiments, the modified oligonucleotides comprise at least one modified sugar, modified nucleobase or modified internucleoside linkage relative to an unmodified RNA or DNA. In certain embodiments, an oligonucleotide has a modified nucleoside. A modified nucleoside may comprise a modified sugar, a modified nucleobase or both a modified sugar and a modified nucleobase. Modified oligonucleotides may also include end modifications, e.g., 5'-end modifications and 3'-end modifications.

Sugar Modifications and Motifs

[0150] In certain embodiments, a modified sugar is a substituted furanosyl sugar or non-bicyclic modified sugar. In certain embodiments, a modified sugar is a bicyclic or tricyclic modified sugar. In certain embodiments, a modified sugar is a sugar surrogate. A sugar surrogate may comprise one or more substitutions described herein.

[0151] In certain embodiments, a modified sugar is a substituted furanosyl or non-bicyclic modified sugar. In certain embodiments, the furanosyl sugar is a ribosyl sugar. In certain

embodiments, the furanosyl sugar comprises one or more substituent groups, including, but not limited to, substituent groups at the 2', 3', 4', and 5' positions.

[0152] In certain embodiments, substituents at the 2' position include, but are not limited to, F and OCH₃ ("OMe", "O-methyl" or "methoxy"). In certain embodiments, substituent groups at the 2' position suitable for non-bicyclic modified sugars include, but are not limited to, halo, allyl, amino, azido, SH, CN, OCN, CF₃, OCF₃, F, Cl, Br, SCH₃, SOCH₃, SO₂CH₃, ONO₂, NO₂, N₃, and NH₂. In certain embodiments, substituent groups at the 2' position include, but are not limited to, O-(C₁-C₁₀) alkoxy, alkoxyalkyl, O-alkyl, S-alkyl, N-alkyl, O-alkenyl, S-alkenyl, N-alkenyl, O-alkynyl, S-alkynyl, N-alkynyl, O-alkyl-O-alkyl, alkynyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. In certain embodiments, substituent groups at the 2' position include, but are not limited to, alkaryl, aralkyl, O-alkaryl, and O-aralkyl. In certain embodiments, these 2' substituent groups can be further substituted with one or more substituent groups independently selected from hydroxyl, alkoxy, carboxy, benzyl, phenyl, nitro (NO₂), thiol, thioalkoxy, thioalkyl, halogen, alkyl, aryl, alkenyl, and alkynyl. In certain embodiments, substituent groups at the 2' position include, but are not limited to, O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nCH₃, O(CH₂)_nONH₂, O(CH₂)_nNH₂, O(CH₂)_nSCH₃, and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are independently from 1 to about 10. In certain embodiments, substituent groups at the 2' position include, but are not limited to, OCH₂CH₂OCH₃ ("MOE"), O(CH₂)₂ON(CH₃)₂ ("DMAOE"), O(CH₂)₂O(CH₂)₂N(CH₃)₂ ("DMAEOE"), and OCH₂C(=O)-N(H)CH₃ ("NMA").

[0153] In certain embodiments, substituent groups at the 4' position suitable for non-bicyclic modified sugars include, but are not limited to, alkoxy (e.g., methoxy), alkyl, and those described in Manoharan et al., WO 2015/106128. In certain embodiments, substituent groups at the 5' position suitable for non-bicyclic modified sugars include, but are not limited to, methyl ("Me") (R or S), vinyl, and methoxy. In certain embodiments, substituents described herein for the 2', 4' and 5' position can be added to other specific positions on the sugar. In certain embodiments, such substituents may be added to the 3' position of the sugar on the 3' terminal nucleoside or the 5' position of the 5' terminal nucleoside. In certain embodiments, a non-bicyclic modified sugar may comprise more than one non-bridging sugar substituent. In certain such embodiments, non-bicyclic modified sugars substituents include, but are not limited to, 5'-Me-2'-F, 5'-Me-2'-OMe (including both R and S isomers). In certain embodiments, modified sugar substituents include those described in Migawa et al., WO 2008/101157 and Rajeev et al., US2013/0203836.

[0154] In certain embodiments, a modified sugar is a bicyclic sugar. A bicyclic sugar is a modified sugar comprising two rings, wherein the second ring is formed via a bridge connecting two of the atoms in the first ring thereby forming a bicyclic structure. In certain embodiments, a bicyclic sugar comprises a bridging substituent that bridges two atoms of the furanosyl ring to form a second ring. In certain embodiments, a bicyclic sugar does not comprise a furanosyl moiety. A “bicyclic nucleoside” (“BNA”) is a nucleoside having a bicyclic sugar. In certain embodiments, the bicyclic sugar comprises a bridge between the 4' and 2' furanose ring atoms. In certain embodiments, the bicyclic sugar comprises a bridge between the 5' and 3' furanose ring atoms. In certain such embodiments, the furanose ring is a ribose ring. In certain embodiments, 4' to 2' bridging substituents include, but are not limited to, 4'-CH₂-2', 4'-(CH₂)₂-2', 4'-(CH₂)₃-2', 4'-CH₂-O-2' (“LNA”), 4'-CH₂-S-2', 4'-(CH₂)₂-O-2' (“ENA”), 4'-CH(CH₃)-O-2' (“constrained ethyl” or “cEt” when in the S configuration), 4'-CH₂-O-CH₂-2', 4'-CH₂-N(R)-2', 4'-CH(CH₂OCH₃)-O-2' (“constrained MOE” or “cMOE”) and analogs thereof (e.g., U.S. Patent No. 7,399,845), 4'-C(CH₃)(CH₃)-O-2' and analogs thereof (e.g., U.S. Patent No. 8,278,283), 4'-CH₂-N(OCH₃)-2' and analogs thereof (e.g., U.S. Patent No. 8,278,425), 4'-CH₂-O-N(CH₃)-2' (e.g., U.S. Patent Publication No. 2004/0171570), 4'-CH₂-N(R)-O-2', wherein R is H, C₁-C₁₂ alkyl, or a protecting group (e.g., U.S. Patent No. 7,427,672), 4'-CH₂-C(H)(CH₃)-2' (e.g., Chattopadhyaya et al., J. Org. Chem., 2009, 74, 118-134), and 4'-CH₂-C(=CH₂)-2' and analogs thereof (e.g., U.S. Patent No. 8,278,426). The entire contents of each of the foregoing are hereby incorporated herein by reference. Additional representative U.S. Patents and U.S. Patent Publications that teach the preparation of bicyclic nucleic acid nucleotides include, but are not limited to, the following: U.S. Patent Nos. 6,268,490; 6,525,191; 6,670,461; 6,770,748; 6,794,499; 6,998,484; 7,053,207; 7,034,133; 7,084,125; 7,399,845; 7,427,672; 7,569,686; 7,741,457; 8,022,193; 8,030,467; 8,278,425; 8,278,426; 8,278,283; US 2008/0039618; and US 2009/0012281, US 2013/0190383; and WO 2013/036868, the entire contents of each of which are hereby incorporated herein by reference. Any of the foregoing bicyclic nucleosides can be prepared having one or more stereochemical sugar configurations including for example α -L-ribofuranose and β -D-ribofuranose (see e.g., WO 99/14226). Specified bicyclic nucleosides herein are in the β -D configuration, unless otherwise specified.

[0155] In certain embodiments, a modified sugar is a sugar surrogate. In certain embodiments, a sugar surrogate has the oxygen atom replaced, e.g., with a sulfur, carbon or nitrogen atom. In certain such embodiments, the sugar surrogate may also comprise bridging and/or non-bridging substituents as described herein. In certain embodiments, sugar

surrogates comprise rings having other than 5 atoms. In certain such embodiments, the sugar surrogate comprises a cyclobutyl moiety in place of the pentofuranosyl sugar. In certain embodiments, the sugar surrogate comprises a six membered ring in place of the pentofuranosyl sugar. In certain embodiments, the sugar surrogate comprises a tetrahydropyran (“THP”) in place of the pentofuranosyl sugar. In certain embodiments, the sugar surrogate comprises a morpholino in place of the pentofuranosyl sugar. Representative US patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Patent Nos. 4,981,957; 5,118,800; 5,166,315; 5,185,444; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; 5,700,920; 7,875,733; 7,939,677; 8,088,904; 8,440,803; and 9,005,906, the entire contents of each of the foregoing are hereby incorporated herein by reference.

[0156] In some embodiments, sugar surrogates comprise acyclic moieties. In certain embodiments, the sugar surrogate is an unlocked nucleic acid (“UNA”). A UNA is unlocked acyclic nucleic acid, wherein any of the bonds of the sugar has been removed, forming an unlocked "sugar" residue. In one example, UNA also encompasses a monomer where the bonds between C1'-C4' have been removed (i.e. the covalent carbon-oxygen-carbon bond between the C1' and C4' carbons). In another example, the C2'-C3' bond (i.e., the covalent carbon-carbon bond between the C2' and C3' carbons) of the sugar has been removed. Representative U.S. publications that teach the preparation of UNA include, but are not limited to, U.S. Patent No. 8,314,227; and U.S. Patent Publication Nos. 2013/0096289; 2013/0011922; and 2011/0313020, the entire contents of each of which are hereby incorporated herein by reference. In certain embodiments, sugar surrogates comprise peptide nucleic acid (“PNA”), acyclic butyl nucleic acid (see, e.g., Kumar et al., *Org. Biomol. Chem.*, 2013, 11, 5853-5865), and nucleosides and oligonucleotides described in Manoharan et al., US2013/130378, the entire contents of which is hereby incorporated herein by reference. Many other bicyclic and tricyclic sugar and sugar surrogate ring systems are known in the art that can be used in modified nucleosides.

[0157] In certain aspects, the disclosure relates to compounds comprising at least one oligonucleotide wherein the nucleosides of such oligonucleotide comprise one or more types of modified sugars and/or unmodified sugars arranged along the oligonucleotide or region thereof in a defined pattern or “sugar motif”. In certain instances, such sugar motifs include, but are not limited to, any of the patterns of sugar modifications described herein.

[0158] In certain embodiments, an oligonucleotide comprises a gapmer sugar motif. A gapmer oligonucleotide comprises or consists of a region having two external “wing” regions and a central or internal “gap” region. The gap and wing regions form a contiguous sequence of nucleosides, wherein the majority of nucleoside sugars of each of the wings differ from the majority of nucleoside sugars of the gap. In certain embodiments, the wing regions comprise a majority of modified sugars and the gap comprises a majority of unmodified sugars. In certain embodiments, the nucleosides of the gap are deoxynucleosides. Compounds with a gapmer sugar motif are described in, for example US Patent 8,790,919, the entire contents of which is hereby incorporated herein by reference.

[0159] In certain embodiments, one or both oligonucleotides of a double-stranded compound comprise a triplet sugar motif. An oligonucleotide with a triplet sugar motif comprises three identical sugar modifications on three consecutive nucleosides. In certain embodiments, the triplet is at or near the cleavage site of the oligonucleotide. In certain embodiments, an oligonucleotide of a double-stranded compound may contain more than one triplet sugar motif. In certain embodiments, the identical sugar modification of the triplet sugar motif is a 2'-F modification. Compounds with a triplet sugar motif are disclosed, for example, in US Patent 10,668,170, the entire contents of which is incorporated herein by reference.

[0160] In certain embodiments, one or both oligonucleotides of a double-stranded compound comprise a quadruplet sugar motif. An oligonucleotide with a quadruplet sugar motif comprises four identical sugar modifications on four consecutive nucleosides. In certain embodiments, the quadruplet is at or near the cleavage site. In certain embodiments, an oligonucleotide of a double-stranded compound may contain more than one quadruplet sugar motif. In certain embodiments, the identical sugar modification of the quadruplet sugar motif is a 2'-F modification. For a double-stranded compound having a duplex region of 19-23 nucleotides in length, the cleavage site of the antisense oligonucleotide is typically around the 10, 11, and 12 positions from the 5'-end. In certain embodiments, the quadruplet sugar motif is at the 8, 9, 10, 11 positions; the 9, 10, 11, 12 positions; the 10, 11, 12, 13 positions; the 11, 12, 13, 14 positions; or the 12, 13, 14, 15 positions of the sense oligonucleotide, counting from the first nucleoside of the 5'-end of the sense oligonucleotide, or, the count starting from the first paired nucleotide within the duplex region from the 5'-end of the sense oligonucleotide. In certain embodiments, the quadruplet sugar motif is at the 8, 9, 10, 11 positions; the 9, 10, 11, 12 positions; the 10, 11, 12, 13 positions; the 11, 12, 13, 14 positions; or the 12, 13, 14, 15 positions of the antisense oligonucleotide, counting from the first nucleoside of the 5'-end of the antisense oligonucleotide, or, the count starting from the first

paired nucleotide within the duplex region from the 5' - end of the antisense oligonucleotide. The cleavage site may change according to the length of the duplex region of the double-stranded compound and may change the position of the quadruplet accordingly.

[0161] In certain embodiments, an oligonucleotide comprises an alternating sugar motif. In certain embodiments, one or both oligonucleotides of a double-stranded compound comprise an alternating sugar motif. An oligonucleotide with an alternating sugar motif comprises at least two different sugar modifications wherein one or more consecutive nucleosides comprising a first sugar modification alternates with one or more consecutive nucleosides comprising a second sugar modification and one or more consecutive nucleosides comprising a third sugar modification, etc. For example, if A, B and C each represent one type of modification to the nucleoside, the alternating motif can be “ABABABABABAB...,” “AABBAABBAABB...,” “AABAABAABAAB...,” “AAABAAABAAAB...,” “AAABBBAAABBB...,” or “ABCABCABCABC...” etc. In certain embodiments, the alternating sugar motif is repeated for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 contiguous nucleobases along an oligonucleotide. In certain embodiments, the alternating sugar motif is comprised of two different sugar modifications. In certain embodiments, the alternating sugar motif comprises 2'-OMe and 2'-F sugar modifications.

[0162] In certain embodiments, each nucleoside of an oligonucleotide is independently modified with one or more sugar modifications provided herein. In certain embodiments, each oligonucleotide of a double-stranded compound independently has one or more sugar motifs provided herein. In certain embodiments, an oligonucleotide containing a sugar motif, is fully modified in that each nucleoside other than the nucleosides comprising the sugar motif comprises a sugar modification.

Nucleobase Modifications and Motifs

[0163] In certain embodiments, compounds described herein comprise modified oligonucleotides. In certain embodiments, modified oligonucleotides comprise one or more nucleosides comprising a modified nucleobase. In certain embodiments, modified oligonucleotides comprise one or more nucleosides that do not comprise a nucleobase, referred to as an abasic nucleoside.

[0164] In certain embodiments, modified nucleobases are selected from: 5-substituted pyrimidines, 6-azapyrimidines, alkyl or alkynyl substituted pyrimidines, alkyl substituted purines, and N-2, N-6 and O-6 substituted purines. In certain embodiments, modified nucleobases are selected from: 2-aminopropyladenine, 5- hydroxymethyl cytosine, 5-

methylcytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-N-methylguanine, 6-N-methyladenine, 2-propyladenine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl ($C\equiv C-CH_3$) uracil, 5-propynylcytosine, 6-azouracil, 6-azocytosine, 6-azothymine, 5-ribosyluracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl, 8-aza and other 8-substituted purines, 5-halo, particularly, 5-bromo, 5-trifluoromethyl, 5-halouracil, and 5-halocytosine, 7-methylguanine, 7-methyladenine, 2-F-adenine, 2-aminoadenine, 7-deazaguanine, 7-deazaadenine, 3-deazaguanine, 3-deazaadenine, 6-N-benzoyladenine, 2-N-isobutyrylguanine, 4-N-benzoylcytosine, 4-N-benzoyluracil, 5-methyl 4-N-benzoylcytosine, 5-methyl 4-N-benzoyluracil, universal bases, hydrophobic bases, promiscuous bases, size expanded bases, and fluorinated bases. Further modified nucleobases include tricyclic pyrimidines, such as 1,3-diazaphenoxazine-2-one, 1,3-diazaphenothiazine-2-one, and 9-(2-aminoethoxy)-1,3-diazaphenoxazine-2-one (G-clamp). Modified nucleobases may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example, 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone.

[0165] Further nucleobases include those disclosed in U.S. Patent 3,687,808; Modified Nucleosides in Biochemistry, Biotechnology and Medicine, Herdewijn, P. ed. Wiley-VCH, 2008; The Concise Encyclopedia Of Polymer Science And Engineering, pages 858-859; Kroschwitz, J.L., Ed., John Wiley & Sons, 1990, 858-859; Englisch et al., Angewandte Chemie, International Edition, 1991, 30, 613; Sanghvi, Y.S., Chapter 15, dsRNA Research and Applications, pages 289-302; Antisense Research and Applications, Crooke, S.T. and Lebleu, B., Eds., CRC Press, 1993, 273-288; Antisense Drug Technology, Crooke S.T., Ed., CRC Press, 2008, 163-166 and 442-443 (Chapters 6 and 15), each of which are hereby incorporated herein by reference.

[0166] Publications that teach the preparation of certain of the above noted modified nucleobases, as well as other modified nucleobases include without limitation, US Applications 2003/0158403 and 2003/0175906; U.S. Patents 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,434,257; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121; 5,596,091; 5,614,617; 5,645,985; 5,681,941; 5,811,534; 5,750,692; 5,948,903; 5,587,470; 5,457,191; 5,763,588; 5,830,653; 5,808,027; 6,005,096. 6,015,886; 6,147,200; 6,166,197; 6,166,199; 6,222,025; 6,235,887; 6,380,368; 6,528,640; 6,639,062; 6,617,438; 7,045,610; 7,427,672; and 7,495,088, the entire contents of each of which are hereby incorporated herein by reference.

[0167] In certain embodiments, compounds described herein comprise oligonucleotides. In certain embodiments, oligonucleotides comprise modified and/or unmodified nucleobases arranged along the oligonucleotide or region thereof in a defined pattern or motif. In certain embodiments, each nucleobase is modified. In certain embodiments, none of the nucleobases are modified. In certain embodiments, each purine or each pyrimidine is modified. In certain embodiments, each adenine is modified. In certain embodiments, each guanine is modified. In certain embodiments, each thymine is modified. In certain embodiments, each uracil is modified. In certain embodiments, each cytosine is modified. In certain embodiments, some or all of the cytosine nucleobases in a modified oligonucleotide are 5-methylcytosines.

[0168] In certain embodiments, modified oligonucleotides comprise a block of modified nucleobases. In certain such embodiments, the block is at the 3'-end of the oligonucleotide. In certain embodiments, the block is within 3 nucleosides of the 3'-end of the oligonucleotide. In certain embodiments, the block is at the 5'-end of the oligonucleotide. In certain embodiments, the block is within 3 nucleosides of the 5'-end of the oligonucleotide.

Internucleoside Linkage Modifications and Motifs

[0169] A 3' to 5' phosphodiester linkage is the naturally occurring internucleoside linkage of RNA and DNA. In certain embodiments, compounds described herein have one or more modified, i.e. non-naturally occurring, internucleoside linkages. Certain non-naturally occurring internucleoside linkages may impart desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for target nucleic acids, and increased stability in the presence of nucleases. Representative phosphorus-containing modified internucleoside linkages include, but are not limited to, phosphotriesters, alkylphosphonates (e.g. methylphosphonates), phosphoramidates, and phosphorothioates ("P=S"), and phosphorodithioates ("HS-P=S"). Representative non-phosphorus containing internucleoside linking groups include, but are not limited to, methylenemethylimino (-CH₂-N(CH₃)-O-CH₂), thiodiester, thionocarbamate (-O-C(=O)(NH)-S-); siloxane (-O-SiH₂-O-); and N,N'-dimethylhydrazine (-CH₂-N((CH₃)-N((CH₃)-). Methods of preparation of phosphorous-containing and non-phosphorous-containing internucleoside linkages are well known to those skilled in the art. Neutral internucleoside linkages include, without limitation, phosphotriesters, methylphosphonates, MMI (3'-CH₂-N(CH₃)-O-5'), amide-3 (3'-CH₂-C(=O)-N(H)-5'), amide-4 (3'-CH₂-N(H)-C(=O)-5'), formacetal (3'-O-CH₂-O-5'), methoxypropyl, and thioformacetal (3'-S-CH₂-O-5'). Further neutral internucleoside linkages include nonionic linkages comprising siloxane (dialkylsiloxane), carboxylate ester, carboxamide, sulfide, sulfonate ester and amides (See, for example: Carbohydrate Modifications in Antisense

Research; Y.S. Sanghvi and P.D. Cook, Eds., ACS Symposium Series 580; Chapters 3 and 4, 40-65). Further neutral internucleoside linkages include nonionic linkages comprising mixed N, O, S and CH₂ component parts.

[0170] In certain embodiments, compounds provided herein comprise at least one modified internucleoside linkage. A modified internucleoside linkage may be placed at any position of an oligonucleotide. For double-stranded compounds, a modified internucleoside linkage may be placed within the sense oligonucleotide, antisense oligonucleotide, or both oligonucleotides of the double-stranded compound.

[0171] In certain embodiments, the internucleoside linkage modification may occur on every nucleoside of an oligonucleotide. In certain embodiments, internucleoside linkage modifications may occur in an alternating pattern along an oligonucleotide. In certain embodiments, essentially each internucleoside linking group is a phosphate internucleoside linkage (P=O). In certain embodiments, each internucleoside linking group of a modified oligonucleotide is a phosphorothioate (P=S). In certain embodiments, each internucleoside linking group of a modified oligonucleotide is independently selected from a phosphorothioate and phosphate internucleoside linkage. In certain embodiments, the pattern of the internucleoside linkage modification on each oligonucleotide of a double-stranded compound is the same. In certain embodiments, the pattern of the internucleoside linkage modification on each oligonucleotide of a double-stranded compound is different. In certain embodiments, a double-stranded compound comprises 6-8 modified internucleoside linkages. In certain embodiments, the 6-8 modified internucleoside linkages are phosphorothioate internucleoside linkages or alkylphosphonate internucleoside linkages. In certain embodiments, the sense oligonucleotide comprises at least two modified internucleoside linkages at either or both the 5'-end and the 3'-end. In certain such embodiments, the modified internucleoside linkages are phosphorothioate internucleoside linkages or alkylphosphonate internucleoside linkages. In certain embodiments, the antisense oligonucleotide comprises at least two modified internucleoside linkages at either or both the 5'-end and the 3'-end. In certain such embodiments, the modified internucleoside linkages are phosphorothioate internucleoside linkages or alkylphosphonate internucleoside linkages.

[0172] In certain embodiments, a double-stranded compound comprises an overhang region. In certain embodiments, a double-stranded compound comprises a phosphorothioate or alkylphosphonate internucleoside linkage modification in the overhang region. In certain embodiments, a double-stranded compound comprises a phosphorothioate or alkylphosphonate internucleotide linkage linking the overhang nucleotide with a paired

nucleotide that is next to the overhang nucleotide. For instance, there may be at least two phosphorothioate internucleoside linkages between the terminal three nucleosides, in which two of the three nucleosides are overhang nucleosides, and the third is a paired nucleoside next to the overhang nucleoside. These terminal three nucleosides may be at the 3'-end of the antisense oligonucleotide, the 3'-end of the sense oligonucleotide, the 5'-end of the antisense oligonucleotide, or the 5' end of the antisense oligonucleotide.

[0173] In certain embodiments, modified oligonucleotides comprise one or more internucleoside linkages having chiral centers. Representative chiral internucleoside linkages include, but are not limited to, alkylphosphonates and phosphorothioates. Modified oligonucleotides comprising internucleoside linkages having chiral centers can be prepared as populations of modified oligonucleotides comprising stereorandom internucleoside linkages, or as populations of modified oligonucleotides comprising phosphorothioate linkages in particular stereochemical configurations. In certain embodiments, populations of modified oligonucleotides comprise phosphorothioate internucleoside linkages wherein all of the phosphorothioate internucleoside linkages are stereorandom. Such modified oligonucleotides can be generated using synthetic methods that result in random selection of the stereochemical configuration of each phosphorothioate linkage. As is well understood by those of skill in the art, each individual phosphorothioate of each individual oligonucleotide molecule has a defined stereoconfiguration. In certain embodiments, populations of modified oligonucleotides are enriched for modified oligonucleotides comprising one or more particular phosphorothioate internucleoside linkages in a particular, independently selected stereochemical configuration. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 65% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 70% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 80% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 90% of the molecules in the population. In certain embodiments, the particular configuration of the particular phosphorothioate linkage is present in at least 99% of the molecules in the population. Such enriched populations of modified oligonucleotides can be generated using synthetic methods known in the art, e.g., methods described in Oka et al., JACS 125, 8307 (2003), Wan et al. Nuc. Acid. Res. 42, 13456 (2014), and WO 2017/015555. In certain embodiments, a population of modified oligonucleotides is enriched for modified

oligonucleotides having at least one indicated phosphorothioate in the (Sp) configuration. In certain embodiments, a population of modified oligonucleotides is enriched for modified oligonucleotides having at least one phosphorothioate in the (Rp) configuration.

Conjugate Groups

[0174] In certain embodiments, the compounds described herein comprise or consist of one or more oligonucleotides and, optionally, one or more conjugate groups. Conjugate groups may be attached to either or both ends of an oligonucleotide and/or at any internal position. In certain embodiments, a conjugate group is attached at the 3' end of an oligonucleotide. In certain embodiments, a conjugate group is attached at the 5' end of an oligonucleotide. In certain embodiments, oligonucleotides are covalently attached to one or more conjugate groups.

[0175] In certain embodiments, conjugate groups are terminal groups attached to either or both ends of an oligonucleotide. In certain such embodiments, terminal groups are attached at the 3' end of an oligonucleotide. In certain such embodiments, terminal groups are attached at the 5' end of an oligonucleotide. In certain embodiments, terminal groups include, but are not limited to, capping groups, phosphate moieties, protecting groups, modified or unmodified nucleosides, and two or more nucleosides that are independently modified or unmodified, such as an overhang.

[0176] In certain embodiments, conjugate groups modify one or more properties of the attached oligonucleotide, including, but not limited to, pharmacodynamics, pharmacokinetics, stability, activity, half-life, binding, absorption, tissue distribution, cellular distribution, cellular uptake, charge and clearance. In certain embodiments, conjugate groups enhance the affinity of a compound for a selected target, e.g., molecule, cell or cell type, compartment, e.g., a cellular or organ compartment, tissue, organ or region of the body, as, e.g., compared to a compound absent such a conjugate group. In certain embodiments, conjugate groups impart a new property on the attached oligonucleotide, e.g., fluorophores or reporter groups that enable detection of the oligonucleotide.

[0177] In certain embodiments, conjugate groups include, but are not limited to, intercalators, reporter molecules, polyamines, polyamides, peptides, carbohydrates, vitamin moieties, polyethylene glycols, thioethers, polyethers, cholesterol, thiocholesterol, cholic acid moieties, folate, lipids, phospholipids, biotin, phenazine, phenanthridine, anthraquinone, adamantane, acridine, fluoresceins, rhodamines, coumarins, fluorophores, and dyes.

[0178] In certain embodiments, conjugate groups include an active drug substance, for example, aspirin, warfarin, phenylbutazone, ibuprofen, suprofen, fen-bufen, ketoprofen, (S)-

(+)-pranoprofen, carprofen, dansylsarcosine, 2,3,5-triiodobenzoic acid, fingolimod, flufenamic acid, folinic acid, a benzothiadiazide, chlorothiazide, a diazepine, indo-methicin, a barbiturate, a cephalosporin, a sulfa drug, an antidiabetic, an antibacterial, or an antibiotic.

[0179] In certain embodiments, conjugate groups are targeting moieties. In certain embodiments, a targeting moiety includes, but is not limited to, a lectin, glycoprotein, lipid, protein, peptide, peptide mimetic, receptor ligand, antibody, thyrotropin, melanotropin, surfactant protein A, carbohydrate, carbohydrate derivative, modified carbohydrate, carbohydrate cluster, polysaccharide, modified polysaccharide, or polysaccharide derivative, mucin carbohydrate, multivalent lactose, multivalent galactose, N-acetyl-galactosamine (GalNAc), N-acetylglucosamine multivalent mannose, multivalent fucose, glycosylated polyaminoacids, multivalent galactose, transferrin, bisphosphonate, polyglutamate, polyaspartate, a lipid, cholesterol, a steroid, bile acid, folate, vitamin B12, vitamin A, biotin, or an RGD peptide or RGD peptide mimetic.

[0180] In certain embodiments, conjugate groups may include, but are not limited to, the conjugate groups described in the following references such as cholesterol (e.g., Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86: 6553-6556), cholic acid (e.g., Manoharan et al., *Biorg. Med. Chem. Lett.*, 1994, 4:1053-1060), thioether, e.g., hexyl-S-tritylthiol (e.g., Manoharan et al., *Ann. NY. Acad. Sci.*, 1992, 660:306-309; Manoharan et al., *Biorg. Med. Chem. Lett.*, 1993, 3:2765-2770), thiocholesterol (e.g., Oberhauser et al., *Nucl. Acids Res.*, 1992, 20:533-538), aliphatic chains, e.g., do-decan-diol or undecyl residues (e.g., Saison-Behmoaras et al., *EMBO J*, 1991, 10:1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259:327-330; Svinarchuk et al., *Biochimie*, 1993, 75:49-54), phospholipids, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (e.g., Manoharan et al., *Tetrahedron Lett.*, 1995, 36:3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18:3777-3783), polyamines or a polyethylene glycol chains (e.g., Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14:969-973), adamantane acetic acid (e.g., Manoharan et al., *Tetrahedron Lett.*, 1995, 36:3651-3654), palmityl (e.g., Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264:229-237), octadecylamine or hexylamino-carbonyloxychole sterol moiety (e.g., Crooke et al. *J. Pharmacol. Exp. Ther.*, 1996, 277:923-937), tocopherol (e.g., Nishina et al., *Molecular Therapy Nucleic Acids*, 2015, 4, e220 and Nishina et al., *Molecular Therapy*, 2008, 16:734-740), GalNAc and other carbohydrates (e.g., Maier et al., *Bioconjugate Chemistry*, 2003, 14, 18-29; Rensen et al., *J. Med. Chem.* 2004, 47, 5798-5808; WO2009/073809 and US Patents 8,106,022; 8,450,467 and 8,828,957; and WO2014/179445;

WO2014/179620 and US Patents 9,127,276; 9,181,549 and 10,844,379) each of which is incorporated herein by reference in its entirety.

[0181] Conjugate groups may be attached to oligonucleotides through conjugate linkers. In certain embodiments, a conjugate linker comprises a chain structure, such as a hydrocarbyl chain, or an oligomer of repeating units or combination of such repeating units. In certain embodiments, a conjugate linker comprises one or more groups selected from alkyl, amino, oxo, amide, disulfide, polyethylene glycol, ether, thioether, and hydroxylamino. In certain embodiments, a conjugate linker comprises at least one phosphorus group. In certain embodiments, a conjugate linker comprises at least one phosphate group. In certain embodiments, a conjugate linker includes at least one neutral linking group. In certain embodiments, conjugate linkers include, but are not limited to, pyrrolidine, 8-amino-3,6-dioxaoctanoic acid (ADO), succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) and 6-aminohexanoic acid (AHEx or AHA). Other conjugate linkers include, but are not limited to, substituted or unsubstituted C₁-C₁₀ alkyl, substituted or unsubstituted C₂-C₁₀ alkenyl, or substituted or unsubstituted C₂-C₁₀ alkynyl, wherein a nonlimiting list of preferred substituent groups includes hydroxyl, amino, alkoxy, carboxy, benzyl, phenyl, nitro, thiol, thioalkoxy, halogen, alkyl, aryl, alkenyl, and alkynyl. In certain embodiments, conjugate linkers comprise 1-10 linker-nucleosides. In certain embodiments, such linker-nucleosides may be modified or unmodified nucleosides. It is typically desirable for linker-nucleosides to be cleaved from the compound after it reaches a target tissue. Accordingly, linker-nucleosides herein can be linked to one another and to the remainder of the compound through cleavable bonds. Herein, linker-nucleosides are not considered to be part of the oligonucleotide. Accordingly, in embodiments in which a compound comprises an oligonucleotide consisting of a specified number or range of linked nucleosides and/or a specified percent complementarity to a reference nucleic acid and the compound also comprises a conjugate group comprising a conjugate linker comprising linker-nucleosides, those linker-nucleosides are not counted toward the length of the oligonucleotide and are not used in determining the percent complementarity of the oligonucleotide for the reference nucleic acid.


[0182] In certain embodiments, conjugate groups and conjugate linkers as well as other modifications include, without limitation, those described in the following references: US 5,994,517; US 6,300,319; US 6,660,720; US 6,906,182; US 7,262,177; US 7,491,805; US 8,106,022; US 7,723,509; US 9,127,276; US 2006/0148740; US 2011/0123520; WO2013/033230; WO2012/037254, Biessen et al., J. Med. Chem. 1995, 38, 1846-1852; Lee

et al., *Bioorganic & Medicinal Chemistry* 2011, 19, 2494-2500; Rensen et al., *J. Biol. Chem.* 2001, 276, 37577-37584; Rensen et al., *J. Med. Chem.* 2004, 47, 5798-5808; Sliedregt et al., *J. Med. Chem.* 1999, 42, 609-618; Valentijn et al., *Tetrahedron*, 1997, 53, 759-770; Lee, *Carbohydr Res*, 1978, 67, 509-514; Connolly et al., *J Biol Chem*, 1982, 257, 939-945; Pavia et al., *Int J Pep Protein Res*, 1983, 22, 539-548; Lee et al., *Biochem*, 1984, 23, 4255-4261; Lee et al., *Glycoconjugate J*, 1987, 4, 317-328; Toyokuni et al., *Tetrahedron Lett*, 1990, 31, 2673-2676; Biessen et al., *J Med Chem*, 1995, 38, 1538-1546; Valentijn et al., *Tetrahedron*, 1997, 53, 759-770; Kim et al., *Tetrahedron Lett*, 1997, 38, 3487-3490; Lee et al., *Bioconjug Chem*, 1997, 8, 762-765; Kato et al., *Glycohiol*, 2001, 11, 821-829; Rensen et al., *J Biol Chem*, 2001, 276, 37577-37584; Lee et al., *Methods Enzymol*, 2003, 362, 38-43; Westerlind et al., *Glycoconj J*, 2004, 21, 227-241; Lee et al., *Bioorg Med Chem Lett*, 2006, 16(19), 5132-5135; Maierhofer et al., *Bioorg Med Chem*, 2007, 15, 7661-7676; Khorev et al., *Bioorg Med Chem*, 2008, 16, 5216-5231; Lee et al., *Bioorg Med Chem*, 2011, 19, 2494-2500; Kornilova et al., *Analyt Biochem*, 2012, 425, 43-46; Pujol et al., *Angew Chemie Int Ed Engl*, 2012, 51, 7445-7448; Biessen et al., *J Med Chem*, 1995, 38, 1846-1852; Sliedregt et al., *J Med Chem*, 1999, 42, 609-618; Rensen et al., *J Med Chem*, 2004, 47, 5798-5808; Rensen et al., *Arterioscler Thromb Vase Biol*, 2006, 26, 169-175; van Rossenberg et al., *Gene Ther*, 2004, 11, 457-464; Sato et al., *J Am Chem Soc*, 2004, 126, 14013-14022; Lee et al., *J Org Chem*, 2012, 77, 7564-7571; Biessen et al., *FASEB J*, 2000, 14, 1784-1792; Rajur et al., *Bioconjug Chem*, 1997, 8, 935-940; Duff et al., *Methods Enzymol*, 2000, 313, 297-321; Maier et al., *Bioconjug Chem*, 2003, 14, 18-29; Jayaprakash et al., *Org Lett*, 2010, 12, 5410-5413; Manoharan, *Antisense Nucleic Acid Drug Dev*, 2002, 12, 103-128; Merwin et al., *Bioconjug Chem*, 1994, 5, 612-620; Tomiya et al., *Bioorg Med Chem*, 2013, 21, 5275-5281; International applications WO1998/013381; WO2011/038356; WO1997/046098; WO2008/098788; WO2004/101619; WO2012/037254; WO2011/120053; WO2011/100131; WO2011/163121; WO2012/177947; WO2013/033230; WO2013/075035; WO2012/083185; WO2012/083046; WO2009/082607; WO2009/134487; WO2010/144740; WO2010/148013; WO1997/020563; WO2010/088537; WO2002/043771; WO2010/129709; WO2012/068187; WO2009/126933; WO2004/024757; WO2010/054406; WO2012/089352; WO2012/089602; WO2013/166121; WO2013/165816; U.S. Patents 4,751,219; 7,582,744; 8,552,163; 8,137,695; 6,908,903; 6,383,812; 7,262,177; 6,525,031; 5,994,517; 6,660,720; 6,300,319; 7,723,509; 8,106,022; 7,491,805; 7,491,805; 8,541,548; 8,344,125; 8,313,772; 8,349,308; 8,450,467; 8,501,930; 8,158,601; 7,262,177; 6,906,182; 6,620,916; 8,435,491; 8,404,862; 7,851,615; Published U.S. Patent Application Publications US2011/0097264;

US2011/0097265; US2013/0004427; US2003/0119724; US2011/0207799; US2012/0035115; US2012/0230938; US2005/0164235; US2006/0183886; US2012/0136042; US2012/0095075; US2013/0109817; US2006/0148740; US2008/0206869; US2012/0165393; US2012/0101148; US2013/0121954; US2011/0123520; US2003/0077829; US2008/0108801; and US2009/0203132; each of which is incorporated herein by reference in its entirety.

Certain Targeting Moieties

[0183] In certain embodiments, a compound provided herein comprises a conjugate group. In certain embodiments, an oligonucleotide provided herein comprises a conjugate group. In certain embodiments, the conjugate group is a targeting moiety. In certain embodiments, the targeting moiety comprises one or more GalNAc. In certain embodiments, the one or more GalNAc are attached to one or more positions on a furanose ring. In certain embodiments, the one or more GalNAc are attached to the 2' or 3' position on a furanose ring. In certain embodiments, the furanose ring is a subunit of the oligonucleotide. In certain embodiments, the furanose ring is the 5' nucleoside sugar of an oligonucleotide. In certain embodiments, the furanose ring is the 5' nucleoside sugar of a sense oligonucleotide. In certain embodiments, a compound or oligonucleotide comprises one or more subunits with the following formula or a salt, solvate, or hydrate thereof:



Formula IX

wherein:

R^1 is H, adenine, guanine, thymine, cytosine, uracil, carbocyclyl, heterocyclyl, aryl, heteroaryl, or a nucleobase isostere;

R^2 is the oligonucleotide sequence;

L^1 is alkyl, or alkyl-C(=O)-NH-alkyl;

L^2 is alkyl, or alkyl-C(=O)-NH-alkyl;

L^3 is a bond, a phosphodiester bond, a phosphorothioate bond, a triazole, a tetrazole, an amide, a reverse-amide, a carbamate, a carbonate, urea, O, S, S(=O), S(=O)₂, NH, substituted N group, alkyl, alkenyl, dienyl, alkynyl, heteroalkyl, phosphate;

R^3 is H, -C(=O)-NH-(CH₂CH₂O)_j-GalNAc, or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc;

R^4 is H, -C(=O)-NH-(CH₂CH₂O)_k-GalNAc, or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc;

R^5 is -C(=O)-NH-(CH₂CH₂O)_m-GalNAc, or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc;

R^6 is -C(=O)-NH-(CH₂CH₂O)_n-GalNAc, or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc;

W and Q are each independently O, NH, CH₂, or CH₂O;

S^1 and S^2 are each independently C(R^7) or N, wherein each instance of R^7 is independently H, alkyl, heteroalkyl, or halogen;

j is an integer 1-10, inclusive;

k is an integer 1-10, inclusive;

m is an integer 1-10, inclusive; and

n is an integer 1-10, inclusive.

[0184] In certain embodiments, R^3 , R^4 , R^5 , and R^6 are the same. In certain embodiments, R^3 , R^5 , and R^6 are the same. In certain embodiments, R^3 or R^4 is H.

[0185] In certain embodiments, L^1 and L^2 are the same.

[0186] In certain embodiments, L^1 and L^2 are each independently alkyl; R^3 is H, -C(=O)-NH-(CH₂CH₂O)_j-GalNAc, or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R^4 is H, -C(=O)-NH-(CH₂CH₂O)_k-GalNAc, or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R^5 is -C(=O)-NH-(CH₂CH₂O)_m-GalNAc, or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; and R^6 is -C(=O)-NH-(CH₂CH₂O)_n-GalNAc, or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc.

[0187] In certain embodiments, L^1 and L^2 are each independently alkyl-C(=O)-NH-alkyl; R^3 is H, -C(=O)-NH-(CH₂CH₂O)_j-GalNAc, or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R^4 is H, -C(=O)-NH-(CH₂CH₂O)_k-GalNAc, or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R^5 is

-C(=O)-NH-(CH₂CH₂O)_m-GalNAc, or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; and R^6 is -C(=O)-NH-(CH₂CH₂O)_n-GalNAc, or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc.

[0188] In certain embodiments, R^4 is H.

[0189] In certain embodiments, L^1 and L^2 are each independently alkyl; R^3 is -C(=O)-NH-(CH₂CH₂O)_j-GalNAc, or -C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc; R^4 is H; R^5 is -

$C(=O)-NH-(CH_2CH_2O)_m-GalNAc$, or $-C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc$; and R^6 is $-C(=O)-NH-(CH_2CH_2O)_n-GalNAc$, or $-C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc$.


[0190] In certain embodiments, L^1 and L^2 are each independently $alkyl-C(=O)-NH-alkyl$; R^3 is

$-C(=O)-NH-(CH_2CH_2O)_j-GalNAc$, or $-C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc$; R^4 is H; R^5 is $-C(=O)-NH-(CH_2CH_2O)_m-GalNAc$, or $-C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc$; and R^6 is $-C(=O)-NH-(CH_2CH_2O)_n-GalNAc$, or $-C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc$.

[0191] In certain embodiments, R^3 is $-C(=O)-NH-(CH_2CH_2O)_j-GalNAc$; R^4 is H; R^5 is $-C(=O)-NH-(CH_2CH_2O)_m-GalNAc$; and R^6 is $-C(=O)-NH-(CH_2CH_2O)_n-GalNAc$.

[0192] In certain embodiments, R^3 is $-C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc$; R^4 is H; R^5 is $-C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc$; and R^6 is $-C(=O)-NH-alkyl-NH-C(=O)-alkyl-O-GalNAc$.

[0193] In certain embodiments, a compound or oligonucleotide comprises one or more subunits with the following formula or a salt, solvate, or hydrate thereof:



Formula X

wherein:

R^9 is H, adenine, guanine, thymine, cytosine, or uracil, or adenine, guanine, thymine, cytosine, or uracil, each comprising a Protecting Group (PG), a modified nucleobase, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, or a nucleobase isostere;

L is a bond, a phosphodiester bond, a phosphorothioate bond, a triazole, a tetrazole, an amide, a reverse-amide, a carbamate, a carbonate, urea, alkyl, or heteroalkyl;

R^2 is the oligonucleotide sequence;

Y_1 is O, CH_2 , CH_2O , or optionally substituted NH;

Y_2 is O, CH_2 , CH_2O , or optionally substituted NH;


Y_3 is CO, SO_2 , $P(O)O$, $CH_2-O-C(O)$, $CH_2-NH-C(O)$, $CH_2-NH-SO_2$, or CH_2 ;

Y_4 is CO, SO_2 , $P(O)O$, $CH_2-O-C(O)$, $CH_2-NH-C(O)$, $CH_2-NH-SO_2$, or CH_2 ;

n_2 is 0, 1, 2, 3, 4, 5, or 6; and

each n_1 , n_3 , n_4 and n_5 is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

[0194] In certain embodiments, a compound or oligonucleotide comprises one or more subunits with the following formula or a salt, solvate, or hydrate thereof:



Formula XI

wherein:

each n is independently 1, 2, 3, 4, or 5;

each m is independently 0, 1, 2, 3, 4, 5, or 6;

each o is independently 0, 1, 2, 3, 4, 5, or 6;


each of L_1 , L_2 , and L_3 is independently absent, $C(=O)$, or $C(=O)NH$;

each Y_1 is independently O, $CH(R^a)$, S, $S(=O)$, $S(=O)_2$, NH, substituted N group, $NHC(=O)$, $C(=O)NH$, $P(=O)_2-O-$, $P(=O)(=S)-O-$, $P(=S)_2-O-$, $-O-P(=O)_2-O-$, $-O-P(=O)(=S)-O-$, $-O-P(=S)_2-O-$, $-O-P(=O)_2-$, $-O-P(=O)(=S)-$, $-O-P(=S)_2-$;

each Y_2 is independently O, $CH(R^b)$, S, $S(=O)$, $S(=O)_2$, NH, substituted N group, $NHC(=O)$, $C(=O)NH$, $P(=O)_2-O-$, $P(=O)(=S)-O-$, $P(=S)_2-O-$, $-O-P(=O)_2-O-$, $-O-P(=O)(=S)-O-$, $-O-P(=S)_2-O-$, $-O-P(=O)_2-$, $-O-P(=O)(=S)-$, $-O-P(=S)_2-$;

each of Het_1 , Het_2 , and Het_3 is independently optionally substituted heteroaryl or optionally substituted heterocyclyl;

R¹ is the oligonucleotide sequence linked by a bond, a phosphodiester bond, a phosphorothioate bond, a triazole, a tetrazole, an amide, a reverse-amide, a carbamate, a carbonate, urea, alkyl, or heteroalkyl;



each R₅, R₆, and R₇ is independently

R₉ is optionally substituted heterocyclyl;

each R^a is independently H, alkyl, halo, OR^c, or SR^c;

each R^b is independently H, alkyl, halo, OR^c, or SR^c; and

each R^c is independently H or alkyl.

[0195] In certain embodiments, the subunit is selected from Formulae I through VIII or a salt, solvate, or hydrate thereof, wherein R is the modified oligonucleotide other than the 5' nucleoside. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula I and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula I and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula II and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula II and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula III and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula III and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula IV and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula IV and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula V and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula V and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VI and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VI and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VII and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VII and R' is S. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VIII and R' is O. In certain embodiments, the 5' nucleoside of the modified oligonucleotide is Formula VIII and R' is S.

Target Nucleic Acids and Target Regions

[0196] In certain embodiments, compounds described herein comprise or consist of an oligonucleotide comprising a region that is complementary to a target nucleic acid. In certain embodiments, the target nucleic acid is an endogenous RNA molecule. In certain embodiments, the target nucleic acid encodes a protein. In certain embodiments, the target nucleic acid is non-coding. In certain such embodiments, the target nucleic acid is selected from an mRNA and a pre-mRNA, including intronic, exonic and untranslated regions. In certain embodiments, the target RNA is an mRNA. In certain embodiments, the target nucleic acid is a pre-mRNA. In certain such embodiments, the target region is entirely within an exon. In certain such embodiments, the target region is entirely within an intron. In certain embodiments, the target region spans an intron/exon junction. In certain embodiments, the target region is at least 50% within an intron.

[0197] In certain embodiments, compounds disclosed herein hybridize with a AGT nucleic acid. The most common mechanism of hybridization involves hydrogen bonding between complementary nucleobases of the nucleic acid molecules. Hybridization can occur under varying conditions. Hybridization conditions are sequence-dependent and are determined by the nature and composition of the nucleic acid molecules to be hybridized. Methods of determining whether a sequence hybridizes specifically to a target nucleic acid are well known in the art. In certain embodiments, the compounds provided herein specifically hybridize with a AGT nucleic acid.

[0198] Nucleotide sequences that encode AGT include, without limitation, the following: GENBANK Accession Nos. NM_000029.4 (incorporated herein as SEQ ID NO: 1), the complement of nucleotides 230702523 to 230745583 of NC_000001.11 (incorporated herein as SEQ ID NO: 2), NM_001382817.3 (incorporated herein as SEQ ID NO: 3) and nucleotides 5469 to 17068 of NG_008836.2 (incorporated herein as SEQ ID NO: 4).

Complementarity

[0199] Oligonucleotides provided herein may have a defined percent complementarity to a particular nucleic acid, target region, oligonucleotide, or portion thereof. Non-complementary nucleobases may be tolerated provided that the oligonucleotide remains able to specifically hybridize to the nucleic acid, oligonucleotide, or portion thereof. In certain embodiments, the oligonucleotides provided herein, or a specified portion thereof are at least, or are up to 70%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% complementary to a target nucleic acid, a target region, an oligonucleotide or specified portion thereof. In certain embodiments, the oligonucleotides provided herein, or a specified portion thereof, are 70% to 75%, 75% to 80%, 80% to 85%, 85% to 90%, 90% to

95%, 95% to 100%, or any number in between these ranges, complementary to a target nucleic acid, a target region, an oligonucleotide or specified portion thereof. Percent complementarity of an oligonucleotide with a target nucleic acid, a target region, an oligonucleotide or specified portion thereof can be determined using routine methods. For example, an oligonucleotide in which 18 of 20 nucleobases of the oligonucleotide are complementary to a target region, and would therefore specifically hybridize, would represent 90 percent complementarity. In this example, the remaining non-complementary nucleobases may be clustered or interspersed with complementary nucleobases and need not be contiguous to each other or to complementary nucleobases. As such, an oligonucleotide which is 18 nucleobases in length having four non-complementary nucleobases which are flanked by two regions of complete complementarity with the target nucleic acid would have 77.8% overall complementarity with the target nucleic acid. Percent complementarity of an oligonucleotide with a region of a target nucleic acid, a target region, an oligonucleotide or specified portion thereof can be determined routinely using BLAST programs (basic local alignment search tools) known in the art. In certain embodiments, oligonucleotides described herein, or specified portions thereof, are fully complementary (i.e. 100% complementary) to a target nucleic acid, a target region, an oligonucleotide or specified portion thereof. For example, an oligonucleotide may be fully complementary to a target nucleic acid, a target region, an oligonucleotide, or specified portion thereof. As used herein, “fully complementary” means each nucleobase of an oligonucleotide is complementary to the corresponding nucleobase of a target nucleic acid, a target region, an oligonucleotide, or a specified portion thereof. For example, a 20 nucleobase oligonucleotide is fully complementary to a target sequence that is 400 nucleobases long, so long as there is a corresponding 20 nucleobase portion of the target nucleic acid that is fully complementary to the compound. “Fully complementary” can also be used in reference to a specified portion of the first and/or the second nucleic acid. For example, a 20 nucleobase portion of a 30 nucleobase oligonucleotide can be “fully complementary” to a 20 nucleobase region of a target sequence that is 400 nucleobases long. The 20 nucleobase portion of the 30 nucleobase compound is fully complementary to the target sequence if the target sequence has a corresponding 20 nucleobase portion wherein each nucleobase is complementary to the 20 nucleobase portion of the compound. At the same time, the entire 30 nucleobase compound may or may not be fully complementary to the target sequence, depending on whether the remaining 10 nucleobases of the compound are also complementary to the target sequence. In certain embodiments, oligonucleotides described herein comprise one or more mismatched

nucleobases relative to a target nucleic acid, a target region, an oligonucleotide or a specified portion thereof. In certain embodiments, oligonucleotides described herein that are, or are up to 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 nucleobases in length comprise no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, or specified portion thereof. In certain embodiments, oligonucleotides described herein that are, or are up to 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleobases in length comprise no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 non-complementary nucleobase(s) relative to a target nucleic acid, a target region, an oligonucleotide, or specified portion thereof. In certain embodiments, the mismatch is at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 from the 5'-end of the oligonucleotide. In certain embodiments, the mismatch is at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, 13 or 14 from the 3'-end of the oligonucleotide. In certain embodiments, the mismatch forms a wobble base pair with a corresponding nucleobase on the target nucleic acid. For example, in certain embodiments, the mismatch forms a wobble base pair selected from hypoxanthine (nucleobase of inosine) and uracil (I:U base pair); guanine and uracil (G:U base pair); hypoxanthine and adenine (I:A base pair); and hypoxanthine and cytosine (I:C base pair). Accordingly, in certain embodiments, a mismatched nucleobase on an oligonucleotide comprises hypoxanthine, guanine, or uracil.

[0200] In certain embodiments, oligonucleotides described herein may be complementary to a portion of a nucleic acid. As used herein, "portion" refers to a defined number of contiguous nucleobases within a region of a nucleic acid. A "portion" can also refer to a defined number of contiguous nucleobases of an oligonucleotide. In certain embodiments, the oligonucleotides are complementary to at least an 8 nucleobase portion of a nucleic acid. In certain embodiments, the oligonucleotides are complementary to at least a 9 nucleobase portion of a nucleic acid. In certain embodiments, the oligonucleotides are complementary to at least a 10 nucleobase portion of a nucleic acid. In certain embodiments, the oligonucleotides are complementary to at least an 11 nucleobase portion of a nucleic acid. In certain embodiments, the oligonucleotides are complementary to at least a 12 nucleobase portion of a nucleic acid. In certain embodiments, the oligonucleotides are complementary to at least a 13 nucleobase portion of a nucleic acid. In certain embodiments, the oligonucleotides are complementary to at least a 14 nucleobase portion of a nucleic acid. In certain embodiments, the oligonucleotides are complementary to at least a 15 nucleobase portion of a nucleic acid. In certain embodiments, the oligonucleotides are complementary to

at least a 16 nucleobase portion of a nucleic acid. Also contemplated are oligonucleotides that are complementary to at least a 9, 10, 17, 18, 19, 20, 21, 22, 23 or more nucleobase portion of a nucleic acid, or a range defined by any two of these values. In certain embodiments, the oligonucleotide is an antisense oligonucleotide. In certain embodiments, a portion of the antisense oligonucleotide is compared to an equal length portion of the target nucleic acid. In certain embodiments, an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion is compared to an equal length portion of the target nucleic acid. In certain embodiments, the oligonucleotide is a sense oligonucleotide. In certain embodiments, a portion of the sense oligonucleotide is compared to an equal length portion of an antisense oligonucleotide. In certain embodiments, an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion of a sense oligonucleotide is compared to an equal length portion of an antisense oligonucleotide.

Identity

[0201] The oligonucleotides provided herein may also have a defined percent identity to a particular nucleic acid, target region, oligonucleotide, or specified portion thereof. As used herein, an oligonucleotide is identical to a sequence disclosed herein if it has the same nucleobase pairing ability. For example, a DNA which contains thymidine in place of uracil in a disclosed RNA sequence would be considered identical to the RNA sequence since both uracil and thymidine pair with adenine. Shortened and lengthened versions of the compounds described herein as well as compounds having non-identical bases relative to the compounds provided herein also are contemplated. The non-identical bases may be adjacent to each other or dispersed throughout the compound. Percent identity of an oligonucleotide is calculated according to the number of bases that have identical base pairing relative to the sequence to which it is being compared. In certain embodiments, oligonucleotides described herein, or portions thereof, are, or are at least, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to one or more of the nucleic acids, oligonucleotides, or a portion thereof, disclosed herein. In certain embodiments, oligonucleotides described herein are about 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical, or any percentage between such values, to a particular nucleic acid or oligonucleotide, or portion thereof.

[0202] In certain embodiments, an oligonucleotide may have one or more mismatched nucleobases. In certain such embodiments, the mismatch is at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 from the 5'-end of the oligonucleotide. In certain such embodiments, the mismatch is at position 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12, 13 or 14 from the 3'-end of the

oligonucleotide. In certain embodiments, a portion of the oligonucleotide is compared to an equal length portion of the target nucleic acid. In certain embodiments, an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion is compared to an equal length portion of the target nucleic acid. In certain embodiments, the oligonucleotide is a sense oligonucleotide. In certain embodiments, a portion of the sense oligonucleotide is compared to an equal length portion of the target nucleic acid. In certain embodiments, an 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleobase portion is compared to an equal length portion of the target nucleic acid.

Pharmaceutical Compositions and Formulations

[0203] Compounds described herein may be admixed with pharmaceutically acceptable active or inert substances for the preparation of pharmaceutical compositions or formulations. Compositions and methods for the formulation of pharmaceutical compositions are dependent upon a number of criteria, including, but not limited to, route of administration, extent of disease, or dose to be administered. Certain embodiments provide pharmaceutical compositions comprising one or more compounds or a salt thereof. In certain embodiments, the compounds are antisense oligonucleotides. In certain embodiments, the compounds are oligomeric compounds. In certain embodiments, the compounds comprise or consist of one or more modified oligonucleotides. In certain such embodiments, the pharmaceutical composition comprises one or more compound and a suitable pharmaceutically acceptable diluent or carrier. In certain embodiments, a pharmaceutical composition comprises one or more compound and a sterile saline solution. In certain embodiments, such pharmaceutical composition consists of one compound and a sterile saline solution. In certain embodiments, the sterile saline is pharmaceutical grade saline. In certain embodiments, a pharmaceutical composition comprises one or more compound and sterile water. In certain embodiments, a pharmaceutical composition consists of one compound and sterile water. In certain embodiments, the sterile water is pharmaceutical grade water. In certain embodiments, a pharmaceutical composition comprises one or more compounds and phosphate-buffered saline (PBS). In certain embodiments, a pharmaceutical composition consists of one compound and sterile PBS. In certain embodiments, the sterile PBS is pharmaceutical grade PBS.

[0204] A compound described herein targeted to AGT can be utilized in pharmaceutical compositions by combining the compound with a suitable pharmaceutically acceptable diluent or carrier. In certain embodiments, a pharmaceutically acceptable diluent is water, such as sterile water suitable for injection. Accordingly, in one embodiment, employed in the

methods described herein is a pharmaceutical composition comprising a compound targeted to AGT and a pharmaceutically acceptable diluent. In certain embodiments, the pharmaceutically acceptable diluent is water. In certain embodiments, the compound comprises or consists of one or more modified oligonucleotide provided herein.

[0205] Pharmaceutical compositions comprising compounds provided herein encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other oligonucleotide which, upon administration to an animal, including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. In certain embodiments, the compounds are antisense oligonucleotides. In certain embodiments, the compounds are oligomeric compounds. In certain embodiments, the compound comprises or consists of one or more modified oligonucleotide. Accordingly, for example, the disclosure is also drawn to pharmaceutically acceptable salts of compounds, prodrugs, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents. Suitable pharmaceutically acceptable salts include, but are not limited to, sodium and potassium salts. A prodrug can include the incorporation of additional nucleosides at one or both ends of a compound which are cleaved by endogenous nucleases within the body, to form the active compound. In certain embodiments, the compounds or compositions further comprise a pharmaceutically acceptable carrier or diluent.

EXAMPLES

[0206] The following examples describe the process to identify lead compounds targeted to AGT. Certain compounds are distinguished as having high potency and tolerability.

[0207] The following examples serve only to illustrate the compounds described herein and are not intended to limit the same. The following examples and related sequence listing accompanying this filing may identify sequence as either “RNA” or “DNA”; however, as disclosed herein, those sequences may be modified with any combination of chemical modifications. One of skill in the art will readily appreciate that the designation of a sequence as “RNA” or “DNA” is, in certain instances, arbitrary. For example, an oligonucleotide comprising a nucleoside comprising a 2'-OH sugar moiety and a thymine base could be described as a DNA having a modified sugar (2'-OH for the natural 2'-H of DNA) or as an RNA having a modified base (methylated uracil for natural uracil of RNA). Accordingly, nucleic acid sequences provided herein, including, but not limited to, those in the sequence listing, are intended to encompass nucleic acids containing any combination of natural or

modified RNA and/or DNA, including, but not limited to, such nucleic acids having modified nucleobases.

[0208] Each of the references recited in the present application is incorporated herein by reference in its entirety.

Table 1
Chemical Nomenclature

Abbreviation	Structure
‘m’	2’-O-methyl sugar modification (e.g., mA, mG, mC, mU)
‘f’	2’-F sugar modification (e.g., fA, fG, fC, fU)
‘*’	phosphorothioate internucleoside linkage
‘.’	Phosphate internucleoside linkage
‘dQ’	inverted abasic deoxyribose
‘H1’	Formula I
‘H2’	Formula II
‘H4’	Formula III
‘H9’	Formula VI

Example 1 – Inhibition of AGT in HepG2 Cells

[0209] HepG2 cells (ATCC Cat #HB-8065) were seeded in antibiotic-free media at 10,000 cells/well in a 96-well plate. The following day, test AGT compound was diluted to 1.0 μ M (stock solution is 10 μ M). Transfection mixes were prepared according to instructions for Dharmafect 4 transfection reagent (Dharmacon Cat #T-2004-0). Prepared transfection mixtures were incubated at room temperature for 20 minutes. During this incubation, the medium was replaced in the 96-well plates with 80 μ l of antibiotic-free medium. 20 μ l of the transfection mixture was then added to each well for a final concentration of 10 nM (tested in triplicate). AGT siRNA SMARTpool (Dharmacon Cat # L-010988-00-0005) was used as a positive control. The cells were then incubated at 37°C in 5% CO₂ for 24 hours.

[0210] Cell lysis was performed according to the Cells-To-CT 1 Step TaqMan Kit instructions. Following cell lysis, the 96-well plate was placed on ice while the qRT-PCR reaction was prepared. 2 μ l of cell lysate was added to the reaction mixture containing 5 μ l TaqMan 1-Step qRT-PCR Mix, 1 μ l AGT(FAM) TaqMan Gene Expression Assay (Hs01586213_m1), 1 μ l GAPDH(VIC) TaqMan Gene Expression Assay (Hs02786624_g1) and 11 μ l RT-PCR grade nuclease-free water in a MicroAmp Optical 96-well plate (0.2 mL). qPCR was performed using a QuantStudio3 qPCR machine with the following cycles: 50°C for 1 minute, 95°C for 20 seconds and 40 cycles at 95°C for 15 seconds and 60°C for 1 minute. Results are presented in the tables below as percent inhibition of AGT, relative to

untreated control cells. Unless otherwise indicated in a separate compound chemistry table below, compounds are unmodified. Abbreviations for chemical modifications are provided in Table 1 above. IA and IS in a Ref ID NO:, identifies an antisense strand and sense strand of a compound, respectively.

Table 2
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO: 1 Start Site	SEQ ID NO: 1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD0588	134	154	UAUGUACACCCGGUCACCUGC	10	UGCAGGUGACCGGGUGUACAUAC	167	43
RD0592	144	164	UGAAGGGGUGUAUGUACACCC	15	CGGGUGUACAUACACCCCUCAA	173	26
RD0594	146	166	UUGGAAGGGGUGUAUGUACAC	17	GGUGUACAUACACCCCUCCAAC	175	62
RD0602	186	206	UUGCCAGCUGCUCACAGGUAC	27	AGUACCUGUGAGCAGCUGGCAAA	185	61
RD0604	274	294	UGUAGGGCCUUUUAUCCACA	30	CUGUGGAUGAAAAGGCCCUACAG	188	69
RD0605	361	381	UCCAAGAAGUUGGCCAGCAUC	33	GGAUGCUGGCCAACUUCUUGGAC	191	39
RD0607	367	387	UGGAAGCCCAAGAAGUUGGCC	35	UGGCCAACUUCUUGGGCUUCCA	193	55
RD0608	377	397	UCCAUAUAUACGGAAGCCCAA	37	CUUGGGCUUCCGUUAUAUUGGAA	195	68
RD0610	383	403	UUGCAUGCCAUUAUACGGAA	41	CUUCCGUUAUAUUGGCAUGCAAA	199	76
RD0611	384	404	UGUGCAUGCCAUUAUACGGA	42	UUCGUAUAUAUUGGCAUGCAG	200	60
RD0612	388	408	UCACUGUGCAUGCCAUUAUA	43	GUUAUAUUGGCAUGCAGUGAG	201	51
RD0613	396	416	UCCAUAGCUCACUGUGCAUGC	44	GGCAUGCAGUGAGCUAUGGAG	202	44
RD0618	454	474	UAGGCCAGGGUGCCAAAGACA	49	CUGUCUUUGGCACCCUGGCCU	207	48
RD0622	506	526	UAGGAUUGCCUGUAGCCUGUC	55	UGACAGGCUACAGGCAUCCUAG	213	60
RD0627	537	557	AGGUGCAGUUCUUGUCCUCC	60	UGGAAGGACAAGAACUGCACCUC	218	17
RD0628	538	558	UAGGUGCAGUUCUUGUCCUUC	61	GGAAGGACAAGAACUGCACCUC	219	52
RD0632	564	584	ACAGGACCUUGUGCGCAUCCA	66	CUGGAUGCGCACAAGGUCCUGUC	224	44
RD0634	584	604	UUGUACAGCCUGCAGGGCAGA	68	GUCUGCCCUGCAGGCUGUACAAG	226	22
RD0638	693	713	UCACAAACGGCUGCUUCAGGU	72	CACCUGAAGCAGCCGUUUGUGAA	230	46
RD0641	696	716	UCUGCACAAACGGCUGCUUCA	75	CUGAAGCAGCCGUUUGUGCAGAG	233	53
RD0648	793	813	ACAGCCUGCAUGAACCUGUCA	85	UUGACAGGUUCAUGCAGGCUGUG	243	76
RD0650	801	821	AUCCUGUCACAGCCUGCAUGA	87	UUCAUGCAGGCUGUGACAGGAUG	246	48

Table 3
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO: 1 Start Site	SEQ ID NO: 1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD0589	135	155	UUAUGUACACCCGGUCACCUG	11	GCAGGUGACCGGGUGUACAUAAA	168	49
RD0595	151	171	ACGAGGUGGAAGGGGUGUAUG	18	ACAUAACCCCUUCCACCUCGUC	176	65
RD0596	152	172	UACGAGGUGGAAGGGGUGUAU	19	CAUACACCCCUUCCACCUCGUAA	177	47
RD0597	153	173	UGACGAGGUGGAAGGGGUGUA	20	AUACACCCCUUCCACCUCGUCAU	178	74
RD0598	154	174	AUGACGAGGUGGAAGGGGUGU	21	UACACCCCUUCCACCUCGUCAUC	179	88
RD0599	155	175	UAUGACGAGGUGGAAGGGGUG	22	ACACCCCUUCCACCUCGUCAUAC	180	60
RD0600	156	176	UGAUGACGAGGUGGAAGGGGU	23	CACCCCUUCCACCUCGUCAUCAA	181	80

Compound Number	Seq ID NO: 1 Start Site	SEQ ID NO: 1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD0601	185	205	UGCCAGCUGCUCACAGGUACU	26	GAGUACCUUGAGCAGCUGGCAA	184	77
RD0603	187	207	UUUGCCAGCUGCUCACAGGUA	28	GUACCUUGAGCAGCUGGCAAAG	186	93
RD0606	362	382	UCCCAAGAAGUUGGCCAGCAU	34	GAUGCUGGCCAACUUCUUGGGAU	192	22
RD0614	397	417	UCCCAUAGCUCACUGUGCAUG	45	GCAUGCACAGUGAGCUAUGGGAC	203	85
RD0615	404	424	UACCACGCCCAUAGCUCACU	46	CAGUGAGCUAUGGGGCGUGGUAC	204	73
RD0616	448	468	AGGGUGCCAAAGACAGCCGUU	47	CAACGGCUGUCUUUGGCACCCUG	205	63
RD0617	449	469	UAGGGUGCCAAAGACAGCCGU	48	AACGGCUGUCUUUGGCACCCUAG	206	95
RD0619	462	482	UAUAGAGAGAGGCCAGGGUGC	50	GGCACCCUGGCCUCUCUCUAUAU	208	86
RD0620	463	483	AGAUAGAGAGAGGCCAGGGUG	51	GCACCCUGGCCUCUCUCUAUCUG	209	80
RD0621	505	525	AGGAUUGCCUGUAGCCUGCA	54	CUGACAGGCUACAGGCAAUCCUG	212	74
RD0623	507	527	UCAGGAUUGCCUGUAGCCUGU	56	GACAGGCUACAGGCAAUCCUGAG	214	81
RD0624	508	528	UCCAGGAUUGCCUGUAGCCUG	57	ACAGGCUACAGGCAAUCCUGGAU	215	66
RD0625	509	529	ACCCAGGAUUGCCUGUAGCCU	58	CAGGCUACAGGCAAUCCUGGGUG	216	77
RD0626	510	530	UACCCAGGAUUGCCUGUAGCC	59	AGGCUACAGGCAAUCCUGGGUAU	217	51
RD0630	540	560	UGGAGGUGCAGUUCUUGUCCU	63	AAGGACAAGAACUGCACCUCAG	221	68
RD0631	563	583	UAGGACCUUGUGCGCAUCCAG	65	GCUGGAUGCGCACAAGGUCCUAU	223	67
RD0633	565	585	UACAGGACCUUGUGCGCAUCC	67	UGGAUGCGCACAAGGUCCUGUAU	225	65
RD0635	594	614	UUAGCAGGCCCUUACAGCCU	69	CAGGCUGUACAGGGCCUGCUAAU	227	34
RD0636	691	711	ACAAACGGCUGCUUCAGGUGC	70	UGCACCUGAAGCAGCCGUUUGUG	228	62
RD0637	692	712	UACAAACGGCUGCUUCAGGUG	71	GCACCUGAAGCAGCCGUUUGUAC	229	84
RD0639	694	714	UGCACAAACGGCUGCUUCAGG	73	ACCUGAAGCAGCCGUUUGUGCAG	231	82
RD0640	695	715	UUGCACAAACGGCUGCUUCAG	74	CCUGAAGCAGCCGUUUGUGCAAG	232	89
RD0642	713	733	UGUAUAGAGAGCCAGGCCUG	76	GCAGGGCCUGGCUCUCUAUACAC	234	92
RD0643	747	767	UUGUGAAGUCCAGAGAGCGUG	78	CCACGCUCUCUGGACUUCACAAA	236	75
RD0644	748	768	UCUGUGAAGUCCAGAGAGCGU	80	CACGCUCUCUGGACUUCACAGAA	238	78
RD0645	749	769	UUCUGUGAAGUCCAGAGAGCG	81	ACGCUCUCUGGACUUCACAGAAC	239	65
RD0646	750	770	UUUCUGUGAAGUCCAGAGAGC	82	CGCUCUCUGGACUUCACAGAAU	240	89
RD0649	794	814	UACAGCCUGCAUGAACCUUGC	86	UGACAGGUUCAUGCAGGCUGUAA	245	78
RD0650	801	821	AUCCUGUCACAGCCUGCAUGA	87	UUAUGCAGGCUGUGACAGGAUG	246	35
RD0651	802	822	UAUCCUGUCACAGCCUGCAUG	88	UCAUGCAGGCUGUGACAGGAUAG	247	82
RD0652	803	823	UCAUCCUGUCACAGCCUGCAU	89	CAUGCAGGCUGUGACAGGAUGAA	248	76
RD0653	804	824	UCCAUCCUGUCACAGCCUGCA	90	AUGCAGGCUGUGACAGGAUGGAA	249	91
RD0654	805	825	UUCCAUCCUGUCACAGCCUGC	91	UGCAGGCUGUGACAGGAUGAAG	250	79
RD0655	806	826	UUUCCAUCCUGUCACAGCCUG	93	GCAGGCUGUGACAGGAUGGAAA	252	94
RD0656	871	891	AAGUGGACGUAGGUGUUGAAA	95	CUUUAACACCUACGUCCACUUC	254	62
RD0657	936	956	UGCUGUUGUCCACCCAGAACU	96	GAGUUCUGGGUGGACAACAGCAC	255	25
RD0658	937	957	UUGCUGUUGUCCACCCAGAAC	97	AGUUCUGGGUGGACAACAGCAAC	256	71

Table 4
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD0659	946	966	UACACUGAGGUGCUGUUGUCC	98	UGGACAACAGCACCUCAGUGUAU	257	76
RD0660	990	1010	UACUCCAGUGCUGGAAGGUGC	99	GGCACCUUCCAGCACUGGAGUAA	258	56
RD0661	991	1011	UCACUCCAGUGCUGGAAGGUG	100	GCACCUUCCAGCACUGGAGUGAC	259	55
RD0662	1087	1107	ACCUUGUCCAGGUCAGAGGCA	104	AUGCCUCUGACCUGGACAAGGUG	263	54
RD0663	1088	1108	UACCUUGUCCAGGUCAGAGGC	106	UGCCUCUGACCUGGACAAGGUAG	265	20
RD0664	1089	1109	UCACCUUGUCCAGGUCAGAGG	107	GCCUCUGACCUGGACAAGGUGAA	266	15
RD0665	1090	1110	UCCACCUUGUCCAGGUCAGAG	108	CCUCUGACCUGGACAAGGUGGAG	267	27

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD0666	1091	1111	UUCCACCUUGUCCAGGUCAGA	109	CUCUGACCUGGACAAGGUGGAAG	268	13
RD0667	1099	1119	UUGAGACCCUCCACCUUGUCC	110	UGGACAAGGUGGAGGGUCUCAAU	269	69
RD0668	1109	1129	UUGCUGGAAAGUGAGACCCUC	113	GGAGGGUCUCACUUUCCAGCAAA	272	73
RD0669	1166	1186	UGGCAUGGUCAGGUGGAUGGU	116	GACCAUCCACCUGACCAUGCCAC	275	41
RD0670	1169	1189	UUUGGGCAUGGUCAGGUGGAU	117	CAUCCACCUGACCAUGCCCCAAC	276	63
RD0671	1170	1190	UUUGGGGCAUGGUCAGGUGGA	118	AUCCACCUGACCAUGCCCCAAAU	277	24
RD0672	1200	1220	UCUGCAGGUAUAGAUAUCCU	119	CAAGGAUCUUUAUGACCUGCAGAA	278	53
RD0673	1201	1221	UCCUGCAGGUAUAGAUAUCCU	120	AAGGAUCUUUAUGACCUGCAGGAC	279	46
RD0674	1202	1222	UUCCUGCAGGUAUAGAUAUCC	121	AGGAUCUUUAUGACCUGCAGGAAC	280	0
RD0675	1209	1229	UGAGCAGGUCCUGCAGGUCAU	122	UAUGACCUGCAGGACCUGCUCAC	281	11
RD0676	1263	1283	UCAAUUUUUUGCAGGUUCAGCU	123	GAGCUGAACCUGCAAAAAUUGAG	282	62
RD0677	1264	1284	UUCAAUUUUUUGCAGGUUCAGC	124	AGCUGAACCUGCAAAAAUUGAAC	283	64
RD0678	1343	1363	UUCUGUGGGCUCUCUCUCAUC	125	GGAUGAGAGAGAGCCCACAGAAU	284	57
RD0679	1350	1370	UGGUAGACUCUGUGGGCUCUC	126	AGAGAGCCCACAGAGUCUACCAA	285	61
RD0680	1351	1371	UGGGUAGACUCUGUGGGCUCU	127	GAGAGCCCACAGAGUCUACCCAA	286	74
RD0591	143	163	UAAGGGGUGUAUGUACACCCG	14	CCGGGUGUAUACACCCCUUAC	172	45
RD0593	145	165	UGGAAGGGGUGUAUGUACACC	16	GGGUGUAUACACCCCUUCCAC	174	33
RD0609	382	402	UGCAUGCCAUAUAUACGGAAG	39	GCUUCCGUUAUAUUGGCAUGCAC	197	41
RD0681	1352	1372	UUUGGGUAGACUCUGUGGGCUC	128	AGAGCCCACAGAGUCUACCCAAC	287	73
RD0682	1353	1373	UUUGGGUAGACUCUGUGGGCU	129	GAGCCCACAGAGUCUACCCAAAA	288	88
RD0683	1603	1623	AGAAAAGGUGGGAGACUGGGG	138	CCCCAGUCUCCACCUUUUUCU	299	89
RD0684	1617	1637	UUCGACUCAUAAGAAGAAAAG	140	CCUUUUUCUUAUAUGAGUCGAU	301	87
RD0685	1758	1778	UACUGGUUCUUGCCUCCCCAC	143	GGUGGGGAGGCAAGAACCAGUAU	304	87
RD0686	1759	1779	ACACUGGUUCUUGCCUCCCCA	144	GUGGGGAGGCAAGAACCAGUGUU	305	86
RD0687	1760	1780	AACACUGGUUCUUGCCUCCCC	145	UGGGGAGGCAAGAACCAGUGUUU	306	83
RD0688	1761	1781	AAACACUGGUUCUUGCCUCCC	147	GGGGAGGCAAGAACCAGUGUUUA	308	80
RD0689	1771	1791	UUCCCGCGCUAAACACUGGUU	152	GAACCAGUGUUUAGCGCGGGAAU	313	86
RD0690	1772	1792	AGUCCCGCGCUAAACACUGGU	153	AACCAGUGUUUAGCGCGGGACUA	314	71
RD0691	1773	1793	UAGUCCCGCGCUAAACACUGG	154	ACCAGUGUUUAGCGCGGGACUAC	315	78
RD0692	1774	1794	UUAGUCCCGCGCUAAACACUG	155	CCAGUGUUUAGCGCGGGACUAAU	316	79
RD0693	1795	1815	UUUGGAAUUCUUUUGGAACA	157	CUGUCCAAAAAGAAUUCCAAAC	318	75
RD0694	1800	1820	UGUCGGUUGGAAUUCUUUUUG	158	CCAAAAAGAAUCCAACCGACAA	319	85

Table 5
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD0590	142	162	AAGGGGUGUAUGUACACCCGG	13	ACCGGGUGUAUACACCCCUUC	171	61
RD0598	154	174	AUGACGAGGUGGAAGGGGUGU	21	UACACCCCUUCCACCUCGUCAUC	179	67
RD0608	377	397	UCCAUAUAUACGGAAGCCCAA	37	CUUGGGCUUCCGUUAUAUUGGAA	195	67
RD0617	449	469	UAGGGUGCCAAAGACAGCCGU	48	AACGGCUGUCUUUGGCACCCUAG	206	75
RD0629	539	559	UGAGGUGCAGUUCUUGUCCUU	62	GAAGGACAAGACUGCACCUCAC	220	50
RD0642	713	733	UGUAUAGAGAGCCAGGCCUG	76	GCAGGGCCUGGCUCUCUAUACAC	234	75
RD0646	750	770	UUUCUGUGAAGUCCAGAGAGC	82	CGCUCUCUGGACUUCACAGAAAU	240	75
RD0647	751	771	AGUUCUGUGAAGUCCAGAGAG	83	GCUCUCUGGACUUCACAGAACUG	241	68
RD0653	804	824	UCCAUCCUGUCACAGCCUGCA	90	AUGCAGGCUUGACAGGAUGGAA	249	78
RD0655	806	826	UUUCCAUCCUGUCACAGCCUG	93	GCAGGCUUGACAGGAUGGAAAA	252	88

Table 6
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD0608	377	397	UCCAUAUAUACGGAAGCCCAA	37	CUUGGGCUUCCGUUAUAUAUGGAA	195	73
RD0653	804	824	UCCAUCCUGUCACAGCCUGCA	90	AUGCAGGCUGUGACAGGAUGGAA	249	86
RD0655	806	826	UUUCCAUCCUGUCACAGCCUG	93	GCAGGCUGUGACAGGAUGGAAAA	252	88
RD1033	376	397	UCCAUAUAUACGGAAGCCCGUA	36	UACGGGCUUCCGUUAUAUAUGGAU	194	21

Table 7
Compound Chemistry

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD1033	mU*fc*mC.mA.mU.fA.mU.fA.mU.mA.mC.mG.mG.fA.mA.fG.mC.mC.mC*fg*mU.mA	IA0297	36
	H1.mA*mC.mG.fG.mG.mC.fU.mU.mC.fC.fG.fU.mA.mU.fA.mU.mA.fU.mG.mG*mA*mU	IS0297	194

Table 8
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD0608	377	397	UCCAUAUAUACGGAAGCCCAA	37	CUUGGGCUUCCGUUAUAUAUGGAA	195	79
RD0653	804	824	UCCAUCCUGUCACAGCCUGCA	90	AUGCAGGCUGUGACAGGAUGGAA	249	82
RD0655	806	826	UUUCCAUCCUGUCACAGCCUG	93	GCAGGCUGUGACAGGAUGGAAAA	252	88
RD1033	376	397	UCCAUAUAUACGGAAGCCCGUA	36	UACGGGCUUCCGUUAUAUAUGGAU	194	45
RD1045	805	826	UUUCCAUCCUGUCACAGCCUCA	92	UGAGGCUGUGACAGGAUGGAAAU	251	66

Table 9
Compound Chemistry

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD1033	mU*fc*mC.mA.mU.fA.mU.fA.mU.mA.mC.mG.mG.fA.mA.fG.mC.mC.mC*fg*mU.mA	IA0297	36
	H1.mA*mC.mG.fG.mG.mC.fU.mU.mC.fC.fG.fU.mA.mU.fA.mU.mA.fU.mG.mG*mA*mU	IS0297	194
RD1045	mU*fU*mU.mC.mC.fA.mU.fC.mC.mU.mG.mU.mC.fA.mC.fA.mG.mC.mC*fU*mC.mA	IA0304	92
	H1.mG*mA.mG.fG.mC.mU.fG.mU.mG.fA.fC.fA.mG.mG.fA.mU.mG.fG.mA.mA*mA*mU	IS0303	251

Table 10
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition

RD1033	376	397	UCCAUAUAUACGGAAGCCCGUA	36	UACGGGCUUCCGUUAUAUUGGAU	194	35
RD1036	747	768	UCUGUGAAGUCCAGAGAGCGUA	79	UACGCUCUCUGGACUUCACAGAU	237	29
RD1037	1760	1781	UAACACUGGUUCUUGCCUCGGA	146	UCCGAGGCAAGAACCAGUGUUAU	307	83
RD1045	805	826	UUUCCAUCUGUCACAGCCUCA	92	UGAGGCUUGACAGGAUGGAAAU	251	66
RD1046	382	403	AUGCAUGCCAUAUAUACGGUGA	40	UCACCGUAUAUUGGCAUGCAUU	198	22

Table 11
Compound Chemistry

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD1033	mU*fc*mC.mA.mU.fA.mU.fA.mU.mA.mC.mG.mG.fA.mA.fG.mC.mC.mC*fg*mU.mA	IA0297	36
	H1.mA*mC.mG.fG.mG.mC.fU.mU.mC.fC.fG.fU.mA.mU.fA.mU.mA.fU.mG.mG*mA*mU	IS0297	194
RD1036	mU*fc*mU.mG.mU.fG.mA.fA.mG.mU.mC.mC.mA.fG.mA.fG.mA.mG.mC*fg*mU.mA	IA0300	79
	H1.mA*mC.mG.fC.mU.mC.fU.mC.mU.fG.fG.fA.mC.mU.fU.mC.mA.fC.mA.mG*mA*mU	IS0300	237
RD1037	mU*fA*mA.mC.mA.fC.mU.fG.mG.mU.mU.mC.mU.fU.mG.fC.mC.mU.mC*fg*mG.mA	IA0301	146
	H1.mC*mC.mG.fA.mG.mG.fC.mA.mA.fG.fA.fA.mC.mC.fA.mG.mU.fG.mU.mU*mA*mU	IS0301	307
RD1045	mU*fU*mU.mC.mC.fA.mU.fC.mC.mU.mG.mU.mC.fA.mC.fA.mG.mC.mC*fU*mC.mA	IA0304	92
	H1.mG*mA.mG.fG.mC.mU.fG.mU.mG.fA.fC.fA.mG.mG.fA.mU.mG.fG.mA.mA*mA*mU	IS0303	251
RD1046	mA*fU*mG.mC.mA.fU.mG.fC.mC.mA.mU.mA.mU.fA.mU.fA.mC.mG.mG*fU*mG.mA	IA0305	40
	H1.mC*mA.mC.fC.mG.mU.fA.mU.mA.fU.fA.fU.mG.mG.fC.mA.mU.fG.mC.mA*mU*mU	IS0304	198

Table 12
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD1298	1104	1125	UGGAAAGUGAGACUCCACCA	111	UGGUGGAGAGUCACACUUCCA	270	27

Table 13
Compound Chemistry

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD1298	mU*fg*mG.mA.mA.fA.mG.fU.mG.mA.mG.mA.mC.fU.mC.fU.mC.mC.mA*fc*mC.mA	IA0335	111
	H1.mG*mG.mU.fG.mG.mA.fG.mA.mG.fU.fC.fU.mC.mA.fC.mU.mU.fU.mC.mC*mA*mU	IS0334	270

Table 14
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD1270	136	156	UGUAUGUACACCCIGUCACCU	12	UAGGUGACCGGGUGUACAUACAU	169	66
RD1271	263	283	UUCAUCCACAGGGIAUGUCUC	29	UGAGACAUCCCUUGUGGAUGAAU	187	39
RD1272	464	484	UAGAUAGAGAGAGICAGGGU	52	UACCCUGGCCUCUCUCUAUCUAU	210	59
RD1273	862	882	UAGGUGUUGAAAGUCAGGGUG	94	UCACCCUGACUUUAACACCUAU	253	83
RD1274	993	1013	UGUCACUCCAGUGUUGGAAGG	101	UCCUCCAACACUGGAGUGACAU	260	69

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD1275	1035	1055	UCUCAGUGAAGGGUACUUGAG	103	UCUCAAGUACCCUUCACUGAGAU	262	71
RD1276	1105	1125	UGGAAAGUGAGACUCCACC	112	UGGUGGAGAGUCUCACUUCCA	270	73
RD1278	1408	1428	UCAACAGGAAUGIGCGGUUC	131	UGAACCGCCCAUUCUGUUUGAU	290	81
RD1279	1413	1433	ACACAGCAAACAGIAAUGGGC	132	UGCCCAUUCUGUUUGCUGUGUU	291	62
RD1280	1420	1440	UGAUCAUACACAGUAAACAGG	134	UCCUGUUUACUGUGUAUGAUCAU	293	75
RD1281	1649	1669	ACCAAGGAGAAACIGCUGCUU	141	UAAGCAGCCGUUUCUCCUUGGUU	302	86
RD1282	1678	1698	CUACUGCUCACUCUAUGCAGC	142	UGCUGCAUAGAGUGAGCAGUAGU	303	40
RD1283	1781	1801	UGGAACAGUAGUCUCGCGCUA	156	UUAGCGGAGACUACUGUCCA	317	84
RD1284	1841	1861	CAACUUGAAAAGGIAACACUG	159	UCAGUGUCCCUUUUCAAGUUGU	320	78
RD1285	1842	1862	UCAACUUGAAAAGIGAACACU	160	UAGUGUCCCUUUUCAAGUUGAU	321	87
RD1286	1842	1862	UCAACUUGAAAAGIGAACACG	161	UCGUGUCCCUUUUCAAGUUGAU	322	87
RD1287	1900	1920	UACAAACCGAAGGUAAUGCAA	162	UUUGCAUUACCUUCGGUUUGUAU	323	36
RD1288	1900	1920	UACAAACCGAAGGUAAUGCAG	163	UCUGCAUUACCUUCGGUUUGUAU	324	39
RD1289	1906	1926	ACUAAAUAACAAACUGAAGGCG	164	UCGCCUUCAGUUUGUAUUAGUU	325	22
RD1290	1945	1965	ACAGACACUACACIGAGGUCA	165	UUGACCUCCGUGUAGUGUCUGUU	326	21
RD1291	1945	1965	ACAGACACUACACIGAGGUCG	166	UCGACCUCCGUGUAGUGUCUGUU	327	27
RD1292	163	183	UCAUUGUGGAUGAUGAGGUGG	25	UCCACCUCACUACUCCACAAUGAU	182	70
RD1298	1104	1125	UGGAAAGUGAGACUCCACCA	111	UGGUGGAGAGUCUCACUUCCA	270	9

Table 15
Compound Chemistry

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD1298	mU*fG*mG.mA.mA.fA.mG.fU.mG.mA.mG.mA.mC.fU.mC.fU.mC.mC.mA*fC*mC.mA	IA0335	111
	H1.mG*mG.mU.fG.mG.mA.fG.mA.mG.fU.fC.fU.mC.mA.fC.mU.mU.fU.mC.mC*mA*mU	IS0334	270

Table 16
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD1277	1407	1427	UAAACAGGAAUGGICGGUUA	130	UUGAACCGCCCAUUCUGUUUAU	289	17
RD1324	1104	1125	UGGAAAGUGAGACUCCACCA	111	UGGUGGAGAGUCUCACUUCCA	270	65
RD1354	162	183	UCAUUGUGGAUGAUGAGGUGGA	24	UCCACCUCACUACUCCACAAUGAU	182	44
RD1355	736	757	UAGAGAGCGUGGGAGGACCACA	77	UGUGGUCCUCCACGCUCUCUAU	235	83
RD1356	769	790	UUUCUCAGCAGCAACAUCAGAG	84	UCUGGAUGUUGCUGCUGAGAAAU	242	55
RD1377	1019	1041	ACUUGAGUCACCGAGAAGUUGGA	102	UCCAACUUCUCGGUGACUCAAGUU	261	85
RD1378	304	325	AAGUUUUGCAGCGACUAGCACA	31	UGUGCUAGUCGUGCAAAACUUU	189	12
RD1379	483	504	UCUGUGUGGUCCAAGGCUCCCA	53	UGGGAGCCUUGGACCACACAGAU	211	34
RD1380	556	577	UUUGUGCGCAUCCAGCCGGGAA	64	UUCCCGGCGUGGAUGCGCACAAU	222	66

Table 17
Compound Chemistry

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD1324	mU*fg*mG.mA.mA.fA.mG.fU.mG.mA.mG.mA.mC.fU.mC.fU.mC.mC.mA*fc*mC.mA	IA0335	111
	H2.mG*mG.mU.fG.mG.mA.fG.mA.mG.fU.fC.fU.mC.mA.fC.mU.mU.fU.mC.mC*mA*mU	IS0336	270
RD1354	mU*fc*mA.mU.mU.fG.mU.fG.mG.mA.mU.mG.mA.fU.mG.fA.mG.mG.mU*fg*mG.mA	IA0336	24
	H2.mC*mC.mA.fC.mC.mU.fC.mA.mU.fC.fA.fU.mC.mC.fA.mC.mA.fA.mU.mG*mA*mU	IS0340	182
RD1355	mU*fa*mG.mA.mG.fA.mG.fC.mG.mU.mG.mG.mG.fA.mG.fG.mA.mC.mC*mA*mC.mA	IA0337	77
	H2.mG*mU.mG.fG.mU.mC.fC.mU.mC.fC.fC.fA.mC.mG.fC.mU.mC.fU.mC.mU*mA*mU	IS0344	235
RD1356	mU*fU*mU.mC.mU.fC.mA.fG.mC.mA.mG.mC.mA.fA.mC.fA.mU.mC.mC*mA*mG.mA	IA0338	84
	H2.mC*mU.mG.fG.mA.mU.fG.mU.mU.fG.fC.fU.mG.mC.fU.mG.mA.fG.mA.mA*mA*mU	IS0345	242
RD1377	mA*fc*mU.fU.mG.fA.mG.fU.mC.fA.mC.fC.mG.fA.mG.fA.mA.fG.mU.fU*mG*mG.mA	IA0343	102
	H2.mC*mC.mA.mA.fC.mU.mU.fC.mU.mC.fG.fG.fU.mG.mA.fC.mU.mC.fA.mA.mG*mU*mU	IS0346	261
RD1378	mA*fa*mG.fU.mU.fU.mU.fG.mC.fA.mG.fC.mG.fA.mC.fU.mA.fG.mC*fa*mC.mA	IA0344	31
	H2.mG*mU*mG.fC.mU.mA.fG.mU.mC.fG.fC.fU.mG.mC.fA.mA.mA.fA.mC.mU*mU*mU	IS0347	189
RD1379	mU*fc*mU.fG.mU.fG.mU.fG.mG.fU.mC.fC.mA.fA.mG.fG.mC.fU.mC*fc*mC.mA	IA0345	53
	H2.mG*mG*mG.fA.mG.mC.fC.mU.mU.fG.fG.fA.mC.mC.fA.mC.mA.fC.mA.mG*mA*mU	IS0348	211
RD1380	mU*fU*mU.fG.mU.fG.mC.fG.mC.fA.mU.fC.mC.fA.mG.fC.mC.fG.mG*fg*mA.mA	IA0346	64
	H2.mU*mC*mC.fC.mG.mG.fC.mU.mG.fG.fA.fU.mG.mC.fG.mC.mA.fC.mA.mA*mA*mU	IS0349	222

Table 18
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD0608	377	397	UCCAUAUAUACGGAAGCCCAA	37	CUUGGGCUUCCGUUAUAUUGGAA	195	74
RD0644	748	768	UCUGUGAAGUCCAGAGAGCGU	80	CACGCUCUCUGGACUUCACAGAA	238	66
RD0655	806	826	UUUCCAUCUGUCACAGCCUG	93	GCAGGCUGUGACAGGAUGGAAAA	252	94
RD0688	1761	1781	AAACACUGGUUCUUGCCUCCC	147	GGGGAGGCAAGAACCAGUGUUUA	308	88
RD1389	376	397	UCCAUAUAUACGGAAGCCCGUA	36	UACGGGCUUCCGUUAUAUUGGAU	194	40
RD1390	747	768	UCUGUGAAGUCCAGAGAGCGUA	79	UACGCUCUCUGGACUUCACAGAU	237	18
RD1392	805	826	UUUCCAUCUGUCACAGCCUCA	92	UGAGGCUGUGACAGGAUGGAAAU	251	33
RD1402	376	397	UCCAUAUAUACGGAAGCCCGUA	36	UACGGGCUUCCGUUAUAUUGGAU	194	81
RD1403	747	768	UCUGUGAAGUCCAGAGAGCGUA	79	UACGCUCUCUGGACUUCACAGAU	237	61
RD1405	805	826	UUUCCAUCUGUCACAGCCUCA	92	UGAGGCUGUGACAGGAUGGAAAU	251	71
RD1415	376	397	UCCAUAUAUACGGAAGCCCGUA	36	UACGGGCUUCCGUUAUAUUGGAU	194	77
RD1416	747	768	UCUGUGAAGUCCAGAGAGCGUA	79	UACGCUCUCUGGACUUCACAGAU	237	65
RD1418	805	826	UUUCCAUCUGUCACAGCCUCA	92	UGAGGCUGUGACAGGAUGGAAAU	251	81
RD1037	1760	1781	UAACACUGGUUCUUGCCUCGGA	146	UCCGAGGCAAGAACCAGUGUUAU	307	87
RD1033	376	397	UCCAUAUAUACGGAAGCCCGUA	36	UACGGGCUUCCGUUAUAUUGGAU	194	30
RD1045	805	826	UUUCCAUCUGUCACAGCCUCA	92	UGAGGCUGUGACAGGAUGGAAAU	251	50

Table 19
Compound Chemistry

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD1389	mU*fc*mC.fA.mU.fA.mU.fA.mU.fA.mC.fG.mG.fA.mA.fG.mC.fC.mC.fG*mU.mA	IA0347	36
	mU.mA*mC*mG.fG.mG.mC.fU.mU.fC.mC.fG.fU.mA.mU.fA.mU.mA.fU.mG.mG*mA*mU	IS0350	194
RD1390	mU*fc*mU.fG.mU.fG.mA.fA.mG.fU.mC.fC.mA.fG.mA.fG.mA.fG.mC.fG*mU.mA	IA0348	79
	mU.mA*mC*mG.fC.mU.mC.fU.mC.fU.mG.fG.fA.mC.mU.fU.mC.mA.fC.mA.mG*mA*mU	IS0351	237
RD1392	mU*fU*mU.fC.mC.fA.mU.fC.mC.fU.mG.fU.mC.fA.mC.fA.mG.fC.mC.fU*mC.mA	IA0350	92
	mU.mG*mA*mG.fG.mC.mU.fG.mU.fG.mA.fC.fA.mG.mG.fA.mU.mG.fG.mA.mA*mA*mU	IS0353	251
RD1402	mU*fc*mC.fA.mU.fA.mU.fA.mU.fA.mC.fG.mG.fA.mA.fG.mC.fC.mC.fG*mU.mA	IA0347	36

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD1403	mU.mA*mC*mG.fG.mG.mC.fU.mU.fC.fC.fG.fU.mA.mU.fA.mU.mA.fU.mG.mG*mA*mU	IS0363	194
	mU*fC*mU.fG.mU.fG.mA.fA.mG.fU.mC.fC.mA.fG.mA.fG.mA.fG.mC.fG*mU.mA	IA0348	79
	mU.mA*mC*mG.fC.mU.mC.fU.mC.fU.fG.fG.fA.mC.mU.fU.mC.mA.fC.mA.mG*mA*mU	IS0364	237
RD1405	mU*fU*mU.fC.mC.fA.mU.fC.mC.fU.mG.fU.mC.fA.mC.fA.mG.fC.mC.fU*mC.mA	IA0350	92
	mU.mG*mA*mG.fG.mC.mU.fG.mU.fG.fA.fC.fA.mG.mG.fA.mU.mG.fG.mA.mA*mA*mU	IS0366	251
RD1415	mU*fC*mC.fA.mU.fA.mU.fA.mU.fA.mC.fG.mG.fA.mA.fG.mC.fC.mC.fG*mU.mA	IA0347	36
	mU.mA*mC*mG.mG.mG.mC.fU.mU.fC.fC.fG.fU.mA.mU.mA.mU.mA.mU.mG.mG*mA*mU	IS0376	194
RD1416	mU*fC*mU.fG.mU.fG.mA.fA.mG.fU.mC.fC.mA.fG.mA.fG.mA.fG.mC.fG*mU.mA	IA0348	79
	mU.mA*mC*mG.mC.mU.mC.fU.mC.fU.fG.fG.fA.mC.mU.mU.mC.mA.mC.mA.mG*mA*mU	IS0377	237
RD1418	mU*fU*mU.fC.mC.fA.mU.fC.mC.fU.mG.fU.mC.fA.mC.fA.mG.fC.mC.fU*mC.mA	IA0350	92
	mU.mG*mA*mG.mG.mC.mU.fG.mU.fG.fA.fC.fA.mG.mG.mA.mU.mG.mG.mA.mA*mA*mU	IS0379	251
RD1037	mU*fA*mA.mC.mA.fC.mU.fG.mG.mU.mU.mC.mU.fU.mG.fC.mC.mU.mC*fG*mG.mA	IA0301	146
	H1.mC*mC.mG.fA.mG.mG.fC.mA.mA.fG.fA.fA.mC.mC.fA.mG.mU.fG.mU.mU*mA*mU	IS0301	307
RD1033	mU*fC*mC.mA.mU.fA.mU.fA.mU.mA.mC.mG.mG.fA.mA.fG.mC.mC.mC*fG*mU.mA	IA0297	36
	H1.mA*mC.mG.fG.mG.mC.fU.mU.mC.fC.fG.fU.mA.mU.fA.mU.mA.fU.mG.mG*mA*mU	IS0297	194
RD1045	mU*fU*mU.mC.mC.fA.mU.fC.mC.mU.mG.mU.mC.fA.mC.fA.mG.mC.mC*fU*mC.mA	IA0304	92
	H1.mG*mA.mG.fG.mC.mU.fG.mU.mG.fA.fC.fA.mG.mG.fA.mU.mG.fG.mA.mA*mA*mU	IS0303	251

Table 20
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD1276	1105	1125	UGGAAAGUGAGACUCUCCACC	112	UGGUGGAGAGUCUCACUUUCCAU	270	61
RD1292	163	183	UCAUUGUGGAUGAUGAGGUGG	25	UCCACCUCUAUCCACAAUGAU	182	62
RD1393	382	403	AUGCAUGCCAUUAUACGGUGA	40	UCACCGUAUAUUGGCAUGCAUU	198	43
RD1394	1104	1125	UGGAAAGUGAGACUCUCCACCA	111	UGGUGGAGAGUCUCACUUUCCAU	270	31
RD1395	162	183	UCAUUGUGGAUGAUGAGGUGGA	24	UCCACCUCUAUCCACAAUGAU	182	51
RD1396	736	757	UAGAGAGCGUGGGAGGACCACA	77	UGUGGUCCUCCACGCUCUCUAU	235	22
RD1397	769	790	UUUCUCAGCAGCAACAUCCAGA	84	UCUGGAUGUUGCUGCUGAGAAU	242	77
RD1398	1019	1041	ACUUGAGUCACCGAGAAGUUGGA	102	UCCAACUUCUCGGUGACUCAAGUU	261	29
RD1400	483	504	UCUGUGUGGUCCAAGGCUCCCA	53	UGGGAGCCUUGGACCACACAGAU	211	22
RD1401	556	577	UUUGUGCGCAUCCAGCCGGGAA	64	UUCCCGGCUUGGAGCGACAAAU	222	25
RD1406	382	403	AUGCAUGCCAUUAUACGGUGA	40	UCACCGUAUAUUGGCAUGCAUU	198	78
RD1407	1104	1125	UGGAAAGUGAGACUCUCCACCA	111	UGGUGGAGAGUCUCACUUUCCAU	270	34
RD1408	162	183	UCAUUGUGGAUGAUGAGGUGGA	24	UCCACCUCUAUCCACAAUGAU	182	77
RD1409	736	757	UAGAGAGCGUGGGAGGACCACA	77	UGUGGUCCUCCACGCUCUCUAU	235	43
RD1410	769	790	UUUCUCAGCAGCAACAUCCAGA	84	UCUGGAUGUUGCUGCUGAGAAU	242	86
RD1411	1019	1041	ACUUGAGUCACCGAGAAGUUGGA	102	UCCAACUUCUCGGUGACUCAAGUU	261	63
RD1413	483	504	UCUGUGUGGUCCAAGGCUCCCA	53	UGGGAGCCUUGGACCACACAGAU	211	32
RD1414	556	577	UUUGUGCGCAUCCAGCCGGGAA	64	UUCCCGGCUUGGAGCGACAAAU	222	32
RD1419	382	403	AUGCAUGCCAUUAUACGGUGA	40	UCACCGUAUAUUGGCAUGCAUU	198	83
RD1420	1104	1125	UGGAAAGUGAGACUCUCCACCA	111	UGGUGGAGAGUCUCACUUUCCAU	270	42
RD1421	162	183	UCAUUGUGGAUGAUGAGGUGGA	24	UCCACCUCUAUCCACAAUGAU	182	80
RD1422	736	757	UAGAGAGCGUGGGAGGACCACA	77	UGUGGUCCUCCACGCUCUCUAU	235	44
RD1423	769	790	UUUCUCAGCAGCAACAUCCAGA	84	UCUGGAUGUUGCUGCUGAGAAU	242	89
RD1424	1019	1041	ACUUGAGUCACCGAGAAGUUGGA	102	UCCAACUUCUCGGUGACUCAAGUU	261	72
RD1426	483	504	UCUGUGUGGUCCAAGGCUCCCA	53	UGGGAGCCUUGGACCACACAGAU	211	27
RD1427	556	577	UUUGUGCGCAUCCAGCCGGGAA	64	UUCCCGGCUUGGAGCGACAAAU	222	51
RD1037	1760	1781	UAACACUGGUUCUUGCCUCGGA	146	UCCGAGGCAAGAACCAGUGUUAU	307	77
RD1046	382	403	AUGCAUGCCAUUAUACGGUGA	40	UCACCGUAUAUUGGCAUGCAUU	198	25
RD1298	1104	1125	UGGAAAGUGAGACUCUCCACCA	111	UGGUGGAGAGUCUCACUUUCCAU	270	11

Table 21
Compound Chemistry

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD1393	mA*FU*mG.fC.mA.fU.mG.fC.mC.fA.mU.fA.mU.fA.mC.fG.mG.fU*mG.mA	IA0351	40
	mU.mC*mA*mC.fC.mG.mU.fA.mU.fA.mU.fA.fU.mG.mG.fC.mA.mU.fG.mC.mA*mU*mU	IS0354	198
RD1394	mU*FG*mG.fA.mA.fA.mG.fU.mG.fA.mG.fA.mC.fU.mC.fU.mC.fC.mA.fC*mC.mA	IA0352	111
	mU.mG*mG*mU.fG.mG.mA.fG.mA.fG.mU.fC.fU.mC.mA.fC.mU.mU.fU.mC.mC*mA*mU	IS0355	270
RD1395	mU*FC*mA.fU.mU.fG.mU.fG.mG.fA.mU.fG.mA.fU.mG.fA.mG.fG.mU.fG*mG.mA	IA0353	24
	mU.mC*mC*mA.fC.mC.mU.fC.mA.fU.mC.fA.fU.mC.mC.fA.mC.mA.fA.mU.mG*mA*mU	IS0356	182
RD1396	mU*fA*mG.fA.mG.fA.mG.fC.mG.fU.mG.fG.mG.fA.mG.fG.mA.fC.mC.fA*mC.mA	IA0354	77
	mU.mG*mU*mG.fG.mU.mC.fC.mU.fC.mC.fC.fA.mC.mG.fC.mU.mC.fU.mC.mU*mA*mU	IS0357	235
RD1397	mU*FU*mU.fC.mU.fC.mA.fG.mC.fA.mG.fC.mA.fA.mC.fA.mU.fC.mC.fA*mG.mA	IA0355	84
	mU.mC*mU*mG.fG.mA.mU.fG.mU.fU.mG.fC.fU.mG.mC.fU.mG.mA.fG.mA.mA*mA*mU	IS0358	242
RD1398	mA*FC*mU.fU.mG.fA.mG.fU.mC.fA.mC.fC.mG.fA.mG.fA.mA.fG.mU.fU.mG*mG.mA	IA0356	102
	mU.mC*mC*mA.mA.fC.mU.mU.fC.mU.fC.mG.fG.fU.mG.mA.fC.mU.mC.fA.mA.mG*mU*mU	IS0359	261
RD1400	mU*FC*mU.fG.mU.fG.mU.fG.mG.fU.mC.fC.mA.fA.mG.fG.mC.fU.mC.fC*mC.mA	IA0358	53
	mU.mG*mG*mG.fA.mG.mC.fC.mU.fU.mG.fG.fA.mC.mC.fA.mC.mA.fC.mA.mG*mA*mU	IS0361	211
RD1401	mU*FU*mU.fG.mU.fG.mC.fG.mC.fA.mU.fC.mC.fA.mG.fC.mC.fG.mG.fG*mA.mA	IA0359	64
	mU.mU*mC*mC.fC.mG.mG.fC.mU.fG.mG.fA.fU.mG.mC.fG.mC.mA.fC.mA.mA*mA*mU	IS0362	222
RD1406	mA*FU*mG.fC.mA.fU.mG.fC.mC.fA.mU.fA.mU.fA.mU.fA.mC.fG.mG.fU*mG.mA	IA0351	40
	mU.mC*mA*mC.fC.mG.mU.fA.mU.fA.fU.fA.fU.mG.mG.fC.mA.mU.fG.mC.mA*mU*mU	IS0367	198
RD1407	mU*FG*mG.fA.mA.fA.mG.fU.mG.fA.mG.fA.mC.fU.mC.fU.mC.fC.mA.fC*mC.mA	IA0352	111
	mU.mG*mG*mU.fG.mG.mA.fG.mA.fG.fU.fC.fU.mC.mA.fC.mU.mU.fU.mC.mC*mA*mU	IS0368	270
RD1408	mU*FC*mA.fU.mU.fG.mU.fG.mG.fA.mU.fG.mA.fU.mG.fA.mG.fG.mU.fG*mG.mA	IA0353	24
	mU.mC*mC*mA.fC.mC.mU.fC.mA.fU.fC.fA.fU.mC.mC.fA.mC.mA.fA.mU.mG*mA*mU	IS0369	182
RD1409	mU*fA*mG.fA.mG.fA.mG.fC.mG.fU.mG.fG.mG.fA.mG.fG.mA.fC.mC.fA*mC.mA	IA0354	77
	mU.mG*mU*mG.fG.mU.mC.fC.mU.fC.fC.fC.fA.mC.mG.fC.mU.mC.fU.mC.mU*mA*mU	IS0370	235
RD1410	mU*FU*mU.fC.mU.fC.mA.fG.mC.fA.mG.fC.mA.fA.mC.fA.mU.fC.mC.fA*mG.mA	IA0355	84
	mU.mC*mU*mG.fG.mA.mU.fG.mU.fU.fG.fC.fU.mG.mC.fU.mG.mA.fG.mA.mA*mA*mU	IS0371	242
RD1411	mA*FC*mU.fU.mG.fA.mG.fU.mC.fA.mC.fC.mG.fA.mG.fA.mA.fG.mU.fU.mG*mG.mA	IA0356	102
	mU.mC*mC*mA.mA.fC.mU.mU.fC.mU.fC.fG.fG.fU.mG.mA.fC.mU.mC.fA.mA.mG*mU*mU	IS0372	261
RD1413	mU*FC*mU.fG.mU.fG.mU.fG.mG.fU.mC.fC.mA.fA.mG.fG.mC.fU.mC.fC*mC.mA	IA0358	53
	mU.mG*mG*mG.fA.mG.mC.fC.mU.fU.fG.fG.fA.mC.mC.fA.mC.mA.fC.mA.mG*mA*mU	IS0374	211
RD1414	mU*FU*mU.fG.mU.fG.mC.fG.mC.fA.mU.fC.mC.fA.mG.fC.mC.fG.mG.fG*mA.mA	IA0359	64
	mU.mU*mC*mC.fC.mG.mG.fC.mU.fG.fG.fA.fU.mG.mC.fG.mC.mA.fC.mA.mA*mA*mU	IS0375	222
RD1419	mA*FU*mG.fC.mA.fU.mG.fC.mC.fA.mU.fA.mU.fA.mU.fA.mC.fG.mG.fU*mG.mA	IA0351	40
	mU.mC*mA*mC.mC.mG.mU.fA.mU.fA.fU.fA.fU.mG.mG.mC.mA.mU.mG.mC.mA*mU*mU	IS0380	198
RD1420	mU*FG*mG.fA.mA.fA.mG.fU.mG.fA.mG.fA.mC.fU.mC.fU.mC.fC.mA.fC*mC.mA	IA0352	111
	mU.mG*mG*mU.mG.mG.mA.fG.mA.fG.fU.fC.fU.mC.mA.mC.mU.mU.mU.mC.mC*mA*mU	IS0381	270
RD1421	mU*FC*mA.fU.mU.fG.mU.fG.mG.fA.mU.fG.mA.fU.mG.fA.mG.fG.mU.fG*mG.mA	IA0353	24
	mU.mC*mC*mA.mC.mC.mU.fC.mA.fU.fC.fA.fU.mC.mC.mA.mC.mA.mA.mU.mG*mA*mU	IS0382	182
RD1422	mU*fA*mG.fA.mG.fA.mG.fC.mG.fU.mG.fG.mG.fA.mG.fG.mA.fC.mC.fA*mC.mA	IA0354	77
	mU.mG*mU*mG.mG.mU.mC.fC.mU.fC.fC.fC.fA.mC.mG.mC.mU.mC.mU.mC.mU*mA*mU	IS0383	235
RD1423	mU*FU*mU.fC.mU.fC.mA.fG.mC.fA.mG.fC.mA.fA.mC.fA.mU.fC.mC.fA*mG.mA	IA0355	84
	mU.mC*mU*mG.mG.mA.mU.fG.mU.fU.fG.fC.fU.mG.mC.mU.mG.mA.mG.mA.mA*mA*mU	IS0384	242
RD1424	mA*FC*mU.fU.mG.fA.mG.fU.mC.fA.mC.fC.mG.fA.mG.fA.mA.fG.mU.fU.mG*mG.mA	IA0356	102
	mU.mC*mC*mA.mA.mC.mU.mU.fC.mU.fC.fG.fG.fU.mG.mA.mC.mU.mC.mA.mA.mG*mU*mU	IS0385	261
RD1426	mU*FC*mU.fG.mU.fG.mU.fG.mG.fU.mC.fC.mA.fA.mG.fG.mC.fU.mC.fC*mC.mA	IA0358	53
	mU.mG*mG*mG.mA.mG.mC.fC.mU.fU.fG.fG.fA.mC.mC.mA.mC.mA.mC.mA.mG*mA*mU	IS0387	211
RD1427	mU*FU*mU.fG.mU.fG.mC.fG.mC.fA.mU.fC.mC.fA.mG.fC.mC.fG.mG.fG*mA.mA	IA0359	64
	mU.mU*mC*mC.mC.mG.mG.fC.mU.fG.fG.fA.fU.mG.mC.mG.mC.mA.mC.mA.mA*mA*mU	IS0388	222
RD1037	mU*fA*mA.mC.mA.fC.mU.fG.mG.mU.mU.mC.mU.fU.mG.fC.mC.mU.mC*FG*mG.mA	IA0301	146
	H1.mC*mC.mG.fA.mG.mG.fC.mA.mA.fG.fA.fA.mC.mC.fA.mG.mU.fG.mU.mU*mA*mU	IS0301	307
RD1046	mA*FU*mG.mC.mA.fU.mG.fC.mC.mA.mU.mA.mU.fA.mU.fA.mC.mG.mG*FU*mG.mA	IA0305	40
	H1.mC*mA.mC.fC.mG.mU.fA.mU.mA.fU.fA.fU.mG.mG.fC.mA.mU.fG.mC.mA*mU*mU	IS0304	198
RD1298	mU*FG*mG.mA.mA.fA.mG.fU.mG.mA.mG.mA.mC.fU.mC.fU.mC.mC.mA*FC*mC.mA	IA0335	111

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
	H1.mG*mG.mU.fG.mG.mA.fG.mA.mG.fU.fC.fU.mC.mA.fC.mU.mU.fU.mC.mC*mA*mU	IS0334	270

Table 22
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD1391	1760	1781	UAACACUGGUUCUUGCCUCGGA	146	UCCGAGGCAAGAACCAGUGUUAU	307	84
RD1399	304	325	AAGUUUUGCAGCGACUAGCACA	31	UGUGCUAGUCGUGCAAAACUUU	189	84
RD1404	1760	1781	UAACACUGGUUCUUGCCUCGGA	146	UCCGAGGCAAGAACCAGUGUUAU	307	88
RD1412	304	325	AAGUUUUGCAGCGACUAGCACA	31	UGUGCUAGUCGUGCAAAACUUU	189	7
RD1417	1760	1781	UAACACUGGUUCUUGCCUCGGA	146	UCCGAGGCAAGAACCAGUGUUAU	307	87
RD1425	304	325	AAGUUUUGCAGCGACUAGCACA	31	UGUGCUAGUCGUGCAAAACUUU	189	87
RD1553	1761	1781	UAACACUGGUUCUUGCCUCCC	148	UGGGAGGCAAGAACCAGUGUUAU	309	81
RD1554	1761	1781	UAACACUGGUUCUUGCCUCCG	149	UCGGAGGCAAGAACCAGUGUUAU	310	82
RD1037	1760	1781	UAACACUGGUUCUUGCCUCGGA	146	UCCGAGGCAAGAACCAGUGUUAU	307	76

Table 23
Compound Chemistry

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD1391	mU*fA*mA.fC.mA.fC.mU.fG.mG.fU.mU.fC.mU.fU.mG.fC.mC.fU.mC.fG*mG.mA	IA0349	146
	mU.mC*mC*mG.fA.mG.mG.fC.mA.fA.mG.fA.fA.mC.mC.fA.mG.mU.fG.mU.mU*mA*mU	IS0352	307
RD1399	mA*fA*mG.fU.mU.fU.mU.fG.mC.fA.mG.fC.mG.fA.mC.fU.mA.fG.mC.fA*mC.mA	IA0357	31
	mU.mG*mU*mG.fC.mU.mA.fG.mU.fC.mG.fC.fU.mG.mC.fA.mA.mA.fA.mC.mU*mU*mU	IS0360	189
RD1404	mU*fA*mA.fC.mA.fC.mU.fG.mG.fU.mU.fC.mU.fU.mG.fC.mC.fU.mC.fG*mG.mA	IA0349	146
	mU.mC*mC*mG.fA.mG.mG.fC.mA.fA.fG.fA.fA.mC.mC.fA.mG.mU.fG.mU.mU*mA*mU	IS0365	307
RD1412	mA*fA*mG.fU.mU.fU.mU.fG.mC.fA.mG.fC.mG.fA.mC.fU.mA.fG.mC.fA*mC.mA	IA0357	31
	mU.mG*mU*mG.fC.mU.mA.fG.mU.fC.fG.fC.fU.mG.mC.fA.mA.mA.fA.mC.mU*mU*mU	IS0373	189
RD1417	mU*fA*mA.fC.mA.fC.mU.fG.mG.fU.mU.fC.mU.fU.mG.fC.mC.fU.mC.fG*mG.mA	IA0349	146
	mU.mC*mC*mG.mA.mG.mG.fC.mA.fA.fG.fA.fA.mC.mC.mA.mG.mU.mG.mU.mU*mA*mU	IS0378	307
RD1425	mA*fA*mG.fU.mU.fU.mU.fG.mC.fA.mG.fC.mG.fA.mC.fU.mA.fG.mC.fA*mC.mA	IA0357	31
	mU.mG*mU*mG.mC.mU.mA.fG.mU.fC.fG.fC.fU.mG.mC.mA.mA.mA.mA.mC.mU*mU*mU	IS0386	189
RD1553	mU*fA*mA.fC.mA.fC.mU.fG.mG.fU.mU.fC.mU.fU.mG.fC.mC.fU.mC*fC*mC	IA0431	148
	mU.mG*mG*mG.fA.mG.mG.fC.mA.fA.mG.fA.fA.mC.mC.fA.mG.mU.fG.mU.mU*mA*mU	IS0491	309
RD1554	mU*fA*mA.fC.mA.fC.mU.fG.mG.fU.mU.fC.mU.fU.mG.fC.mC.fU.mC*fC*mG	IA0432	149
	mU.mC*mG*mG.fA.mG.mG.fC.mA.fA.mG.fA.fA.mC.mC.fA.mG.mU.fG.mU.mU*mA*mU	IS0492	310
RD1037	mU*fA*mA.mC.mA.fC.mU.fG.mG.mU.mU.mC.mU.fU.mG.fC.mC.mU.mC*fG*mG.mA	IA0301	146
	H1.mC*mC.mG.fA.mG.mG.fC.mA.mA.fG.fA.fA.mC.mC.fA.mG.mU.fG.mU.mU*mA*mU	IS0301	307

Table 24
Inhibition of AGT mRNA by double-stranded compounds targeting SEQ ID NO: 1

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD1404	1760	1781	UAACACUGGUUCUUGCCUCGGA	146	UCCGAGGCAAGAACCAGUGUUAU	307	86

Compound Number	Seq ID NO:1 Start Site	SEQ ID NO:1 Stop Site	Antisense Sequence (5'-3')	SEQ ID NO:	Sense Sequence (5'-3')	SEQ ID NO:	AGT % Inhibition
RD1412	304	325	AAGUUUUGCAGCGACUAGCACA	31	UGUGCUAGUCGUGCAAAACUUU	189	86
RD1037	1760	1781	UAACACUGGUUCUUGCCUCGGA	146	UCCGAGGCAAGAACCAGUGUUU	307	80
RD1613	377	397	UCCAUAUAUACGGAAGCCAG	38	UCUGGGCUUCCGUUAUAUGGA	196	76
RD1614	1761	1781	AAACACUGGUUCUUGCCUCCC	147	UGGGAGGCAAGAACCAGUGUUU	311	81
RD1615	1607	1629	AUUAGAAGAAAAGGUGGGAGACU	139	UUCUCCACCUUUUCUUCUAAU	300	85
RD1622	136	156	UGUAUGUACACCCIGUCACCU	12	UAGGUGACCGGGUGUACAUACA	170	66
RD1623	1420	1440	UGAUCAUACACAGUAAACAGG	134	UCCUGUUUACUGUGUAUGAUA	294	74
RD1624	163	183	UCAUUGUGGAUGAUGAGGUGG	25	UCCACCUCAUCAUCCACAAUGA	183	76
RD1625	793	813	ACAGCCUGCAUGAACCUUGCA	85	UUGACAGGUUCAUGCAGACUGU	244	76
RD1626	1087	1107	ACCUUGUCCAGGUUAGAGGCA	105	UUGCCUCUAACCUUGGAUAAGGU	264	66

Table 25
Compound Chemistry

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD1404	mU*fA*mA.fC.mA.fC.mU.fG.mG.fU.mU.fC.mU.fU.mG.fC.mC.fU.mC.fG*mG.mA	IA0349	146
	mU.mC*mC*mG.fA.mG.mG.fC.mA.fA.fG.fA.fA.mC.mC.fA.mG.mU.fG.mU.mU*mA*mU	IS0365	307
RD1412	mA*fA*mG.fU.mU.fU.mU.fG.mC.fA.mG.fC.mG.fA.mC.fU.mA.fG.mC.fA*mC.mA	IA0357	31
	mU.mG*mU*mG.fC.mU.mA.fG.mU.fC.fG.fC.fU.mG.mC.fA.mA.mA.fA.mC.mU*mU*mU	IS0373	189
RD1037	mU*fA*mA.mC.mA.fC.mU.fG.mG.mU.mU.mC.mU.fU.mG.fC.mC.mU.mC*fG*mG.mA	IA0301	146
	H1.mC*mC.mG.fA.mG.mG.fC.mA.mA.fG.fA.fA.mC.mC.fA.mG.mU.fG.mU.mU*mA*mU	IS0301	307
RD1613	mU*fC*mC.fA.mU.fA.mU.fA.mU.fA.mC.fG.mG.fA.mA.fG.mC.fC.mC*fA*mG	IA0440	38
	H2.mC*mU*mG.mG.mG.mC.fU.mU.fC.fC.fG.fU.mA.mU.mA.mU.mA.mU.mG.mG*mA*dQ	IS0499	196
RD1614	mA*fA*mA.fC.mA.fC.mU.fG.mG.fU.mU.fC.mU.fU.mG.fC.mC.fU.mC*fC*mC	IA0435	147
	H2.mG*mG*mG.mA.mG.mG.fC.mA.fA.fG.fA.fA.mC.mC.mA.mG.mU.mG.mU.mU*mU*dQ	IS0500	311
RD1615	mA*fU*mU.mA.mG.fA.mA.mG.mA.mA.mA.mA.mG.fG.mU.fG.mG.mG.mA.mG.mA*mC*mU	IA0441	139
	H2.mU*mC*mU.mC.mC.mC.fA.mC.fC.fU.fU.mU.mU.mC.mU.mU.mC.mU.mA.mA.mU*dQ	IS0501	300
RD1622	mU*fG*mU.fA.mU.fG.mU.fA.mC.fA.mC.fC.mC.fl.mG.fU.mC.fA.mC.fC*mU	IA0442	12
	H2.mA*mG*mG.mU.mG.mA.fC.mC.fG.fG.fG.fU.mG.mU.mA.mC.mA.mU.mA.mC*mA*dQ	IS0504	170
RD1623	mU*fG*mA.fU.mC.fA.mU.fA.mC.fA.mC.fA.mG.fU.mA.fA.mA.fC.mA.fG*mG	IA0443	134
	H2.mC*mC*mU.mG.mU.mU.fU.mA.fC.fU.fG.fU.mG.mU.mA.mU.mG.mA.mU.mC*mA*dQ	IS0505	294
RD1624	mU*fC*mA.fU.mU.fG.mU.fG.mG.fA.mU.fG.mA.fU.mG.fA.mG.fG.mU*fG*mG	IA0444	25
	H2.mC*mC*mA.mC.mC.mU.fC.mA.fU.fC.fA.fU.mC.mC.mA.mC.mA.mU.mG*mA*dQ	IS0508	183
RD1625	mA*fC*mA.fG.mC.fC.mU.fG.mC.fA.mU.fG.mA.fA.mC.fC.mU.fG.mU.fC*mA	IA0445	85
	H2.mU*mG*mA.mC.mA.mG.fG.mU.fU.fC.fA.fU.mG.mC.mA.mG.mA.mC.mU.mG*mU*dQ	IS0509	244
RD1626	mA*fC*mC.fU.mU.fG.mU.fC.mC.fA.mG.fG.mU.fU.mA.fG.mA.fG.mG.fC*mA	IA0446	105
	H2.mU*mG*mC.mC.mU.mC.fU.mA.fA.fC.fC.fU.mG.mG.mA.mU.mA.mA.mG.mG*mU*dQ	IS0510	264

Example 2: Effect of compounds targeting human AGT in cynomolgus Monkeys

[0211] Compounds of interest, identified from in vitro gene expression screening, were evaluated in cynomolgus monkeys. Prior to the study the monkeys were kept in quarantine during which the animals were observed daily for general health. The monkeys were 6-8.5 years old and weighed 3.7-6.8 kg. 2 groups of 3 cynomolgus monkeys each were injected with a single 3 mg/kg subcutaneous dose of oligonucleotide (1 monkey) or two 3 mg/kg subcutaneous doses of oligonucleotide (5 monkeys). The first dose was on Day 1 of the study

and the second dose was on Day 17. During the study period, the monkeys were observed daily for signs of illness or distress. Animals were bled on day -6 and on days 1 (prior to dosing), 4, 8, 15, 25, 32, 39, 53 and 60 for serum collection and analysis. The protocols described were approved by the Institutional Animal Care and Use Committee (IACUC). Circulating AGT levels were quantified using an ELISA specific for human angiotensinogen (and cross-reactive with cynomolgus), according to manufacturer's protocol (IBL America #27412). AGT inhibition data were expressed as percent of baseline value (Day 1 prior to dosing) and presented as a group average for each compound.

Table 26
Average AGT Inhibition

Compound	Days								
	4	8	15	25	32	39	46	53	60
RD1033	20	34	49	57	66	70	63	67	62
RD1045	24	33	42	49	59	54	47	49	46

Example 3: Effect of compounds targeting human AGT in cynomolgus Monkeys

[0212] Compounds of interest, identified from in vitro gene expression screening, were evaluated in cynomolgus monkeys. Prior to the study the monkeys were kept in quarantine during which the animals were observed daily for general health. The monkeys were 3.5-4 years old and weighed 3.1-4.6 kg. Three groups of 3 cynomolgus monkeys each were injected with a single 3 mg/kg subcutaneous dose of oligonucleotide on Day 1 of the study. During the study period, the monkeys were observed daily for signs of illness or distress. Animals were bled on day -6 and on days 1 (prior to dosing), 4, 8, 15, 22, 29, 36 and 43 for serum analysis. The protocols described were approved by the Institutional Animal Care and Use Committee (IACUC). Circulating AGT levels were quantified using an ELISA specific for human angiotensinogen (and cross-reactive with cynomolgus), according to manufacturer's protocol (IBL America #27412). AGT inhibition data were expressed as percent of baseline value (Day 1 prior to dosing) and presented as a group average for each compound.

Table 27
Average AGT Inhibition

Compound	Day 15	Day 22
RD1036	12	0
RD1046	15	0

Table 28

Average AGT Inhibition

	Days						
Compound	4	8	15	22	29	36	43
RD1037	21	39	52	62	64	62	50

Example 4: Effect of compounds targeting human AGT in cynomolgus Monkeys

[0213] Compounds of interest, identified from in vitro gene expression screening, were evaluated in cynomolgus monkeys. Prior to the study the monkeys were kept in quarantine during which the animals were observed daily for general health. The monkeys were 2.6-5.3 years old and weighed 2.2-4.4 kg. Eight groups of 2 cynomolgus monkeys each were injected with a single 3 mg/kg subcutaneous dose of oligonucleotide on Day 1 of the study. Animals were bled on day -6 and on days 1 (prior to dosing), 4, 8, 15, 22, 29, 36 and 43 for serum analysis. One group (RD1354) was injected with a 2nd dose of 3 mg/kg on Day 43 and the study continued for a total of 92 days. These animals were subsequently bled on days 50, 57, 64, 71, 78, 85 and 92. The protocols described were approved by the Institutional Animal Care and Use Committee (IACUC). Circulating AGT levels were quantified using an ELISA specific for human angiotensinogen (and cross-reactive with cynomolgus), according to manufacturer's protocol (IBL America #27412). AGT inhibition data were expressed as percent of baseline value (Day 1 prior to dosing) and presented as a group average for each compound. Clinical chemistry was performed on Day 43 or 92 (RD1354 group). There were no test article-related effects on body weight and all serum chemistry values were within reference ranges.

Table 29**Average AGT Inhibition**

Compound	Day 15
RD1324	0
RD1355	0
RD1356	16
RD1377	15
RD1378	25
RD1379	7
RD1380	24

Table 30**Average AGT Inhibition**

	Days													
Compound	4	8	15	22	29	36	43	50	57	64	71	78	85	92
RD1354	29	46	53	61	57	62	52	60	65	71	64	69	64	62

Table 31
Body Weight (kg)

Compound	Day 1	Day 35	Day 92
RD1324 Cyno#1	2.6	3.0	
RD1324 Cyno#2	3.4	3.4	
RD1354 Cyno#1	3.2	3.4	3.3
RD1354 Cyno#2	2.7	2.8	2.8
RD1355 Cyno#1	2.4	2.8	
RD1355 Cyno#2	2.6	2.8	
RD1356 Cyno#1	3.2	3.4	
RD1356 Cyno#2	3.1	3.2	
RD1377 Cyno#1	3.3	4.0	
RD1377 Cyno#2	2.6	3.1	
RD1378 Cyno#1	2.5	2.8	
RD1378 Cyno#2	2.7	2.8	
RD1379 Cyno#1	3.1	3.2	
RD1379 Cyno#2	4.4	4.8	
RD1380 Cyno#1	2.3	2.4	
RD1380 Cyno#2	2.4	2.4	

Table 32
Liver Function Markers

Compound	ALT Day 43 [U/L]	ALT Day 92 [U/L]	AST Day 43 [U/L]	AST Day 92 [U/L]	Bilirubin Day 43 [mg/dL]	Bilirubin Day 92 [mg/dL]	Albumin Day 43 [g/dL]	Albumin Day 92 [g/dL]
RD1324 Cyno#1	61		49		0.35		4.1	
RD1324 Cyno#2	66		48		0.18		4.4	
RD1354 Cyno#1	57	47	48	32	0.29	0.26	4.9	4.9
RD1354 Cyno#2	40	31	40	28	0.24	0.14	4.2	4.0
RD1355 Cyno#1	56		46		0.25		3.9	
RD1355 Cyno#2	62		42		0.22		4.0	
RD1356 Cyno#1	48		74		0.31		4.2	
RD1356 Cyno#2	48		39		0.24		4.0	

Compound	ALT Day 43 [U/L]	ALT Day 92 [U/L]	AST Day 43 [U/L]	AST Day 92 [U/L]	Bilirubin Day 43 [mg/dL]	Bilirubin Day 92 [mg/dL]	Albumin Day 43 [g/dL]	Albumin Day 92 [g/dL]
RD1377 Cyno#1	55		68		0.22		4.9	
RD1377 Cyno#2	33		52		0.36		4.4	
RD1378 Cyno#1	50		39		0.19		4.7	
RD1378 Cyno#2	34		38		0.23		4.7	
RD1379 Cyno#1	32		30		0.15		4.0	
RD1379 Cyno#2	50		35		0.15		4.5	
RD1380 Cyno#1	64		45		0.37		4.5	
RD1380 Cyno#2	39		50		0.16		4.0	

Table 33

Kidney Function Markers

Compound	Bun Day 43 [mg/dL]	Bun Day 92 [mg/dL]	Creatinine Day 43 [mg/dL]	Creatinine Day 92 [mg/dL]
RD1324 Cyno#1	19		0.56	
RD1324 Cyno#2	20		0.73	
RD1354 Cyno#1	28	25	0.72	0.65
RD1354 Cyno#2	21	18	0.54	0.41
RD1355 Cyno#1	22		0.52	
RD1355 Cyno#2	29		0.90	
RD1356 Cyno#1	22		0.48	
RD1356 Cyno#2	23		0.59	
RD1377 Cyno#1	34		0.76	
RD1377 Cyno#2	23		0.50	
RD1378 Cyno#1	27		0.58	
RD1378 Cyno#2	19		0.50	
RD1379 Cyno#1	28		0.59	
RD1379 Cyno#2	24		0.62	
RD1380 Cyno#1	24		0.46	
RD1380 Cyno#2	27		0.49	

Example 5: Effect of compounds targeting human AGT in cynomolgus Monkeys

[0214] Compounds of interest, identified from in vitro gene expression screening, were evaluated in cynomolgus monkeys. Prior to the study the monkeys were kept in quarantine during which the animals were observed daily for general health. The monkeys were 2.3-3.1 years old and weighed 1.8-2.4 kg. Eight groups of 2 cynomolgus monkeys each were injected with a 3 mg/kg subcutaneous dose of oligonucleotide on Day 1 and Day 22 of the study. All animals were bled on day -6 and on days 1 (prior to dosing), 4, 8, 14, 22, 29, 36, 43, 50, and 57 for serum analysis. Four of the groups (RD1614, RD1615, RD1623 and RD1625) were kept on the study an additional 35 days (for a total of 92 days) and were subsequently bled on days 64, 71, 78, 85 and 92. The protocols described were approved by the Institutional Animal Care and Use Committee (IACUC). Circulating AGT levels were quantified using an ELISA specific for human angiotensinogen (and cross-reactive with cynomolgus), according to manufacturer's protocol (IBL America #27412). AGT inhibition data were expressed as percent of baseline value (Day 1 prior to dosing) and presented as a group average for each compound. Clinical chemistry was performed on Day -6 and 57 (RD1613, RD1622, RD1624 and RD1626) or 92 (RD1614, RD1615, RD1623 and RD1625). There were no test article-related effects on body weight and all serum chemistry values were generally within reference ranges.

Table 34
Average AGT Inhibition

Compound	Day 14	Day 22
RD1613	42	51
RD1614	66	70
RD1615	81	88
RD1622	39	44
RD1624	50	48
RD1626	14	36

Table 35
Average AGT Inhibition

Compound	Days													
	4	8	14	22	29	36	43	50	57	64	71	78	85	92
RD1623	25	46	60	72	76	78	78	73	81	68	66	66	62	55
RD1625	20	47	63	63	68	75	77	73	75	65	69	63	61	61

Table 36
Body Weight (kg)

Compound	Day 1	Day 57	Day 92
RD1613 Cyno #1	2.1	2.3	
RD1613 Cyno #2	2.2	2.4	
RD1614 Cyno #1	2.6	2.8	2.8
RD1614 Cyno #2	1.9	2.1	1.9
RD1615 Cyno #1	2.1	2.6	2.1
RD1615 Cyno #2	2.1	2.4	2.1
RD1622 Cyno #1	1.8	2.0	
RD1622 Cyno #2	2.1	2.3	
RD1623 Cyno #1	2.4	2.6	2.5
RD1623 Cyno #2	2.1	2.3	2.1
RD1624 Cyno #1	2.1	2.2	
RD1624 Cyno #2	1.7	1.9	
RD1625 Cyno #1	2.0	2.2	1.9
RD1625 Cyno #2	2.1	2.3	2.1
RD1626 Cyno #1	2.1	2.3	
RD1626 Cyno #2	1.7	1.0	

Table 37
Liver Function Markers

Compound	ALT Day -6 [U/L]	ALT Day 57 [U/L]	ALT Day 92 [U/L]	AST Day -6 [U/L]	AST Day 57 [U/L]	AST Day 92 [U/L]
RD1613 Cyno #1	86	70		55	43	
RD1613 Cyno #2	70	61		53	54	
RD1614 Cyno #1	42		51	48		44
RD1614 Cyno #2	82		87	73		57
RD1615 Cyno #1	41		42	62		38
RD1615 Cyno #2	125		128	66		71
RD1622 Cyno #1	88	71		69	80	
RD1622 Cyno #2	105	74		58	44	
RD1623 Cyno #1	25		26			
RD1623 Cyno #2	49		49			
RD1624 Cyno #1	66	57		67	55	
RD1624 Cyno #2	29	34		43	62	
RD1625 Cyno #1	62		53			
RD1625 Cyno #2	38		29			
RD1626 Cyno #1	57	42		90	40	
RD1626 Cyno #2	64	57		59	45	

Table 38

Liver Function Markers

Compound	Bilirubin Day -6 [mg/dL]	Bilirubin Day 57 [mg/dL]	Bilirubin Day 92 [mg/dL]	Albumin Day -6 [g/dL]	Albumin Day 57 [g/dL]	Albumin Day 92 [g/dL]
RD1613 Cyno #1	0.33	0.15		4.1	4.2	
RD1613 Cyno #2	0.35		0.22	4.2	3.9	
RD1614 Cyno #1	0.39		0.35	4.2		4.5
RD1614 Cyno #2	0.34		0.27	4.3		4.9
RD1615 Cyno #1	0.26		0.31	4.2		4.4
RD1615 Cyno #2	0.50		0.33	3.8		3.9
RD1622 Cyno #1	0.41	0.17		4.6	4.5	
RD1622 Cyno #2	0.29	0.18		4.6	4.3	
RD1623 Cyno #1	0.34		0.31	4.5		4.4
RD1623 Cyno #2	0.34		0.29	4.6		4.8
RD1624 Cyno #1	0.33	0.20		4.7	4.7	
RD1624 Cyno #2	0.50	0.29		4.2	4.5	
RD1625 Cyno #1	0.19		0.21	4.4		4.5
RD1625 Cyno #2	0.27		0.46	4.4		4.7
RD1626 Cyno #1	0.39	0.12		3.8	3.9	
RD1626 Cyno #2	0.30	0.18		4.7	4.6	

Table 39**Kidney Function Markers**

Compound	Bun Day -6 [mg/dL]	Bun Day 57 [mg/dL]	Bun Day 92 [mg/dL]	Creatinine Day -6 [mg/dL]	Creatinine Day 57 [mg/dL]	Creatinine Day 92 [mg/dL]
RD1613 Cyno #1	34	27		0.44	0.49	
RD1613 Cyno #2	33	34		0.55	0.54	
RD1614 Cyno #1	27		55	0.61		0.71
RD1614 Cyno #2	29		26	0.55		0.66
RD1615 Cyno #1	20		31	0.44		0.55
RD1615 Cyno #2	35		26	0.33		0.32
RD1622 Cyno #1	23	25		0.70	0.63	
RD1622 Cyno #2	29	27		0.53	0.38	
RD1623 Cyno #1	28		28	0.49		0.48
RD1623 Cyno #2	23		25	0.47		0.46
RD1624 Cyno #1	36	29		0.71	0.55	
RD1624 Cyno #2	29	27		0.42	0.48	
RD1625 Cyno #1	32		40	0.61		0.76
RD1625 Cyno #2	31		24	0.55		0.54
RD1626 Cyno #1	38	29		0.44	0.52	
RD1626 Cyno #2	26	24		0.46	0.50	

Example 6: Effect of compounds targeting human AGT in cynomolgus Monkeys

[0215] Compounds of interest were evaluated in cynomolgus monkeys. Prior to the study the monkeys were kept in quarantine during which the animals were observed daily for general health. The monkeys were 3.86-4.28 years old and weighed 2.98-3.92 kg. Two groups of 2 cynomolgus monkeys each were injected with a single 5 mg/kg subcutaneous dose of

oligonucleotide on Day 1 of the study. All animals were bled on day -8 and on days 1 (prior to dosing), 4, 8, 15, 22, 27, 36, 43, 50, and 57 for serum analysis. The protocols described were approved by the Institutional Animal Care and Use Committee (IACUC). Circulating AGT levels were quantified using an ELISA specific for human angiotensinogen (and cross-reactive with cynomolgus), according to manufacturer's protocol (IBL America #27412). AGT inhibition data were expressed as percent of baseline value (Day 1 prior to dosing) and presented as a group average for each compound. There were no test article-related effects on body weight.

Table 40
Average AGT Inhibition

Compound	Days								
	4	8	15	22	27	36	43	50	57
RD1623	21	40	73	83	84	81	81	81	85
RD1625	38	63	77	80	81	80	80	76	79

Table 41
Body Weight (kg)

Compound	Day 1	Day 57
RD1623 Cyno#1	3.76	3.83
RD1623 Cyno#2	2.98	3.15
RD1623 Cyno#3	3.92	4.54
RD1625 Cyno#1	3.40	3.44
RD1625 Cyno#2	3.22	3.32
RD1625 Cyno#3	2.98	3.16

Example 7: Effect of compounds targeting human AGT in cynomolgus Monkeys

[0216] Compounds of interest were evaluated in cynomolgus monkeys. Prior to the study the monkeys were kept in quarantine during which the animals were observed daily for general health. The monkeys were 3-5.6 years old and weighed 2.8-3.4 kg. Two groups of 2 cynomolgus monkeys each were injected with a single 3 mg/kg subcutaneous dose of oligonucleotide on Day 1 of the study. All animals were bled on day -6 and on days 1 (prior to dosing), 7, 14, 21, 28, 36 and 42 for serum analysis. The protocols described were approved by the Institutional Animal Care and Use Committee (IACUC). Circulating AGT levels were quantified using an ELISA specific for human angiotensinogen (and cross-reactive with cynomolgus), according to manufacturer's protocol (IBL America #27412). AGT inhibition

data were expressed as percent of baseline value (Day 1 prior to dosing) and presented as a group average for each compound. There were no test article-related effects on body weight.

Table 42
Compound Chemistry

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD2052	mU*fG*mA.fU.mC.fA.mU.fA.mC.fA.mC.fA.mG.fU.mA.fA.mA.fC.mA.fC.mC*mG*mG	IA0727	136
	H2.mC*mC*mG.mG.mU.mG.mU.mU.fU.mA.fC.fU.fG.fU.mG.mU.mA.mU.mG.mA.mU.mC*mA*dQ	IS0833	297
RD2053	mU*fG*mA.fU.mC.fA.mU.fA.mC.fA.mC.fA.mG.fU.mA.fA.mA.fC.mA.fG.mC*mG*mG	IA0728	137
	H2.mC*mC*mG.mC.mU.mG.mU.mU.fU.mA.fC.fU.fG.fU.mG.mU.mA.mU.mG.mA.mU.mC*mA*dQ	IS0834	298

Table 43
Average AGT Inhibition

Compound	Days				
	7	14	21	28	42
RD2052	30	52	63	55	41
RD2053	26	43	62	49	51

Table 44
Body Weight (kg)

Compound	Day 1	Day 42
RD2052 Cyno #1	3.0	3.4
RD2052 Cyno #2	2.8	2.9
RD2053 Cyno #1	3.1	3.4
RD2053 Cyno #2	3.4	3.4

Example 8: Effect of modified oligonucleotides targeting human AGT in cynomolgus Monkeys

[0217] Compounds of interest were evaluated in cynomolgus monkeys. Prior to the study the monkeys were kept in quarantine during which the animals were observed daily for general health. The monkeys were 2.9-6.1 years old and weighed 2.4-3.5 kg. Three groups of 2 cynomolgus monkeys each were injected with a single 3 mg/kg subcutaneous dose of oligonucleotide on Day 1 of the study. All animals were bled on day -6 and on days 1 (prior to dosing), 4, 8, 15, 22, 29, 36, 43, 50, 57 and 64 for serum analysis. The protocols described were approved by the Institutional Animal Care and Use Committee (IACUC). Circulating AGT levels were quantified using an ELISA specific for human angiotensinogen (and cross-reactive with cynomolgus), according to manufacturer's protocol (IBL America #27412). AGT inhibition data were expressed as percent of baseline value (average of Day -6 and Day 1 prior to dosing) and presented as a group average for each compound. Clinical chemistry was

performed on Day -6 and 64. There were no test article-related effects on body weight and all serum chemistry values were generally within reference ranges.

Table 45
Compound Chemistry

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD2263	mU*fG*mA.fU.mC.fA.mU.fA.mC.fA.mC.fA.mG.fU.mA.fA.mA.fC.mA.fG*mG	IA0443	134
	H4.mC*mC*mU.mG.mU.mU.fU.mA.fC.fU.fG.fU.mG.mU.mA.mU.mG.mA.mU.mC*mA*dQ	IS0970	295
RD2264	mU*fG*mA.fU.mC.fA.mU.fA.mC.fA.mC.fA.mG.fU.mA.fA.mA.fC.mA.fG.mG*mG*mA	IA0501	135
	H4.mC*mC*mC.mU.mG.mU.mU.fU.mA.fC.fU.fG.fU.mG.mU.mA.mU.mG.mA.mU.mC*mA*dQ	IS0971	296
RD2265	mU*fG*mA.fU.mC.fA.mU.fA.mC.fA.mC.fA.mG.fU.mA.fA.mA.fC.mA.fG.mG*mA*mA	IA0500	133
	H4.mC*mC*mU.mG.mU.mU.fU.mA.fC.fU.fG.fU.mG.mU.mA.mU.mG.mA.mU.mC*mA*dQ	IS0970	292

Table 46
Average AGT Inhibition

Compound	Days									
	4	8	15	22	29	36	43	50	57	64
RD2263	12	21	49	54	55	47	47	33	34	34
RD2264	7	36	50	48	49	48	44	34	40	33
RD2265	11	37	58	61	59	57	58	46	43	36

Table 47
Body Weight (kg)

Compound	Day 1	Day 63
RD2263 Cyno#1	3.5	3.4
RD2263 Cyno#2	3.0	3.1
RD2264 Cyno#1	3.0	2.8
RD2264 Cyno#2	3.0	3.2
RD2265 Cyno#1	2.6	2.7
RD2265 Cyno#2	2.4	2.5

Table 48
Liver Function Markers

Compound	ALT Day 1 [U/L]	ALT Day 64 [U/L]	AST Day 1 [U/L]	AST Day 64 [U/L]	Bilirubin Day 1 [mg/dL]	Bilirubin Day 64 [mg/dL]	Albumin Day 1 [g/dL]	Albumin Day 64 [g/dL]
RD2263 Cyno#1	56	60	36	37	0.30	0.26	5.0	4.7
RD2263 Cyno#2	68	76	29	35	0.22	0.17	4.6	4.5

RD2264 Cyno#1	34	39	28	30	0.23	0.19	4.1	3.8
RD2264 Cyno#2	69	67	35	34	0.26	0.17	4.4	4.2
RD2265 Cyno#1	39	42	43	51	0.74	0.45	4.2	4.0
RD2265 Cyno#2	84	83	65	93	0.36	0.32	4.2	4.1

Table 49
Kidney Function Markers

Compound	Bun Day 1 [mg/dL]	Bun Day 64 [mg/dL]	Creatinine Day 1 [mg/dL]	Creatinine Day 64 [mg/dL]
RD2263 Cyno#1	23	24	0.72	0.72
RD2263 Cyno#2	24	24	0.66	0.68
RD2264 Cyno#1	17	17	0.48	0.51
RD2264 Cyno#2	17	15	0.37	0.34
RD2265 Cyno#1	28	24	0.50	0.48
RD2265 Cyno#2	21	16	0.40	0.36

Example 9: Effect of modified oligonucleotides targeting human AGT in cynomolgus Monkeys

[0218] Compounds of interest were evaluated in cynomolgus monkeys. Prior to the study the monkeys were kept in quarantine during which the animals were observed daily for general health. The monkeys were 2.9-6.1 years old and weighed 2.4-3.5 kg. Two groups of 2 cynomolgus monkeys each were injected with a single 3 mg/kg subcutaneous dose of oligonucleotide on Day 1 of the study. All animals were scheduled to be bled on day -6 and on days 1 (prior to dosing), 8, 15, 22, 29, 36, 43, 50, 57 and 64 for serum analysis. The study was ended after day 29. The protocols described were approved by the Institutional Animal Care and Use Committee (IACUC). Circulating AGT levels were quantified using an ELISA specific for human angiotensinogen (and cross-reactive with cynomolgus), according to manufacturer's protocol (IBL America #27412). AGT inhibition data is expressed as percent of baseline value (average of Day -6 and Day 1 prior to dosing) and presented as a group average for each compound. Clinical chemistry was scheduled to be performed on Day -6 and 64.

Table 50

Compound Chemistry

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD2497	mU*fC*mA.fA.mG.fA.mA.fG.mU.fU.mG.fG.mC.fC.mA.fG.mC.fA.mU.fC.mC*mG*mC	IA0868	32
	H2*mG*mG.mA.mU.mG.mC.fU.mG.fG.fC.fC.fA.mA.mC.mU.mU.mC.mU.mU.mG*mA*dQ	IS1078	190
RD2498	mU*fU*mU.fU.mG.fC.mU.fG.mG.fA.mA.fA.mG.fU.mG.fA.mG.fA.mC.fC.mC*mU*mC	IA0869	114
	H2*mG*mG.mG.mU.mC.mU.fC.mA.fC.fU.fU.fU.mC.mC.mA.mG.mC.mA.mA.mA*mA*dQ	IS1079	273

Table 51**Average AGT Inhibition**

Compound	Days			
	8	15	22	29
RD2497	10	6	12	9
RD2498	40	56	42	35

Example 10: Effect of modified oligonucleotides targeting human AGT in cynomolgus Monkeys

[0219] Compounds of interest were evaluated in cynomolgus monkeys. Prior to the study the monkeys were kept in quarantine during which the animals were observed daily for general health. The monkeys were 2.9-6.1 years old and weighed 2.4-3.5 kg. Two groups of 2 cynomolgus monkeys each were injected with a single 3 mg/kg subcutaneous dose of oligonucleotide on Day 1 of the study. All animals were scheduled to be bled on day -6 and on days 1 (prior to dosing), 4, 8, 15, 22, 29, 36, 43, 50, 57 and 64 for serum analysis. The study was ended after day 43. The protocols described were approved by the Institutional Animal Care and Use Committee (IACUC). Circulating AGT levels were quantified using an ELISA specific for human angiotensinogen (and cross-reactive with cynomolgus), according to manufacturer's protocol (IBL America #27412). AGT inhibition data is expressed as percent of baseline value (average of Day -6 and Day 1 prior to dosing) and presented as a group average for each compound. Clinical chemistry was scheduled to be performed on Day -6 and 64.

Table 52**Compound Chemistry**

Compound Number	Modified Strand (5'-3')	Ref ID NO:	SEQ ID NO:
RD2499	mA*fG*mU.fU.mU.fC.mU.fU.mC.fA.mU.fC.mC.fA.mG.fU.mU.fG.mA.fG.mG*mG*mA	IA0870	115
	H9*mC*mC.mU.mC.mA.mA.fC.mU.fG.fG.fA.fU.mG.mA.mA.mG.mA.mA.mA.mC*mU*dQ	IS1080	274
RD2500	mU*fC*mU.fA.mA.fA.mC.fA.mC.fU.mG.fG.mU.fU.mC.fU.mU.fG.mC.fC.mU*mC*mC	IA0871	151
	H2*mA*mG.mG.mC.mA.mA.fG.mA.fA.fC.fC.fA.mG.mU.mG.mU.mU.mU.mA.mG*mA*dQ	IS1081	311

Table 53
Average AGT Inhibition

Compound	Days						
	4	8	15	22	29	36	43
RD2499	23	34	38	41	52	55	33
RD2500	26	34	29	39	59	51	36

SEQ ID NO: 1

GAAGAAGCTGCCGTTGTTCTGGGTACTACAGCAGAAGGGTATGCGGAAGCGAGCACCCAGTCTGAGATGGCTCCTGCC
GGTGTGAGCCTGAGGGCCACCATCCTCTGCCTCCTGGCCTGGGCTGGCTGGCTGCAGGTGACCGGGTGACATACACCC
CTTCCACCTCGTCATCCACAATGAGAGTACCTGTGAGCAGCTGGCAAAGGCCAATGCCGGAAGCCCAAAGACCCACCT
TCATACCTGCTCCAATTACAGGCCAAGACATCCCTGTGGATGAAAAGGCCCTACAGGACCAGCTGGTGCTAGTCGTGCA
AAACTTGACACCGAAGACAAGTTGAGGGCCGCAATGGTCGGGATGCTGGCCAACCTCTTGGGCTTCCGTATATATGGCAT
GCACAGTGAGCTATGGGGCGTGGTCCATGGGGCCACCGTCCTCTCCCAACGGCTGTCTTTGGCACCCCTGGCCTCTCTTA
TCTGGGAGCCTTGGACCACACAGCTGACAGGCTACAGGCAATCCTGGGTGTTCTTGAAGGACAAGAAGTGCACCTCCC
GGCTGGATGCGCACAAGGTCTGTCTGCCCTGCAGGCTGTACAGGGCCTGCTAGTGGCCCAGGGCAGGGCTGATAGCCA
GGCCCAGCTGCTGCTGTCCACGGTGGTGGGCGTGTTACAGCCCCAGGCCTGCACCTGAAGCAGCCGTTTGTGCAGGGC
CTGGCTCTCTATACCCCTGTGGTCCTCCACGCTCTCTGGACTTCACAGAAGTGGATGTTGCTGCTGAGAAGATTGACAGG
TTCATGCAGGCTGTGACAGGATGGAAGACTGGCTGTCCCTGATGGGAGCCAGTGTGGACAGCACCCCTGGCTTTCAACAC
CTACGTCCACTTCCAAGGGAAGATGAAGGGCTTCTCCCTGTGGCCGAGCCCCAGGAGTTCTGGGTGGACAACAGCACCT
CAGTGTCTGTTCCCATGCTCTCTGGCATGGGCACCTTCCAGCACTGGAGTGACATCCAGGACAACCTCTCGGTGACTCAAG
TGCCCTTCACTGAGAGCGCCTGCCTGCTGCTGATCCAGCCTCACTATGCCTCTGACCTGGACAAGGTGGAGGGTCTCACTT
TCCAGCAAACTCCCTCAACTGGATGAAGAACTATCTCCCCGACCATCCACCTGACCATGCCCAACTGGTGCTGCAAG
GATCTTATGACCTGCAGGACCTGCTCGCCCAGGCTGAGCTGCCCGCCATTCTGCACACCGAGCTGAACCTGCAAAAATTG
AGCAATGACCGCATCAGGGTGGGGGAGGTGCTGAACAGCATTTTTTTTGTAGCTTGAAGCGGATGAGAGAGAGCCCACAG
AGTCTACCAACAGCTTAACAAGCCTGAGGTCTTGGAGGTGACCTGAACCGCCCATTCTGTTTGTGTGTATGATCAAA
GCGCCACTGCCCTGCACTTCTGGGCCGCGTGCCAACCGCTGAGCACAGCATGAGGCCAGGGCCCCAGAACACAGTG
CCTGGCAAGGCCTCTGCCCCTGGCCTTTGAGGCAAAGGCCAGCAGCAGATAACAACCCCGGACAAATCAGCGATGTGTCA
CCCCAGTCTCCACCTTTTCTTCTAATGAGTCGACTTTGAGCTGGAAAGCAGCCGTTTCTCCTTGGTCTAAGTGTGCTGCA
TGGAGTGAGCAGTAGAAGCCTGCAGCGGCACAAATGCACCTCCAGTTTGTGGGTTATTTTAGAGAATGGGGGTGGG
GAGGCAAGAACCAGTGTTTAGCGCGGACTACTGTTCAAAAAGAATTCCAACCGACCAGCTTGTGTGAAACAAAAA
GTGTTCCCTTTTCAAGTTGAGAACAAAAATTGGGTTTTAAATTAAGTATACATTTTGCATTGCCTTCGGTTGTATTTA
GTGTCTTGAATGTAAGAACATGACCTCCGTGTAGTGTCTGTAATACCTTAGTTTTTCCACAGATGCTTGTGATTTTGAAC
AATACGTGAAAGATGCAAGCACCTGAATTTCTGTTTGAATGCGGAACCATAGCTGGTTATTTCTCCCTTGTGTTAGTAATA
AACGTCTTGCCACAATAAGCCTCCAAAAA


CLAIMS

What is claimed is:

1. A compound comprising a modified oligonucleotide 14 to 23 linked nucleosides in length having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166.
2. A compound comprising a modified oligonucleotide 14 to 23 linked nucleosides in length having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166.
3. A compound comprising a modified oligonucleotide having a nucleobase sequence selected from any one of the nucleobase sequences of SEQ ID NOs: 10-166.
4. The compound of any one of claims 1-3, wherein the nucleobase sequence of the modified oligonucleotide is at least 80%, at least 85%, at least 90%, or at least 95% complementary to the nucleobase sequence of SEQ ID NO: 1 or 3.
5. The compound of any one of claims 1-4, wherein the modified oligonucleotide comprises at least one modification selected from a modified internucleoside linkage, a modified sugar, and a modified nucleobase.
6. The compound of any one of claims 1-5, wherein the compound is double-stranded.
7. A compound comprising a first modified oligonucleotide 14 to 23 linked nucleosides in length having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166 and 167-327 and a second modified oligonucleotide 14 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide.
8. A compound comprising a first modified oligonucleotide 14 to 23 linked nucleosides in length having a nucleobase sequence comprising the nucleobase sequence of any one of SEQ ID NOs: 10-166 or 167-327 and a second modified oligonucleotide 14 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide.
9. A compound comprising a first modified oligonucleotide having a nucleobase sequence selected from the nucleobase sequences of any one of SEQ ID NOs: 10-166 and 167-327 and a second modified oligonucleotide 19 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide.

10. The compound of any one of claims 7-9, wherein the nucleobase sequence of the first modified oligonucleotide has at least 80%, at least 85%, at least 90%, or at least 95% complementarity or identity to the nucleobase sequence of SEQ ID NO: 1 or 3 over its length.
11. The compound of any one of claims 7-10, wherein the nucleobase sequence of the first modified oligonucleotide has at least 1, at least 2, at least 3 mismatches to a region of the nucleobase sequence of SEQ ID NO: 1 or 3 that is the same length as the first modified oligonucleotide.
12. The compound of any one of claims 7-11, wherein the region of complementarity between the first modified oligonucleotide and the second modified oligonucleotide is 14 to 23 linked nucleosides in length.
13. The compound of any one of claims 7-11, wherein the region of complementarity between the first modified oligonucleotide and the second modified oligonucleotide is 19 to 23 linked nucleosides in length.
14. The compound of any one of claims 7-11, wherein the region of complementarity between the first modified oligonucleotide and the second modified oligonucleotide is 21 to 23 linked nucleosides in length.
15. The compound of any one of claims 7-11, wherein the first modified oligonucleotide is fully complementary to the second modified oligonucleotide.
16. The compound of any one of claims 7-15, wherein the first modified oligonucleotide comprises at least one modification selected from a modified internucleoside linkage, a modified sugar, and a modified nucleobase.
17. The compound of any one of claims 7-16, wherein the second modified oligonucleotide comprises at least one modification selected from the group consisting of a modified internucleoside linkage, a modified sugar, and a modified nucleobase.
18. The compound of any one of claims 5, 16 and 17, wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage or a methylphosphonate internucleoside linkage.
19. The compound of claim 18, wherein the phosphorothioate internucleoside linkage or methylphosphonate internucleoside linkage is at the 3' terminus of the first or second modified oligonucleotide or at the 5' terminus of the first modified oligonucleotide.
20. The compound of any one of claims 5, 16 and 17, wherein the modified sugar comprises a modification selected from the group consisting of a halogen, an alkoxy group and a bicyclic sugar.

21. The compound of claim 20, wherein the modified sugar comprises a 2'-F modification.
22. The compound of claim 20, wherein the modified sugar comprises a 2'-OMe modification.
23. The compound of any one of claims 7-15, wherein each nucleoside of the first modified oligonucleotide comprises a modified sugar.
24. The compound of any one of claims 7-15, wherein each nucleoside of the second modified oligonucleotide comprises a modified sugar.
25. The compound of claim 23 or 24, wherein the modified sugar comprises a modification selected from the group consisting of a halogen, an alkoxy group and a bicyclic sugar, or a combination thereof.
26. The compound of claim 25, wherein the modified sugar comprises a modification selected from group consisting of LNA, cEt, 2'-MOE, 2'-F, 2'-OMe, and 2'-deoxy, or a combination thereof.
27. The compound of claim 23, wherein the first modified oligonucleotide comprises no more than ten 2'-F sugar modifications.
28. The compound of claim 24, wherein the second modified oligonucleotide comprises no more than five 2'-F sugar modifications.
29. The compound of any preceding claim, comprising a conjugate group.
30. The compound of claim 29, wherein the conjugate group is attached to the 5' end of the modified oligonucleotide.
31. The compound of claim 29 or 30, wherein the conjugate group comprises a targeting moiety.
32. The compound of claim 31, wherein the targeting moiety comprises one or more GalNAc.
33. The compound of claim 32, wherein the modified oligonucleotide is the second modified oligonucleotide.
34. The compound of claim 32 or 33, wherein the one or more GalNAc are attached to the 2' or 3' position of the ribosyl ring of the 5' nucleoside of the modified oligonucleotide.
35. The compound of claim 34, wherein the 5' nucleoside is of the following formula:

**Formula X,**

wherein:

R^9 is H, adenine, guanine, thymine, cytosine, or uracil, or adenine, guanine, thymine, cytosine, or uracil, each comprising a Protecting Group (PG), a modified nucleobase, optionally substituted alkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, or a nucleobase isostere;

L is a bond, a phosphodiester bond, a phosphorothioate bond, a triazole, a tetrazole, an amide, a reverse-amide, a carbamate, a carbonate, urea, alkyl, or heteroalkyl;

R^2 is the oligonucleotide sequence;

Y_1 is O, CH_2 , CH_2O , or optionally substituted NH;

Y_2 is O, CH_2 , CH_2O , or optionally substituted NH;

Y_3 is CO, SO_2 , $P(O)O$, $CH_2-O-C(O)$, $CH_2-NH-C(O)$, $CH_2-NH-SO_2$, or CH_2 ;

Y_4 is CO, SO_2 , $P(O)O$, $CH_2-O-C(O)$, $CH_2-NH-C(O)$, $CH_2-NH-SO_2$, or CH_2 ;

n_2 is 0, 1, 2, 3, 4, 5, or 6; and

each n_1 , n_3 , n_4 and n_5 is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.

36. The compound of claim 34, wherein the 5' nucleoside is selected from any one of Formulae I-VIII and wherein R' is S and R is the portion of the modified oligonucleotide other than the 5' nucleoside.

37. The compound of claim 34, wherein the 5' nucleoside is selected from any one of Formulae I-VIII and wherein R' is O and R is the portion of the modified oligonucleotide other than the 5' nucleoside.

38. A compound comprising a first modified oligonucleotide selected from any one of Ref ID NOs: IA0297, IA0300, IA0301, IA0304, IA0305, IA0335-338, IA0343-359, IA0431-432, IA0435, IA440-446, IA0727-728, IA0500-501, and IA0868, and a second modified oligonucleotide 14 to 21 linked nucleosides in length fully complementary to the first modified oligonucleotide.
39. A compound comprising a first modified oligonucleotide selected from Ref ID NOs: IA0443 and IA0445 and a second modified oligonucleotide selected from Ref ID NOs: IS0505 and IS0509.
40. A compound of any one of claims 1-39, wherein the compound is in a pharmaceutically acceptable salt form.
41. The compound of claim 40, wherein the pharmaceutically acceptable salt is a sodium salt.
42. The compound of claim 40, wherein the pharmaceutically acceptable salt is a potassium salt.
43. A composition comprising the compound of any one of claims 1-42 and a pharmaceutically acceptable carrier.
44. A composition comprising a compound of any preceding claim, for use in therapy.
45. A method of treating, preventing or ameliorating a disease, disorder or condition associated with AGT in an individual comprising administering to the individual a compound targeted to AGT, thereby treating, preventing, or ameliorating the disease, disorder or condition.
46. A method of administering the compound of any one of claims 1-42 or composition of claim 43 or 44 to an individual.
47. The method of claim 45 or 46, wherein the disease, disorder or condition is RAAS related disease, disorder or condition or a symptom thereof, hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment.
48. The method of any one of claims 45-47, wherein administering the compound inhibits or reduces or improves RAAS related disease, disorder or condition or a symptom thereof, hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial

infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment.

49. A method of inhibiting expression of AGT in a cell comprising contacting the cell with a compound targeted to AGT, thereby inhibiting expression of AGT in the cell.

50. The method of claim 49, wherein the cell is in the liver of an individual.

51. The method of claim 50, wherein the individual has, or is at risk of having, RAAS related disease, disorder or condition or a symptom thereof, hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment.

52. A method of reducing or inhibiting RAAS related disease, disorder or condition or a symptom thereof, hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment in an individual, comprising administering a compound targeted to AGT to the individual, thereby reducing or inhibiting RAAS related disease, disorder or condition or a symptom thereof, hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment in the individual.

53. The method of claim 52, wherein the individual has, or is at risk of having, RAAS related disease, disorder or condition or a symptom thereof, hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment.

54. The method of any one of claims 45-53, wherein the compound is a compound targeted to AGT.

55. The method of any one of claims 45-54, wherein the compound is the compound of any one of claims 1-42 or composition of claim 43 or 44.

56. The method of claim 55, wherein the compound or composition is administered parenterally.

57. Use of a compound targeted to AGT for treating, preventing, or ameliorating a disease, disorder or condition associated with AGT.
58. The use of claim 57, wherein the disease, disorder or condition is a RAAS related disease, disorder or condition or a symptom thereof, hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment.
59. The use of claim 57 or 58, wherein the compound is a compound targeted to AGT.
60. The use of any one of claims 57-59, wherein the compound is the compound of any one of claims 1-42 or composition of claim 43 or 44.
61. Use of a compound targeted to AGT in the manufacture of a medicament for treating, preventing, or ameliorating a disease, disorder or condition associated with AGT.
62. The use of claim 61, wherein the disease is a RAAS related disease, disorder or condition or a symptom thereof, hypertension, resistant hypertension, fibrosis, kidney disease, chronic kidney disease, cardiovascular disease (e.g., coronary heart disease, heart failure, stroke, myocardial infarction, atrial fibrillation, aneurysm and peripheral artery disease), organ damage (e.g., heart, liver or kidney), inflammatory bowel disease or cognitive impairment.
63. The use of claim 61 or 62, wherein the compound is a compound targeted to AGT.
64. The use of any one of claims 61-63, wherein the compound is the compound of any one of claims 1-42 or composition of claim 43 or 44.
65. The method or use of any preceding claim, wherein the compound or composition is administered to an individual about once every three months to about once every year.
66. The method or use of any preceding claim, wherein the compound or composition is administered to an individual about once every three months, about once every six months, or about once every year.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 22/77389

A. CLASSIFICATION OF SUBJECT MATTER

IPC - INV. A61P 9/12, C07H 21/02, C12N 15/113 (2023.01)

ADD. A61K 31/712, A61K 31/713, A61K 31/7125 (2023.01)

CPC - INV. A61P 9/12, C07H 21/02, C12N 15/1136

ADD. C12N 2310/11, C12N 2310/315, C12N 2310/3231, C12N 2310/341, C12N 2310/346

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X -- A	US 2019/0298842 A1 (ALNYLAM PHARMACEUTICALS, INC.) 03 October 2019 (03.10.2019) Claim 1, Table 11, SEQ ID NO: 873	1, 4/1, 7, 10/7 ----- 2-3, 4/(2-3), 8-9, 10/(8-9)
A	US 2019/0160090 A1 (IONIS PHARMACEUTICALS, INC.) 30 May 2019 (30.05.2019) Claim 1, para [0009], Table 8, SEQ ID NO: 1287	2-3, 4/(2-3), 8-9, 10/(8-9)

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"D" document cited by the applicant in the international application

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

9 January 2023

Date of mailing of the international search report

FEB 08 2023

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-8300

Authorized officer

Kari Rodriguez

Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 22/77389

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:

a. ☒ forming part of the international application as filed.

b. ☐ furnished subsequent to the international filing date for the purposes of international search (Rule 13ter.1(a)),

☐ accompanied by a statement to the effect that the sequence listing does not go beyond the disclosure in the international application as filed.

2. ☐ With regard to any nucleotide and/or amino acid sequence disclosed in the international application, this report has been established to the extent that a meaningful search could be carried out without a WIPO Standard ST.26 compliant sequence listing.

3. Additional comments:

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 22/77389

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 5-6, 11-37, 40-44, 46-48, 54-56, 60, 64-66
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
- see extra sheet for Box No. III Observations where unity of invention is lacking -

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-4, 7-10 limited to SEQ ID NO: 10

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 22/77389

Continuation of:

Box No. III. Observations where unity of invention is lacking

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Groups I+: Claims 1-4, 7-10, 38-39, drawn to a compound for inhibiting expression of AGT in a cell comprising a modified oligonucleotide 14 to 23 linked nucleosides and a second modified oligonucleotide 14 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide. The composition will be searched to the extent that the compound encompasses the first named oligonucleotide sequence, SEQ ID NO: 10 (see claim 1). This first named invention has been selected based on the guidance set forth in section 10.54 of the PCT International Search and Preliminary Examination Guidelines. It is believed that claims 1-4, 7-10 encompass this first named invention, and thus these claims will be searched without fee to the extent that they encompass SEQ ID NO: 10. Additional compound(s) will be searched upon the payment of additional fees. Applicants must specify the claims that encompass any additionally elected compound(s). Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched. An exemplary election would be a compound comprising the oligonucleotide sequence, SEQ ID NO: 36 (Note, Ref ID NO: IA0297 comprises the modified SEQ ID NO: 36) (Claims 1-4, 7-10, 38).

Group II: Claims 45, 49-53, 57-59, 61-63, drawn to a method of treating, preventing or ameliorating a disease, disorder or condition associated with AGT in an individual

The inventions listed as Groups I+ and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I+ include the special technical feature of a composition which differs from the special technical feature of a method, as disclosed by Group II.

No technical features are shared between the oligonucleotide sequences of Groups I+ and, accordingly, these groups lack unity a priori.

Additionally, even if Groups I+ and II were considered to share the technical features of including: a compound for inhibiting expression of AGT in a cell, these shared technical features are previously disclosed by US 2019/0298842 A1 to Alnylam Pharmaceuticals, Inc. (hereinafter "Alnylam").

Alnylam teaches (instant claim 7) a compound comprising a first modified oligonucleotide 14 to 23 linked nucleosides in length (Claim 1, A double-stranded ribonucleic acid (RNAi) agent for inhibiting expression of angiotensinogen (AGT) in a cell, wherein said double-stranded RNAi agent comprises a sense strand and an antisense strand forming a double-stranded region, wherein the sense strand comprises at least 15 contiguous nucleotides of nucleotides 803-843....of the nucleotide sequence of SEQ ID NO:1 and the antisense strand comprises at least 15 contiguous nucleotides of the nucleotides at the corresponding position of the nucleotide sequence of SEQ ID NO:2, wherein the antisense strand is substantially complementary to the sense strand, and wherein substantially all of the nucleotides of said sense strand are modified nucleotides, substantially all of the nucleotides of said antisense strand are modified nucleotides, or substantially all of the nucleotides of said sense strand and substantially all of the nucleotides of said antisense strand are modified nucleotides.) having a nucleobase sequence comprising at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23 contiguous nucleobases of any of the nucleobase sequences of SEQ ID NOs: 10-166 and 167-327 (Table 11 (page 91), Duplex AD-67909-1, antisense oligo A-136045.1 "UUGUAUGUACACCCGGUCA" SEQ ID NO: 873; Note, nucleotides 4-19 of SEQ ID NO: 873 is 100% match to nucleotide 1-16 of SEQ ID NO: 10 of instant claim) and a second modified oligonucleotide 14 to 23 linked nucleosides in length having a region of complementarity to the first modified oligonucleotide (Table 11 (page 91), Duplex AD-67909-1, Sense oligo A-136044.1 "UGACCGGGUGUACAUACAA" SEQ ID NO: 676).

Alnylam teaches (instant claim 38) a compound (Claim 1) comprising a first modified oligonucleotide (Table 8 (page 97) Duplex AD-60770.1, Sense strand A-122539.1 "CfsasGfcUfuGfuUfGfuGfaAfaCfaAfaAfl.96" SEQ ID NO: 555), and a second modified oligonucleotide 14 to 21 linked nucleosides in length fully complementary to the first modified oligonucleotide (Table 8 (page 98) Duplex AD-60770.1, Antisense strand A-122540.1 "usUfsuUfgUfuUfcAfaAfcAfaGfcUfgsgsu" SEQ ID NO: 593).

As said technical features were known in the art at the time of the invention, these cannot be considered special technical features that would otherwise unify the groups.

Groups I+ and II therefore lack unity under PCT Rule 13 because they do not share a same or corresponding special technical feature.

Item 4 (continued):

Claims 5-6; 11-37, 40-44, 46-48, 54-56, 60, 64-66 are improper multiple dependent claims because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).